

SUPPLEMENT

The effectiveness of COVID-19 vaccines to prevent post COVID cardiac and thromboembolic complications: staggered cohort analyses of data from Spain, Estonia, and the UK.

Table of contents

Figure S1: Details of the country-specific vaccination rollout and study-specific enrolment periods and definition of priority groups for vaccination.....	7
Table S1: Details of the country-specific vaccination rollout Country-specific lists of conditions characterising people as “clinically extremely vulnerable/high risk” or “at risk” for severe COVID-19.	8
Figure S2: Study Design using UK vaccination rollout (CPRD AURUM and GOLD) as illustrative example.....	10
Figure S3: Follow-up in vaccinated and unvaccinated cohorts.....	11
(A) Main analysis. (B) Follow-up ends at first vaccine dose after index date. (C) Post COVID outcomes refer to the first event within a year after COVID-19 infection.	11
Figure S4: Study Inclusion Flowchart CPRD AURUM	12
Figure S5: Study Inclusion Flowchart CPRD GOLD.....	13
Figure S6: Study Inclusion Flowchart SIDIAP.....	14
Figure S7: Study Inclusion Flowchart CORIVA.	15
Table S2: Characteristics of unweighted populations in CPRD AURUM, database, stratified by staggered cohort and exposure status. Exposure is any COVID-19 vaccine.	16
Table S3: Characteristics of weighted populations in CPRD AURUM, database, stratified by staggered cohort and exposure status. Exposure is ChAdOx1 vaccine.....	18
Table S4: Characteristics of unweighted populations in CPRD AURUM, database, stratified by staggered cohort and exposure status. Exposure is ChAdOx1 vaccine.....	20
Table S5: Characteristics of weighted populations in CPRD AURUM, database, stratified by staggered cohort and exposure status. Exposure is BNT162b2 vaccine.....	22
Table S6: Characteristics of unweighted populations in CPRD AURUM, database, stratified by staggered cohort and exposure status. Exposure is BNT162b2 vaccine.....	24
Table S7: Characteristics of weighted populations in CPRD GOLD, database, stratified by staggered cohort and exposure status. Exposure is any COVID-19 vaccine.	26
Table S8: Characteristics of unweighted populations in CPRD GOLD, database, stratified by staggered cohort and exposure status. Exposure is any COVID-19 vaccine.	28
Table S9: Characteristics of weighted populations in CPRD GOLD, database, stratified by staggered cohort and exposure status. Exposure is ChAdOx1 vaccine.....	30
Table S10: Characteristics of unweighted populations in CPRD GOLD, database, stratified by staggered cohort and exposure status. Exposure is ChAdOx1 vaccine.....	32
Table S11: Characteristics of weighted populations in CPRD GOLD, database, stratified by staggered cohort and exposure status. Exposure is BNT162b2 vaccine.....	34
Table S12: Characteristics of unweighted populations in CPRD GOLD, database, stratified by staggered cohort and exposure status. Exposure is BNT162b2 vaccine.....	36

Table S13: Characteristics of weighted populations in SIDIAP, database, stratified by staggered cohort and exposure status. Exposure is any COVID-19 vaccine.	38
Table S14: Characteristics of unweighted populations in SIDIAP, database, stratified by staggered cohort and exposure status. Exposure is any COVID-19 vaccine.	40
Table S15: Characteristics of weighted populations in SIDIAP, database, stratified by staggered cohort and exposure status. Exposure is BNT162b2 vaccine	42
Table S16: Characteristics of unweighted populations in SIDIAP, database, stratified by staggered cohort and exposure status. Exposure is BNT162b2 vaccine	44
Table S17: Characteristics of weighted populations in SIDIAP, database, stratified by staggered cohort and exposure status. Exposure is ChAdOx1 vaccine	46
Table S18: Characteristics of unweighted populations in SIDIAP, database, stratified by staggered cohort and exposure status. Exposure is ChAdOx1 vaccine	48
Table S19: Characteristics of weighted populations in CORIVA, database, stratified by staggered cohort and exposure status. Exposure is any COVID-19 vaccine.	50
Table S20: Characteristics of unweighted populations in CORIVA, database, stratified by staggered cohort and exposure status. Exposure is any COVID-19 vaccine.	52
Table S21: Characteristics of weighted populations in CORIVA, database, stratified by staggered cohort and exposure status. Exposure is BNT162b2 vaccine	54
Table S22: Characteristics of unweighted populations in CORIVA, database, stratified by staggered cohort and exposure status. Exposure is BNT162b2 vaccine	56
Table S23: Characteristics of weighted populations in CPRD AURUM database, stratified by staggered cohort and vaccine brand	58
Table S24: Characteristics of unweighted populations in CPRD AURUM database, stratified by staggered cohort and vaccine brand	60
Table S25: Characteristics of weighted populations in CPRD GOLD database, stratified by staggered cohort and vaccine brand	62
Table S26: Characteristics of unweighted populations in CPRD GOLD database, stratified by staggered cohort and vaccine brand	64
Table S27: Number of records (and risk per 10,000 individuals) for post COVID-19 cardiac and thromboembolic complications, across cohorts and databases, stratified by exposure status (any COVID-19 vaccine). Follow-up ends at first vaccine dose after index date	66
Table S28: Number of records (and risk per 10,000 individuals) for post COVID-19 cardiac and thromboembolic complications, across cohorts and databases, stratified by exposure status (any COVID-19 vaccine). Only first outcome after COVID-19 captured	70
Table S29: Number of records (and risk per 10,000 individuals) for post COVID-19 cardiac and thromboembolic complications, across cohorts and databases, stratified by exposure status (ChAdOx1 vaccine)	74
Table S30: Number of records (and risk per 10,000 individuals) for post COVID-19 cardiac and thromboembolic complications, across cohorts and databases, stratified by exposure status (ChAdOx1 vaccine). Follow-up ends at first vaccine dose after index date	78
Table S31: Number of records (and risk per 10,000 individuals) for post COVID-19 cardiac and thromboembolic complications, across cohorts and databases, stratified by exposure status (ChAdOx1 vaccine). Only first outcome after COVID-19 captured	82

Table S32: Number of records (and risk per 10,000 individuals) for post COVID-19 cardiac and thromboembolic complications, across cohorts and databases, stratified by exposure status (BNT162b2 vaccine).	86
Table S33: Number of records (and risk per 10,000 individuals) for post COVID-19 cardiac and thromboembolic complications, across cohorts and databases, stratified by exposure status (BNT162b2 vaccine). Follow-up ends at first vaccine dose after index date.	90
Table S34: Number of records (and risk per 10,000 individuals) for post COVID-19 cardiac and thromboembolic complications, across cohorts and databases, stratified by exposure status (BNT162b2 vaccine). Only first outcome after COVID-19 captured.	94
Table S35: Number of records (and risk per 10,000 individuals) for post COVID-19 cardiac and thromboembolic complications, across cohorts and databases, stratified by vaccine brand.	98
Table S36: Number of records (and risk per 10,000 individuals) for post COVID-19 cardiac and thromboembolic complications, across cohorts and databases, stratified by vaccine brand. Follow-up ends at first vaccine dose after index date.	102
Table S37: Number of records (and risk per 10,000 individuals) for post COVID-19 cardiac and thromboembolic complications, across cohorts and databases, stratified by vaccine brand. Only first outcome after COVID-19 captured.	106
Figure S8: Forest plots for vaccine effectiveness (any COVID-19 vaccine), meta-analysis across cohorts and databases. Follow-up ends at first vaccine dose after index date. Dashed line represents a level of heterogeneity $I^2 > 0.4$.	110
Figure S9: Forest plots for vaccine effectiveness (any COVID-19 vaccine), meta-analysis across cohorts and databases. Only first outcome after COVID-19 captured. Dashed line represents a level of heterogeneity $I^2 > 0.4$.	111
Figure S10: Forest plots for vaccine effectiveness (ChAdOx1 vaccine), meta-analysis across cohorts and databases. Dashed line represents a level of heterogeneity $I^2 > 0.4$.	112
Figure S11: Forest plots for vaccine effectiveness (ChAdOx1 vaccine), meta-analysis across cohorts and databases. Follow-up ends at first vaccine dose after index date. Dashed line represents a level of heterogeneity $I^2 > 0.4$.	113
Figure S12: Forest plots for vaccine effectiveness (ChAdOx1 vaccine), meta-analysis across cohorts and databases. Only first outcome after COVID-19 captured. Dashed line represents a level of heterogeneity $I^2 > 0.4$.	114
Figure S13: Forest plots for vaccine effectiveness (BNT162b2 vaccine), meta-analysis across cohorts and databases. Dashed line represents a level of heterogeneity $I^2 > 0.4$.	115
Figure S14: Forest plots for vaccine effectiveness (BNT162b2 vaccine), meta-analysis across cohorts and databases. Follow-up ends at first vaccine dose after index date. Dashed line represents a level of heterogeneity $I^2 > 0.4$.	116
Figure S15: Forest plots for vaccine effectiveness (BNT162b2 vaccine), meta-analysis across cohorts and databases. Only first outcome after COVID-19 captured. Dashed line represents a level of heterogeneity $I^2 > 0.4$.	117
Figure S16: Forest plots for vaccine effectiveness (any COVID-19 vaccine) on preventing venous thromboembolism complications, for each cohort and database (meta-analysis estimates across cohorts in the last panel). Dashed line represents a level of heterogeneity $I^2 > 0.4$.	118
Figure S17: Forest plots for vaccine effectiveness (any COVID-19 vaccine) on preventing venous thromboembolism complications, for each cohort and database (meta-analysis estimates across cohorts in the	

last panel). Follow-up ends at first vaccine dose after index date. Dashed line represents a level of heterogeneity $I^2 > 0.4$.	119
Figure S18: Forest plots for vaccine effectiveness (any COVID-19 vaccine) on preventing venous thromboembolism complications , for each cohort and database (meta-analysis estimates across cohorts in the last panel). Only first outcome after COVID-19 captured. Dashed line represents a level of heterogeneity $I^2 > 0.4$.	120
Figure S19: Forest plots for vaccine effectiveness (ChAdOx1 vaccine) on preventing venous thromboembolism complications , for each cohort and database (meta-analysis estimates across cohorts in the last panel). Dashed line represents a level of heterogeneity $I^2 > 0.4$.	121
Figure S20: Forest plots for vaccine effectiveness (ChAdOx1 vaccine) on preventing venous thromboembolism complications , for each cohort and database (meta-analysis estimates across cohorts in the last panel). Follow-up ends at first vaccine dose after index date. Dashed line represents a level of heterogeneity $I^2 > 0.4$.	122
Figure S21: Forest plots for vaccine effectiveness (ChAdOx1 vaccine) on preventing venous thromboembolism complications , for each cohort and database (meta-analysis estimates across cohorts in the last panel). Only first outcome after COVID-19 captured. Dashed line represents a level of heterogeneity $I^2 > 0.4$.	123
Figure S22: Forest plots for vaccine effectiveness (BNT162b2 vaccine) on preventing venous thromboembolism complications , for each cohort and database (meta-analysis estimates across cohorts in the last panel). Dashed line represents a level of heterogeneity $I^2 > 0.4$.	124
Figure S23: Forest plots for vaccine effectiveness (BNT162b2 vaccine) on preventing venous thromboembolism complications , for each cohort and database (meta-analysis estimates across cohorts in the last panel). Follow-up ends at first vaccine dose after index date. Dashed line represents a level of heterogeneity $I^2 > 0.4$.	125
Figure S24: Forest plots for vaccine effectiveness (BNT162b2 vaccine) on preventing venous thromboembolism complications , for each cohort and database (meta-analysis estimates across cohorts in the last panel). Only first outcome after COVID-19 captured. Dashed line represents a level of heterogeneity $I^2 > 0.4$.	126
Figure S25: Forest plots for vaccine effectiveness (any COVID-19 vaccine) on preventing arterial thromboembolism complications , for each cohort and database (meta-analysis estimates across cohorts in the last panel). Dashed line represents a level of heterogeneity $I^2 > 0.4$.	127
Figure S26: Forest plots for vaccine effectiveness (any COVID-19 vaccine) on preventing arterial thromboembolism complications , for each cohort and database (meta-analysis estimates across cohorts in the last panel). Follow-up ends at first vaccine dose after index date. Dashed line represents a level of heterogeneity $I^2 > 0.4$.	128
Figure S27: Forest plots for vaccine effectiveness (any COVID-19 vaccine) on preventing arterial thromboembolism complications , for each cohort and database (meta-analysis estimates across cohorts in the last panel). Only first outcome after COVID-19 captured. Dashed line represents a level of heterogeneity $I^2 > 0.4$.	129
Figure S28: Forest plots for vaccine effectiveness (ChAdOx1 vaccine) on preventing arterial thromboembolism complications , for each cohort and database (meta-analysis estimates across cohorts in the last panel). Dashed line represents a level of heterogeneity $I^2 > 0.4$.	130
Figure S29: Forest plots for vaccine effectiveness (ChAdOx1 vaccine) on preventing arterial thromboembolism complications , for each cohort and database (meta-analysis estimates across cohorts in the last panel). Follow-up ends at first vaccine dose after index date. Dashed line represents a level of heterogeneity $I^2 > 0.4$.	131

Figure S30: Forest plots for vaccine effectiveness (ChAdOx1 vaccine) on preventing arterial thromboembolism complications, for each cohort and database (meta-analysis estimates across cohorts in the last panel).Only first outcome after COVID-19 captured. Dashed line represents a level of heterogeneity $I^2 > 0.4$ 132

Figure S31: Forest plots for vaccine effectiveness (BNT162b2 vaccine) on preventing arterial thromboembolism complications, for each cohort and database (meta-analysis estimates across cohorts in the last panel). Dashed line represents a level of heterogeneity $I^2 > 0.4$ 133

Figure S32: Forest plots for vaccine effectiveness (BNT162b2 vaccine) on preventing arterial thromboembolism complications, for each cohort and database (meta-analysis estimates across cohorts in the last panel).Follow-up ends at first vaccine dose after index date. Dashed line represents a level of heterogeneity $I^2 > 0.4$ 134

Figure S33: Forest plots for vaccine effectiveness (BNT162b2 vaccine) on preventing arterial thromboembolism complications, for each cohort and database (meta-analysis estimates across cohorts in the last panel).Only first outcome after COVID-19 captured. Dashed line represents a level of heterogeneity $I^2 > 0.4$ 135

Figure S34: Forest plots for vaccine effectiveness (any COVID-19 vaccine) on preventing cardiac diseases and hemorrhagic stroke, for each cohort and database (meta-analysis estimates across cohorts in the last panel). Dashed line represents a level of heterogeneity $I^2 > 0.4$ 136

Figure S35: Forest plots for vaccine effectiveness (any COVID-19 vaccine) on preventing cardiac diseases and hemorrhagic stroke, for each cohort and database (meta-analysis estimates across cohorts in the last panel).Follow-up ends at first vaccine dose after index date. Dashed line represents a level of heterogeneity $I^2 > 0.4$ 137

Figure S36: Forest plots for vaccine effectiveness (any COVID-19 vaccine) on preventing cardiac diseases and hemorrhagic stroke, for each cohort and database (meta-analysis estimates across cohorts in the last panel).Only first outcome after COVID-19 captured. Dashed line represents a level of heterogeneity $I^2 > 0.4$ 138

Figure S37: Forest plots for vaccine effectiveness (ChAdOx1 vaccine) on preventing cardiac diseases and hemorrhagic stroke, for each cohort and database (meta-analysis estimates across cohorts in the last panel). Dashed line represents a level of heterogeneity $I^2 > 0.4$ 139

Figure S38: Forest plots for vaccine effectiveness (ChAdOx1 vaccine) on preventing cardiac diseases and hemorrhagic stroke, for each cohort and database (meta-analysis estimates across cohorts in the last panel).Follow-up ends at first vaccine dose after index date. Dashed line represents a level of heterogeneity $I^2 > 0.4$ 140

Figure S39: Forest plots for vaccine effectiveness (ChAdOx1 vaccine) on preventing cardiac diseases and hemorrhagic stroke, for each cohort and database (meta-analysis estimates across cohorts in the last panel).Only first outcome after COVID-19 captured. Dashed line represents a level of heterogeneity $I^2 > 0.4$ 141

Figure S40: Forest plots for vaccine effectiveness (BNT162b2 vaccine) on preventing cardiac diseases and hemorrhagic stroke, for each cohort and database (meta-analysis estimates across cohorts in the last panel). Dashed line represents a level of heterogeneity $I^2 > 0.4$ 142

Figure S41: Forest plots for vaccine effectiveness (BNT162b2 vaccine) on preventing cardiac diseases and hemorrhagic stroke, for each cohort and database (meta-analysis estimates across cohorts in the last panel).Follow-up ends at first vaccine dose after index date. Dashed line represents a level of heterogeneity $I^2 > 0.4$ 143

Figure S42: Forest plots for vaccine effectiveness (BNT162b2 vaccine) on preventing cardiac diseases and hemorrhagic stroke, for each cohort and database (meta-analysis estimates across cohorts in the last

panel). Only first outcome after COVID-19 captured. Dashed line represents a level of heterogeneity $I^2 > 0.4$ 144

Figure S43: Forest plots for comparative effectiveness, meta-analysis across cohorts and databases. Follow-up ends at first vaccine dose after index date. Dashed line represents a level of heterogeneity $I^2 > 0.4$ 145

Figure S44: Forest plots for comparative effectiveness, meta-analysis across cohorts and databases. Only first outcome after COVID-19 captured. Dashed line represents a level of heterogeneity $I^2 > 0.4$ 146

Figure S45: Forest plots for comparative effectiveness on preventing venous thromboembolism complications, for each cohort and database (meta-analysis estimates across cohorts in the last panel). Dashed line represents a level of heterogeneity $I^2 > 0.4$ 147

Figure S46: Forest plots for comparative effectiveness on preventing venous thromboembolism complications, for each cohort and database (meta-analysis estimates across cohorts in the last panel). Follow-up ends at first vaccine dose after index date. Dashed line represents a level of heterogeneity $I^2 > 0.4$ 148

Figure S47: Forest plots for comparative effectiveness on preventing venous thromboembolism complications, for each cohort and database (meta-analysis estimates across cohorts in the last panel). Only first outcome after COVID-19 captured. Dashed line represents a level of heterogeneity $I^2 > 0.4$ 149

Figure S48: Forest plots for comparative effectiveness on preventing arterial thromboembolism complications, for each cohort and database (meta-analysis estimates across cohorts in the last panel). Dashed line represents a level of heterogeneity $I^2 > 0.4$ 150

Figure S49: Forest plots for comparative effectiveness on preventing arterial thromboembolism complications, for each cohort and database (meta-analysis estimates across cohorts in the last panel). Follow-up ends at first vaccine dose after index date. Dashed line represents a level of heterogeneity $I^2 > 0.4$ 151

Figure S50: Forest plots for comparative effectiveness on preventing arterial thromboembolism complications, for each cohort and database (meta-analysis estimates across cohorts in the last panel). Only first outcome after COVID-19 captured. Dashed line represents a level of heterogeneity $I^2 > 0.4$ 152

Figure S51: Forest plots for comparative effectiveness on preventing cardiac diseases and hemorrhagic stroke, for each cohort and database (meta-analysis estimates across cohorts in the last panel). Dashed line represents a level of heterogeneity $I^2 > 0.4$ 153

Figure S52: Forest plots for comparative effectiveness on preventing cardiac diseases and hemorrhagic stroke, for each cohort and database (meta-analysis estimates across cohorts in the last panel). Follow-up ends at first vaccine dose after index date. Dashed line represents a level of heterogeneity $I^2 > 0.4$ 154

Figure S53: Forest plots for comparative effectiveness on preventing cardiac diseases and hemorrhagic stroke, for each cohort and database (meta-analysis estimates across cohorts in the last panel). Only first outcome after COVID-19 captured. Dashed line represents a level of heterogeneity $I^2 > 0.4$ 155

Figure S1: Details of the country-specific vaccination rollout and study-specific enrolment periods and definition of priority groups for vaccination

	CPRD (AURUM and GOLD)			SPAIN (SIDIAP)			ESTONIA (CORIVA)		
	Priority group*	Cohort inclusion criteria	Enrolment windows	Priority group*	Cohort inclusion criteria	Enrolment windows	Priority group*	Cohort inclusion criteria	Enrolment windows
	1) Residents in a care home for older adults and staff working in care homes for older adults		excluded as probably vaccinated before 04/01/2021	1) Residents and workers of nursing homes 2) First line healthcare workers 3) Second line healthcare workers 4) Severely disabled		excluded as probably vaccinated before 20/02/2021	Healthcare workers in hospitals, emergency rooms and family medicine centers		excluded as probably vaccinated before 28/01/2021
Study 1	2) All those 80 years of age and over and frontline health and social care workers	Age ≥ 75	04/01/2021-27/01/2021	5A) > 80 years	Age ≥ 80	20/02/2021 - 22/03/2021	People in their 80s, then 70-80-year-olds with chronic diseases	Age ≥ 70	28/01/2021 - 20/04/2021
	3) All those 75 years of age and over						All people 70+		
Study 2	4) All those 70 years of age and over and clinically extremely vulnerable individuals (not including pregnant women and those under 16 years of age)	Age ≥ 65 and clinically extremely vulnerable, at risk people	28/01/2021-28/02/2021	5 B) 70-79 years	Age ≥ 60 and clinically extremely vulnerable	24/03/2021 - 04/05/2021	All people 65+ and people in the risk group < 65 years old	Age ≥ 65 and ≥ 18 with high risk	21/04/2021 - 01/05/2021
	5) All those 65 years of age and over			5C) 66-69 years					
	6) Adults aged 16 to 65 years in an at-risk group			6) Essential workers**					
				7) People >16 years with high risk factors*					
Study 3	7) All those 60 years of age and over	Age ≥ 50	01/03/2021 – 13/04/2021	9) 50-59 years	Age ≥ 40	05/05/2021 - 16/06/2021	Starting vaccination for the age group 60+	Age ≥ 40	02/05/2021 - 12/06/2021
	8) All those 55 years of age and over			10) 40-49 years			Age group 50-59 starting vaccination		
	9) All those 50 years of age and over			Age group 40-49 starting vaccination					
Study 4	10) Rest of the population >=18	Age ≥ 18	14/04/2021 – 31/07/2021	11) 30-39 years	Age ≥ 18	17/06/2021 - 01/08/2021	Age group 30-39 starting vaccination	Age ≥ 19	13/06/2021 - 01/08/2021
				12) 16-29 years			Age group 19-99 starting vaccination		

*Priority groups are country-specific and originally defined for the planning of the respective national vaccination rollout strategy by the respective governmental agency.

**Essential workers, frontline healthcare workers, social care workers could not be identified from the data. Therefore, people were included based on their age and records of conditions relevant for “high risk” and “at risk” categories for prioritisation.

Table S1: Details of the country-specific vaccination rollout Country-specific lists of conditions characterising people as “clinically extremely vulnerable/high risk” or “at risk” for severe COVID-19.

Categories	UK [1]	Spain [2]	Estonia [3]
	Conditions for “high risk”/ ”clinically extremely vulnerable”		
<i>Solid organ transplant</i>	Solid organ transplant recipients who remain on long term immune suppression therapy	Solid organ transplant recipient (or in waiting list for transplant): lung, renal, pancreatic, cardiac, hepatic, or intestinal	organ transplantation (performed up to 2 years ago)
<i>Bone marrow/stem cell transplant</i>	People who have had bone marrow or stem cell transplants in the last 6 months, or still taking immunosuppression drugs	Hematopoietic stem cell transplant recipient in the last 2 years OR >50 years of age AND/OR <80% Karnofsky index	bone marrow transplantation (performed up to 2 years ago)
<i>Immunodeficiencies</i>		Primary immunodeficiencies, excluding IgA deficiency and antibody formation defect	primary immunodeficiency
		HIV infection with <200c/ml in the last 6 months	
<i>Immunosuppressive therapy</i>	People on immunosuppression therapies sufficient to significantly increase risk of infection		people who have received immunosuppressive therapy in the last 5 years with hematological, rheumatological, gastroenterological, neurological diseases
<i>Blood cancer</i>	People with cancers of the blood or bone marrow such as leukaemia, lymphoma, or myeloma at any stage of treatment	Blood cancer in the last 5 years OR uncontrolled cancer AND/OR ECOG 3-4 AND/OR severe neutropenia (<500 neutrophils/mm ³) regardless of years since diagnosis	malignant tumors of lymphoid and hematopoietic tissue (diagnosed up to 5 years ago)
<i>Other active cancer</i>	Cancer undergoing active chemo/ radiotherapy or radical radiotherapy for lung cancer.	Solid organ cancer in treatment with chemotherapy or metastatic, OR receiving radiotherapy for tumours in the thorax with risks of pneumonitis (oesophageal tumour, radiotherapy on lung metastases, etc.)	other tumors (diagnosed up to 1 year ago)
<i>Neurological/muscular disease</i>			demyelinating diseases of the central nervous system
			amyotrophic lateral sclerosis; a stroke within the last year and residual symptoms of a stroke;
			dementia; Parkinson's disease
<i>Down Syndrome</i>		Individuals with Down syndrome aged >40 years	
<i>Kidney failure + Dialysis</i>		Haemodialysis or peritoneal dialysis	Kidney failure
<i>Severe respiratory disease</i>	Cystic Fibrosis, idiopathic pulmonary fibrosis, etc.	Cystic fibrosis –added on 22 June 2021, so can be omitted the purpose of the study	cystic fibrosis
	People with severe respiratory conditions including severe asthma and severe COPD		
<i>Rare diseases</i>	People with rare diseases and inborn errors of metabolism that significantly increase the risk of infections (such as SCID, homozygous sickle cell)		

<i>Pregnancy + Heart disease</i>	People who are pregnant with significant congenital heart disease		
----------------------------------	---	--	--

Categories	Conditions for “at risk”/ ”underlying conditions”		
<i>Severe Chronic Kidney disease</i>	unresolved CKD stage 3-5 diagnosis		
<i>Severe Chronic Liver disease</i>	chronic liver disease diagnosis		
<i>Immunosuppression</i>	immunosuppressive drug treatment within the 12 month period leading up to and including the reporting period end date.		
	expiring immunosuppression diagnosis within the 12 months leading up to and including the reporting period end date which is not resolved		
	unresolved 'persisting' immunosuppression diagnosis		
<i>Diabetes</i>	unresolved diabetes diagnosis.		diabetes
<i>Chronic and severe respiratory disease</i>	chronic respiratory disease diagnosis		chronic bronchitis, emphysema, COPD; severe asthma (oral corticosteroid therapy in the last 5 years, biological therapy), bronchiectasis disease
	Asthma treatment within the 12 month period leading up to the reporting period end date OR Emergency hospital admission due to asthma.		
<i>Obesity</i>	explicit high BMI/ BMI >=40		obesity (BMI ≥40)
<i>Neurological disease</i>	chronic neurological disease diagnosis		
<i>Severe cardiovascular disease</i>	chronic heart disease diagnosis		cardiological diseases
<i>cerebrovascular disease</i>	TIA diagnosis.		
<i>Pregnancy</i>	pregnant in the last 9 months		
<i>Other</i>	'requires influenza virus vaccination'		
	learning disability diagnosis		

Sources for overview table:

[1] NHS Digital. COVID-19 – high risk shielded patient list identification methodology- Rule logic. Update from 8 December 2021 — General Practice Specification and Extraction Service (GPSES), NHS Digital: “Business Rules for Patient-level Data Extracts 2019/20 COVID19 At-risk patients”, Version: 1.1, Version Date: 17/03/2020


[2] <https://beteve.cat/societat/vacunacio-grups-risc-malalties-greus-simultaniament-franja-70-79-anys/>

[3] https://vaksineeri.ee/wp-content/uploads/2021/06/covid-19_vaksineerimise_plaan_19.01_0.pdf

Figure S2: Study Design using UK vaccination rollout (CPRD AURUM and GOLD) as illustrative example.

	Study period				
	Enrolment periods				Follow - up
	04/01 - 27/01	28/01 - 28/02	01/03 - 13/04	14/04 - 31/07	
Study cohort 1 Age >= 75 (UK risk groups 2+3)	Vaccinated	→			
	Unvaccinated	→			
Study cohort 2 Age >= 65 and adult patients clinically extreme vulnerable/at risk (UK risk groups 4-6) + Eligible unvaccinated adults in risk groups 2+3	Vaccinated	→			
	Unvaccinated	→			
Study cohort 3 Age >= 50 (UK risk groups 7-9) + Eligible unvaccinated adults in risk groups 2-6	Vaccinated	→			
	Unvaccinated	→			
Study cohort 4 Age >= 18 (UK risk group 10) + Eligible unvaccinated adults in risk groups 2-9	Vaccinated	→			
	Unvaccinated	→			

Figure S3: Follow-up in vaccinated and unvaccinated cohorts.



(A) Main analysis. (B) Follow-up ends at first vaccine dose after index date. (C) Post COVID outcomes refer to the first event within a year after COVID-19 infection.

Figure S4: Study Inclusion Flowchart CPRD AURUM




Figure S5: Study Inclusion Flowchart CPRD GOLD.




Figure S6: Study Inclusion Flowchart SIDIAP.




Figure S7: Study Inclusion Flowchart CORIVA.




Table S2: Characteristics of unweighted populations in CPRD AURUM, database, stratified by staggered cohort and exposure status. Exposure is any COVID-19 vaccine.

	Cohort 1			Cohort 2			Cohort 3			Cohort 4		
	Unvaccinated	Vaccinated	ASMD	Unvaccinated	Vaccinated	ASMD	Unvaccinated	Vaccinated	ASMD	Unvaccinated	Vaccinated	ASMD
N (individuals)	346,674	552,602		1,975,726	1,563,569		1,510,401	1,528,031		2,027,763	2,085,598	
Age, median [Q25-Q75]	78 [76-82]	81 [78-86]	0.319	42 [32-55]	68 [60-73]	0.995	41 [31-53]	55 [51-60]	0.610	35 [27-45]	35 [27-43]	0.134
Sex: Female, N(%)	192,771 (56%)	314,141 (57%)	0.025	1,244,636 (63%)	852,976 (55%)	0.172	880,404 (58%)	771,929 (51%)	0.157	862,676 (43%)	958,124 (46%)	0.068
Years of prior history*, median [Q25-Q75]	24 [10-35]	25 [11-37]	0.056	15 [7-25]	21 [9-32]	0.278	13 [6-22]	17 [8-27]	0.207	8 [4-16]	8 [3-18]	0.032
Number visits, median [Q25-Q75]	10 [5-17]	11 [6-19]		6 [2-11]	10 [6-17]		4 [1-10]	7 [3-12]		2 [0-5]	3 [1-7]	
Number pcrs, median [Q25-Q75]	0[0-0]	0[0-0]		0[0-0]	0[0-0]		0[0-0]	0[0-0]		0[0-0]	0[0-0]	
Comorbidities**, N(%)												
Anxiety	51,067 (15%)	82,765 (15%)	0.007	435,770 (22%)	309,567 (20%)	0.056	289,563 (19%)	292,336 (19%)	0.001	265,627 (13%)	338,058 (16%)	0.088
Asthma	36,474 (11%)	61,899 (11%)	0.022	501,209 (25%)	275,768 (18%)	0.189	294,123 (19%)	209,708 (14%)	0.155	138,317 (7%)	173,056 (8%)	0.056
Chronic kidney disease	71,083 (21%)	137,953 (25%)	0.107	55,104 (3%)	154,263 (10%)	0.294	24,340 (2%)	30,896 (2%)	0.031	18,625 (1%)	5,796 (0%)	0.083
COPD	28,665 (8%)	47,422 (9%)	0.011	29,729 (2%)	107,297 (7%)	0.270	13,433 (1%)	15,685 (1%)	0.014	10,543 (1%)	2,535 (0%)	0.071
Dementia	16,610 (5%)	32,934 (6%)	0.052	6,692 (0%)	15,828 (1%)	0.082	3,425 (0%)	3,219 (0%)	0.003	2,691 (0%)	575 (0%)	0.037
Depressive disorder	42,145 (12%)	64,840 (12%)	0.013	367,463 (19%)	283,390 (18%)	0.012	236,584 (16%)	265,876 (17%)	0.047	210,644 (10%)	253,317 (12%)	0.056
Diabetes	63,154 (18%)	101,682 (18%)	0.005	107,425 (5%)	253,026 (16%)	0.351	60,932 (4%)	84,224 (6%)	0.069	49,154 (2%)	22,968 (1%)	0.101
GERD	18,336 (5%)	32,360 (6%)	0.025	68,070 (3%)	84,985 (5%)	0.097	39,594 (3%)	58,961 (4%)	0.070	31,119 (2%)	38,612 (2%)	0.025
Heart failure	17,882 (5%)	33,578 (6%)	0.040	12,275 (1%)	37,396 (2%)	0.146	5,641 (0%)	7,204 (0%)	0.015	4,611 (0%)	1,163 (0%)	0.046
Hypertension	172,799 (50%)	301,294 (55%)	0.094	206,105 (10%)	545,782 (35%)	0.611	110,912 (7%)	240,120 (16%)	0.264	86,435 (4%)	54,357 (3%)	0.091
Hypothyroidism	31,444 (9%)	56,367 (10%)	0.038	78,934 (4%)	118,453 (8%)	0.154	43,892 (3%)	67,686 (4%)	0.081	30,993 (2%)	35,364 (2%)	0.013

	Cohort 1			Cohort 2			Cohort 3			Cohort 4		
	Unvaccinated	Vaccinated	ASMD	Unvaccinated	Vaccinated	ASMD	Unvaccinated	Vaccinated	ASMD	Unvaccinated	Vaccinated	ASMD
Malignant neoplastic disease	68,984 (20%)	131,635 (24%)	0.095	60,318 (3%)	207,240 (13%)	0.379	29,689 (2%)	61,923 (4%)	0.122	22,701 (1%)	13,590 (1%)	0.050
Myocardial infarction	16,027 (5%)	29,525 (5%)	0.033	20,259 (1%)	56,161 (4%)	0.172	7,396 (0%)	12,703 (1%)	0.042	5,764 (0%)	1,621 (0%)	0.049
Osteoporosis	29,909 (9%)	59,521 (11%)	0.072	18,263 (1%)	64,108 (4%)	0.204	8,846 (1%)	15,089 (1%)	0.045	6,922 (0%)	2,535 (0%)	0.046
Pneumonia	16,992 (5%)	28,398 (5%)	0.011	31,746 (2%)	50,739 (3%)	0.107	17,785 (1%)	22,064 (1%)	0.023	13,305 (1%)	13,282 (1%)	0.002
Rheumatoid arthritis	6,596 (2%)	11,237 (2%)	0.009	14,811 (1%)	33,173 (2%)	0.116	5,548 (0%)	9,130 (1%)	0.033	3,710 (0%)	1,816 (0%)	0.026
Stroke	15,249 (4%)	26,478 (5%)	0.019	16,942 (1%)	39,907 (3%)	0.131	7,422 (0%)	10,828 (1%)	0.028	6,030 (0%)	2,291 (0%)	0.042
Venous thromboembolism	19,607 (6%)	35,332 (6%)	0.031	28,876 (1%)	63,048 (4%)	0.158	13,608 (1%)	26,299 (2%)	0.072	12,945 (1%)	4,787 (0%)	0.062

The 4 cohorts represent vaccine rollout periods. *Calculated as the days of previous observation in the database before index date. **Assessed anytime before index date. ASMD = Absolute standardized mean difference, COPD = Chronic obstructive pulmonary disease, GERD = Gastro-Esophageal reflux disease

Table S3: Characteristics of weighted populations in CPRD AURUM, database, stratified by staggered cohort and exposure status. Exposure is ChAdOx1 vaccine.

	Cohort 1			Cohort 2			Cohort 3			Cohort 4		
	Unvaccinated	Vaccinated	ASMD	Unvaccinated	Vaccinated	ASMD	Unvaccinated	Vaccinated	ASMD	Unvaccinated	Vaccinated	ASMD
N (individuals)	100,517	99,985		308,608	304,995		448,766	445,397		242,955	243,847	
Age, median [Q25-Q75]	78 [76-84]	78 [76-84]	0.001	62 [47-69]	62 [47-69]	0.007	50 [41-57]	52 [41-57]	0.001	44 [41-48]	44 [41-48]	0.003
Sex: Female, N(%)	57,756 (57%)	57,174 (57%)	0.006	179,574 (58%)	176,871 (58%)	0.004	236,260 (53%)	234,320 (53%)	0.001	101,805 (42%)	100,846 (41%)	0.011
Years of prior history*, median [Q25-Q75]	24 [10-36]	24 [10-36]	0.004	18 [8-29]	18 [8-29]	0.002	14 [6-24]	14 [6-24]	0.002	10 [5-18]	9 [5-18]	0.004
Number visits, median [Q25-Q75]	10 [5-18]	10 [6-18]		8 [3-15]	8 [5-15]		4 [1-11]	6 [2-10]		2 [0-7]	2 [1-7]	
Number pcrs, median [Q25-Q75]	0[0-0]	0[0-0]		0[0-0]	0[0-0]		0[0-0]	0[0-0]		0[0-0]	0[0-0]	
Comorbidities**, N(%)												
Anxiety	15,457 (15%)	15,069 (15%)	0.009	67,125 (22%)	64,408 (21%)	0.015	90,806 (20%)	87,243 (20%)	0.016	37,475 (15%)	38,040 (16%)	0.005
Asthma	10,993 (11%)	10,863 (11%)	0.002	65,274 (21%)	62,424 (20%)	0.017	76,417 (17%)	75,841 (17%)	0.000	17,944 (7%)	17,468 (7%)	0.009
Chronic kidney disease	23,223 (23%)	22,872 (23%)	0.005	23,022 (7%)	24,288 (8%)	0.019	8,460 (2%)	8,356 (2%)	0.001	2,419 (1%)	2,043 (1%)	0.017
COPD	8,669 (9%)	8,770 (9%)	0.005	14,411 (5%)	15,226 (5%)	0.015	5,747 (1%)	4,794 (1%)	0.019	1,263 (1%)	1,250 (1%)	0.001
Dementia	6,529 (6%)	6,431 (6%)	0.003	3,880 (1%)	3,541 (1%)	0.009	898 (0%)	1,004 (0%)	0.006	203 (0%)	399 (0%)	0.023
Depressive disorder	12,559 (12%)	12,267 (12%)	0.007	60,745 (20%)	57,903 (19%)	0.018	80,264 (18%)	77,017 (17%)	0.016	32,304 (13%)	33,302 (14%)	0.011
Diabetes	18,750 (19%)	18,602 (19%)	0.001	39,262 (13%)	38,979 (13%)	0.002	25,334 (6%)	26,121 (6%)	0.009	6,679 (3%)	6,315 (3%)	0.010
GERD	5,590 (6%)	5,471 (5%)	0.004	14,645 (5%)	14,339 (5%)	0.002	14,758 (3%)	14,823 (3%)	0.002	5,727 (2%)	6,021 (2%)	0.007
Heart failure	6,181 (6%)	5,763 (6%)	0.016	6,098 (2%)	5,685 (2%)	0.008	2,241 (0%)	1,983 (0%)	0.008	610 (0%)	545 (0%)	0.006
Hypertension	52,737 (52%)	51,796 (52%)	0.013	78,623 (25%)	79,827 (26%)	0.016	51,054 (11%)	51,059 (11%)	0.003	15,350 (6%)	15,670 (6%)	0.004
Hypothyroidism	9,956 (10%)	9,690 (10%)	0.007	19,720 (6%)	19,562 (6%)	0.001	16,480 (4%)	16,361 (4%)	0.000	5,735 (2%)	5,984 (2%)	0.006

	Cohort 1			Cohort 2			Cohort 3			Cohort 4		
	Unvaccinated	Vaccinated	ASMD	Unvaccinated	Vaccinated	ASMD	Unvaccinated	Vaccinated	ASMD	Unvaccinated	Vaccinated	ASMD
Malignant neoplastic disease	21,691 (22%)	21,468 (21%)	0.003	25,191 (8%)	27,892 (9%)	0.035	13,140 (3%)	12,870 (3%)	0.002	4,003 (2%)	3,621 (1%)	0.013
Myocardial infarction	5,182 (5%)	4,988 (5%)	0.008	7,777 (3%)	8,594 (3%)	0.018	3,415 (1%)	3,228 (1%)	0.004	933 (0%)	636 (0%)	0.022
Osteoporosis	9,975 (10%)	10,018 (10%)	0.003	9,052 (3%)	9,423 (3%)	0.009	3,285 (1%)	3,499 (1%)	0.006	840 (0%)	934 (0%)	0.006
Pneumonia	5,770 (6%)	5,268 (5%)	0.021	9,096 (3%)	8,541 (3%)	0.009	6,196 (1%)	6,077 (1%)	0.001	1,923 (1%)	2,040 (1%)	0.005
Rheumatoid arthritis	2,002 (2%)	2,063 (2%)	0.005	4,856 (2%)	4,971 (2%)	0.004	2,266 (1%)	2,795 (1%)	0.016	665 (0%)	478 (0%)	0.016
Stroke	5,085 (5%)	4,791 (5%)	0.012	6,650 (2%)	6,616 (2%)	0.001	3,150 (1%)	2,942 (1%)	0.005	908 (0%)	773 (0%)	0.010
Venous thromboembolism	6,342 (6%)	6,069 (6%)	0.010	9,208 (3%)	9,850 (3%)	0.014	6,193 (1%)	7,393 (2%)	0.023	2,532 (1%)	1,239 (1%)	0.061

The 4 cohorts represent vaccine rollout periods. *Calculated as the days of previous observation in the database before index date. **Assessed anytime before index date. ASMD = Absolute standardized mean difference, COPD = Chronic obstructive pulmonary disease, GERD = Gastro-Esophageal reflux disease

Table S4: Characteristics of unweighted populations in CPRD AURUM, database, stratified by staggered cohort and exposure status. Exposure is ChAdOx1 vaccine.

	Cohort 1			Cohort 2			Cohort 3			Cohort 4		
	Unvaccinated	Vaccinated	ASMD	Unvaccinated	Vaccinated	ASMD	Unvaccinated	Vaccinated	ASMD	Unvaccinated	Vaccinated	ASMD
N (individuals)	344,687	219,804		1,975,770	969,262		1,510,493	1,473,602		2,066,318	542,670	
Age, median [Q25-Q75]	78 [76-82]	80 [77-85]	0.240	42 [32-55]	69 [63-73]	1.059	41 [31-53]	55 [51-60]	0.605	34 [27-45]	45 [42-48]	0.507
Sex: Female, N(%)	191,649 (56%)	127,656 (58%)	0.050	1,244,532 (63%)	528,692 (55%)	0.172	880,468 (58%)	739,444 (50%)	0.163	880,225 (43%)	242,758 (45%)	0.043
Years of prior history*, median [Q25-Q75]	24 [10-35]	24 [9-36]	0.018	15 [7-25]	21 [9-33]	0.288	13 [6-22]	17 [8-27]	0.203	7 [4-16]	10 [5-18]	0.143
Number visits, median [Q25-Q75]	10 [5-17]	12 [6-19]		6 [2-11]	10 [6-17]		4 [1-10]	7 [3-12]		2 [0-5]	3 [1-8]	
Number pcrs, median [Q25-Q75]	0[0-0]	0[0-0]		0[0-0]	0[0-0]		0[0-0]	0[0-0]		0[0-0]	0[0-0]	
Comorbidities**, N(%)												
Anxiety	50,786 (15%)	33,355 (15%)	0.012	435,737 (22%)	187,469 (19%)	0.067	289,618 (19%)	281,846 (19%)	0.001	268,451 (13%)	86,805 (16%)	0.085
Asthma	36,259 (11%)	24,009 (11%)	0.013	501,234 (25%)	159,162 (16%)	0.221	294,156 (19%)	200,995 (14%)	0.157	140,178 (7%)	41,393 (8%)	0.033
Chronic kidney disease	70,604 (20%)	51,053 (23%)	0.066	55,103 (3%)	97,339 (10%)	0.299	24,361 (2%)	24,198 (2%)	0.002	18,798 (1%)	2,879 (1%)	0.045
COPD	28,448 (8%)	19,105 (9%)	0.016	29,730 (2%)	67,700 (7%)	0.274	13,436 (1%)	13,621 (1%)	0.004	10,647 (1%)	1,510 (0%)	0.038
Dementia	16,327 (5%)	16,795 (8%)	0.121	6,689 (0%)	12,106 (1%)	0.103	3,424 (0%)	1,896 (0%)	0.023	2,729 (0%)	447 (0%)	0.015
Depressive disorder	41,905 (12%)	27,009 (12%)	0.004	367,500 (19%)	170,626 (18%)	0.026	236,628 (16%)	256,789 (17%)	0.047	212,626 (10%)	74,210 (14%)	0.104
Diabetes	62,733 (18%)	39,751 (18%)	0.003	107,449 (5%)	154,348 (16%)	0.344	60,968 (4%)	78,394 (5%)	0.061	49,223 (2%)	9,729 (2%)	0.041
GERD	18,253 (5%)	12,156 (6%)	0.010	68,089 (3%)	52,694 (5%)	0.097	39,619 (3%)	56,444 (4%)	0.068	31,367 (2%)	13,807 (3%)	0.073
Heart failure	17,716 (5%)	13,147 (6%)	0.037	12,277 (1%)	24,276 (3%)	0.152	5,638 (0%)	5,673 (0%)	0.002	4,625 (0%)	681 (0%)	0.024
Hypertension	171,846 (50%)	114,922 (52%)	0.049	206,105 (10%)	345,014 (36%)	0.626	110,975 (7%)	224,543 (15%)	0.251	87,010 (4%)	31,330 (6%)	0.072
Hypothyroidism	31,256 (9%)	21,855 (10%)	0.030	78,921 (4%)	73,992 (8%)	0.156	43,887 (3%)	64,026 (4%)	0.077	31,315 (2%)	13,920 (3%)	0.074
Malignant neoplastic disease	68,598 (20%)	49,023 (22%)	0.059	60,355 (3%)	131,135 (14%)	0.387	29,693 (2%)	55,601 (4%)	0.108	22,873 (1%)	7,505 (1%)	0.025

	Cohort 1			Cohort 2			Cohort 3			Cohort 4		
	Unvaccinated	Vaccinated	ASMD	Unvaccinated	Vaccinated	ASMD	Unvaccinated	Vaccinated	ASMD	Unvaccinated	Vaccinated	ASMD
Myocardial infarction	15,938 (5%)	11,236 (5%)	0.023	20,262 (1%)	33,142 (3%)	0.163	7,401 (0%)	11,237 (1%)	0.035	5,781 (0%)	861 (0%)	0.026
Osteoporosis	29,704 (9%)	22,986 (10%)	0.063	18,255 (1%)	42,319 (4%)	0.216	8,856 (1%)	12,455 (1%)	0.031	6,980 (0%)	1,380 (0%)	0.015
Pneumonia	16,837 (5%)	12,101 (6%)	0.028	31,706 (2%)	33,170 (3%)	0.116	17,787 (1%)	20,399 (1%)	0.018	13,425 (1%)	4,297 (1%)	0.017
Rheumatoid arthritis	6,549 (2%)	4,544 (2%)	0.012	14,813 (1%)	20,294 (2%)	0.114	5,536 (0%)	8,463 (1%)	0.030	3,723 (0%)	821 (0%)	0.007
Stroke	15,118 (4%)	10,876 (5%)	0.027	16,944 (1%)	24,851 (3%)	0.132	7,424 (0%)	9,547 (1%)	0.021	6,059 (0%)	1,153 (0%)	0.016
Venous thromboembolism	19,455 (6%)	13,782 (6%)	0.026	28,887 (1%)	39,415 (4%)	0.159	13,609 (1%)	24,312 (2%)	0.067	13,021 (1%)	1,936 (0%)	0.039

The 4 cohorts represent vaccine rollout periods. *Calculated as the days of previous observation in the database before index date. **Assessed anytime before index date. ASMD = Absolute standardized mean difference, COPD = Chronic obstructive pulmonary disease, GERD = Gastro-Esophageal reflux disease

Table S5: Characteristics of weighted populations in CPRD AURUM, database, stratified by staggered cohort and exposure status. Exposure is BNT162b2 vaccine.

	Cohort 1			Cohort 2			Cohort 3			Cohort 4		
	Unvaccinated	Vaccinated	ASMD	Unvaccinated	Vaccinated	ASMD	Unvaccinated	Vaccinated	ASMD	Unvaccinated	Vaccinated	ASMD
N (individuals)	105,853	106,684		255,400	253,164		37,236	37,227		630,449	633,628	
Age, median [Q25-Q75]	80 [77-85]	80 [77-85]	0.003	58 [46-67]	58 [46-68]	0.006	54 [45-64]	54 [45-64]	0.016	32 [25-37]	32 [25-37]	0.001
Sex: Female, N(%)	60,612 (57%)	60,891 (57%)	0.004	147,020 (58%)	146,572 (58%)	0.007	22,049 (59%)	22,144 (59%)	0.005	278,649 (44%)	282,744 (45%)	0.009
Years of prior history*, median [Q25-Q75]	24 [11-36]	24 [11-35]	0.005	18 [8-29]	18 [8-29]	0.007	16 [7-27]	17 [7-27]	0.007	7 [4-16]	7 [3-18]	0.006
Number visits, median [Q25-Q75]	10 [5-18]	10 [6-17]		8 [3-15]	10 [5-15]		6 [2-15]	8 [4-14]		2 [0-6]	2 [0-6]	
Number pcrs, median [Q25-Q75]	0[0-0]	0[0-0]		0[0-0]	0[0-0]		0[0-0]	0[0-0]		0[0-0]	0[0-0]	
Comorbidities**, N(%)												
Anxiety	15,706 (15%)	15,578 (15%)	0.007	57,951 (23%)	55,594 (22%)	0.018	7,672 (21%)	7,363 (20%)	0.021	96,918 (15%)	96,528 (15%)	0.004
Asthma	11,563 (11%)	11,733 (11%)	0.002	60,265 (24%)	58,010 (23%)	0.016	6,397 (17%)	6,215 (17%)	0.013	50,849 (8%)	48,590 (8%)	0.015
Chronic kidney disease	25,741 (24%)	26,243 (25%)	0.007	17,219 (7%)	18,864 (7%)	0.028	2,790 (7%)	2,621 (7%)	0.017	2,035 (0%)	1,846 (0%)	0.006
COPD	9,240 (9%)	8,999 (8%)	0.011	11,625 (5%)	12,410 (5%)	0.017	1,224 (3%)	886 (2%)	0.055	859 (0%)	807 (0%)	0.002
Dementia	6,683 (6%)	5,727 (5%)	0.040	2,225 (1%)	1,309 (1%)	0.043	618 (2%)	529 (1%)	0.019	112 (0%)	107 (0%)	0.001
Depressive disorder	12,529 (12%)	12,450 (12%)	0.005	52,883 (21%)	50,765 (20%)	0.016	6,588 (18%)	6,431 (17%)	0.011	71,832 (11%)	71,139 (11%)	0.005
Diabetes	20,227 (19%)	20,182 (19%)	0.005	32,557 (13%)	32,989 (13%)	0.008	3,153 (8%)	3,212 (9%)	0.006	8,183 (1%)	7,675 (1%)	0.008
GERD	6,148 (6%)	5,937 (6%)	0.011	12,436 (5%)	12,160 (5%)	0.003	1,552 (4%)	1,509 (4%)	0.006	9,586 (2%)	10,173 (2%)	0.007
Heart failure	6,643 (6%)	6,329 (6%)	0.014	4,618 (2%)	3,987 (2%)	0.018	767 (2%)	552 (1%)	0.044	474 (0%)	344 (0%)	0.008
Hypertension	56,732 (54%)	57,023 (53%)	0.003	62,628 (25%)	63,500 (25%)	0.013	7,802 (21%)	7,697 (21%)	0.007	11,603 (2%)	12,098 (2%)	0.005
Hypothyroidism	10,528 (10%)	10,633 (10%)	0.001	16,084 (6%)	16,368 (6%)	0.007	2,046 (5%)	2,032 (5%)	0.002	8,722 (1%)	8,355 (1%)	0.006
Malignant neoplastic disease	23,367 (22%)	23,618 (22%)	0.002	19,432 (8%)	22,945 (9%)	0.053	2,799 (8%)	2,742 (7%)	0.006	3,432 (1%)	2,913 (0%)	0.012

	Cohort 1			Cohort 2			Cohort 3			Cohort 4		
	Unvaccinated	Vaccinated	ASMD	Unvaccinated	Vaccinated	ASMD	Unvaccinated	Vaccinated	ASMD	Unvaccinated	Vaccinated	ASMD
Myocardial infarction	5,451 (5%)	5,473 (5%)	0.001	6,811 (3%)	7,856 (3%)	0.026	704 (2%)	637 (2%)	0.013	607 (0%)	569 (0%)	0.002
Osteoporosis	10,923 (10%)	10,997 (10%)	0.000	6,664 (3%)	6,208 (2%)	0.010	1,166 (3%)	1,014 (3%)	0.024	653 (0%)	702 (0%)	0.002
Pneumonia	5,814 (5%)	5,303 (5%)	0.023	7,059 (3%)	6,337 (3%)	0.016	991 (3%)	831 (2%)	0.028	3,698 (1%)	3,579 (1%)	0.003
Rheumatoid arthritis	2,115 (2%)	2,076 (2%)	0.004	4,061 (2%)	4,486 (2%)	0.014	330 (1%)	382 (1%)	0.014	723 (0%)	523 (0%)	0.010
Stroke	5,304 (5%)	4,911 (5%)	0.019	5,139 (2%)	5,592 (2%)	0.014	657 (2%)	560 (2%)	0.021	828 (0%)	669 (0%)	0.007
Venous thromboembolism	6,564 (6%)	6,603 (6%)	0.000	7,760 (3%)	7,984 (3%)	0.007	980 (3%)	965 (3%)	0.003	2,860 (0%)	1,602 (0%)	0.034

The 4 cohorts represent vaccine rollout periods. *Calculated as the days of previous observation in the database before index date. **Assessed anytime before index date. ASMD = Absolute standardized mean difference, COPD = Chronic obstructive pulmonary disease, GERD = Gastro-Esophageal reflux disease

Table S6: Characteristics of unweighted populations in CPRD AURUM, database, stratified by staggered cohort and exposure status. Exposure is BNT162b2 vaccine.

	Cohort 1			Cohort 2			Cohort 3			Cohort 4		
	Unvaccinated	Vaccinated	ASMD	Unvaccinated	Vaccinated	ASMD	Unvaccinated	Vaccinated	ASMD	Unvaccinated	Vaccinated	ASMD
N (individuals)	348,052	332,790		1,976,163	594,262		1,510,323	54,102		2,014,161	1,335,671	
Age, median [Q25-Q75]	78 [76-82]	82 [79-86]	0.375	42 [32-55]	67 [56-73]	0.899	41 [31-53]	58 [50-82]	0.777	35 [27-45]	31 [25-37]	0.377
Sex: Female, N(%)	193,520 (56%)	186,481 (56%)	0.009	1,244,798 (63%)	324,259 (55%)	0.172	880,418 (58%)	32,310 (60%)	0.029	856,596 (43%)	625,195 (47%)	0.086
Years of prior history*, median [Q25-Q75]	23 [10-35]	26 [13-38]	0.081	15 [7-25]	21 [9-32]	0.261	13 [6-22]	19 [8-30]	0.308	8 [4-16]	7 [3-19]	0.012
Number visits, median [Q25-Q75]	10 [5-17]	11 [6-18]		6 [2-11]	11 [6-17]		4 [1-10]	10 [5-17]		2 [0-5]	3 [1-7]	
Number pcrs, median [Q25-Q75]	0[0-0]	0[0-0]		0[0-0]	0[0-0]		0[0-0]	0[0-0]		0[0-0]	0[0-0]	
Comorbidities**, N(%)												
Anxiety	51,245 (15%)	49,410 (15%)	0.003	435,705 (22%)	122,087 (21%)	0.037	289,623 (19%)	10,441 (19%)	0.003	264,577 (13%)	218,144 (16%)	0.090
Asthma	36,625 (11%)	37,889 (11%)	0.028	501,289 (25%)	116,596 (20%)	0.138	294,101 (19%)	8,668 (16%)	0.090	137,548 (7%)	114,378 (9%)	0.065
Chronic kidney disease	71,413 (21%)	86,899 (26%)	0.133	55,136 (3%)	56,923 (10%)	0.285	24,372 (2%)	6,692 (12%)	0.431	18,579 (1%)	2,664 (0%)	0.097
COPD	28,829 (8%)	28,317 (9%)	0.008	29,793 (2%)	39,595 (7%)	0.263	13,430 (1%)	2,063 (4%)	0.194	10,501 (1%)	942 (0%)	0.083
Dementia	16,828 (5%)	16,138 (5%)	0.001	6,731 (0%)	3,720 (1%)	0.041	3,424 (0%)	1,323 (2%)	0.194	2,673 (0%)	119 (0%)	0.047
Depressive disorder	42,297 (12%)	37,831 (11%)	0.024	367,534 (19%)	112,753 (19%)	0.010	236,577 (16%)	9,046 (17%)	0.029	209,905 (10%)	155,037 (12%)	0.038
Diabetes	63,483 (18%)	61,929 (19%)	0.010	107,471 (5%)	98,676 (17%)	0.362	60,945 (4%)	5,817 (11%)	0.259	49,143 (2%)	12,040 (1%)	0.120
GERD	18,404 (5%)	20,204 (6%)	0.034	68,110 (3%)	32,288 (5%)	0.097	39,607 (3%)	2,506 (5%)	0.108	31,062 (2%)	21,599 (2%)	0.006
Heart failure	17,980 (5%)	20,430 (6%)	0.042	12,311 (1%)	13,120 (2%)	0.134	5,627 (0%)	1,529 (3%)	0.197	4,614 (0%)	448 (0%)	0.054
Hypertension	173,422 (50%)	186,367 (56%)	0.124	206,136 (10%)	200,762 (34%)	0.586	110,969 (7%)	15,536 (29%)	0.579	86,231 (4%)	19,649 (1%)	0.169
Hypothyroidism	31,595 (9%)	34,512 (10%)	0.044	78,935 (4%)	44,456 (7%)	0.150	43,876 (3%)	3,642 (7%)	0.179	30,913 (2%)	18,516 (1%)	0.012
Malignant neoplastic disease	69,247 (20%)	82,610 (25%)	0.118	60,370 (3%)	76,103 (13%)	0.367	29,693 (2%)	6,311 (12%)	0.392	22,630 (1%)	5,104 (0%)	0.086

	Cohort 1			Cohort 2			Cohort 3			Cohort 4		
	Unvaccinated	Vaccinated	ASMD	Unvaccinated	Vaccinated	ASMD	Unvaccinated	Vaccinated	ASMD	Unvaccinated	Vaccinated	ASMD
Myocardial infarction	16,111 (5%)	18,289 (5%)	0.040	20,304 (1%)	23,019 (4%)	0.185	7,409 (0%)	1,464 (3%)	0.177	5,738 (0%)	715 (0%)	0.056
Osteoporosis	30,053 (9%)	36,535 (11%)	0.079	18,282 (1%)	21,789 (4%)	0.184	8,852 (1%)	2,632 (5%)	0.265	6,904 (0%)	1,028 (0%)	0.058
Pneumonia	17,134 (5%)	16,297 (5%)	0.001	31,724 (2%)	17,567 (3%)	0.091	17,791 (1%)	1,658 (3%)	0.131	13,263 (1%)	7,793 (1%)	0.010
Rheumatoid arthritis	6,613 (2%)	6,693 (2%)	0.008	14,823 (1%)	12,878 (2%)	0.118	5,533 (0%)	667 (1%)	0.097	3,692 (0%)	891 (0%)	0.033
Stroke	15,325 (4%)	15,601 (5%)	0.014	16,962 (1%)	15,056 (3%)	0.130	7,431 (0%)	1,281 (2%)	0.158	6,019 (0%)	1,022 (0%)	0.051
Venous thromboembolism	19,679 (6%)	21,549 (6%)	0.034	28,882 (1%)	23,632 (4%)	0.155	13,639 (1%)	1,980 (4%)	0.185	12,941 (1%)	2,541 (0%)	0.070

The 4 cohorts represent vaccine rollout periods. *Calculated as the days of previous observation in the database before index date. **Assessed anytime before index date. ASMD = Absolute standardized mean difference, COPD = Chronic obstructive pulmonary disease, GERD = Gastro-Esophageal reflux disease

Table S7: Characteristics of weighted populations in CPRD GOLD, database, stratified by staggered cohort and exposure status. Exposure is any COVID-19 vaccine.

	Cohort 1			Cohort 2			Cohort 3			Cohort 4		
	Unvaccinated	Vaccinated	ASMD	Unvaccinated	Vaccinated	ASMD	Unvaccinated	Vaccinated	ASMD	Unvaccinated	Vaccinated	ASMD
N (individuals)	40,084	40,014		111,674	111,393		124,883	124,955		196,235	195,302	
Age, median [Q25-Q75]	82 [78-86]	82 [78-86]	0.004	62 [50-69]	62 [50-69]	0.005	50 [41-58]	52 [41-58]	0.000	34 [26-42]	34 [26-43]	0.004
Sex: Female, N(%)	23,206 (58%)	23,175 (58%)	0.000	63,290 (57%)	63,079 (57%)	0.001	63,572 (51%)	63,955 (51%)	0.006	84,762 (43%)	85,083 (44%)	0.007
Years of prior history*, median [Q25-Q75]	17 [13-20]	18 [13-20]	0.001	17 [11-19]	17 [11-19]	0.005	17 [9-19]	17 [9-19]	0.000	13 [6-18]	14 [5-18]	0.006
Number visits, median [Q25-Q75]	12 [7-20]	12 [8-20]		8 [3-15]	10 [5-15]		4 [0-10]	4 [1-10]		0 [0-5]	2 [0-5]	
Number pcrs, median [Q25-Q75]	0[0-0]	0[0-0]		0[0-0]	0[0-0]		0[0-0]	0[0-0]		0[0-0]	0[0-0]	
Comorbidities**, N(%)												
Anxiety	4,933 (12%)	4,920 (12%)	0.000	22,884 (20%)	22,299 (20%)	0.012	24,993 (20%)	24,695 (20%)	0.006	31,360 (16%)	30,689 (16%)	0.007
Asthma	3,911 (10%)	3,931 (10%)	0.002	18,514 (17%)	18,209 (16%)	0.006	17,431 (14%)	17,388 (14%)	0.001	14,817 (8%)	14,596 (7%)	0.003
Chronic kidney disease	8,998 (22%)	8,953 (22%)	0.002	6,848 (6%)	7,431 (7%)	0.022	2,120 (2%)	2,287 (2%)	0.010	922 (0%)	807 (0%)	0.009
COPD	3,439 (9%)	3,341 (8%)	0.008	5,972 (5%)	6,496 (6%)	0.021	2,089 (2%)	1,938 (2%)	0.010	734 (0%)	688 (0%)	0.004
Dementia	2,634 (7%)	2,332 (6%)	0.031	1,383 (1%)	865 (1%)	0.046	283 (0%)	313 (0%)	0.005	78 (0%)	134 (0%)	0.013
Depressive disorder	3,783 (9%)	3,705 (9%)	0.006	20,874 (19%)	20,246 (18%)	0.013	22,015 (18%)	21,682 (17%)	0.007	23,010 (12%)	22,630 (12%)	0.004
Diabetes	5,928 (15%)	5,802 (14%)	0.008	11,000 (10%)	11,657 (10%)	0.020	5,345 (4%)	5,651 (5%)	0.012	2,586 (1%)	2,366 (1%)	0.009
GERD	1,930 (5%)	1,970 (5%)	0.005	4,521 (4%)	4,479 (4%)	0.001	3,343 (3%)	3,346 (3%)	0.000	2,657 (1%)	2,614 (1%)	0.001
Heart failure	2,417 (6%)	2,205 (6%)	0.022	2,002 (2%)	2,029 (2%)	0.002	639 (1%)	614 (0%)	0.003	250 (0%)	207 (0%)	0.006
Hypertension	14,288 (36%)	14,282 (36%)	0.001	22,488 (20%)	22,695 (20%)	0.006	11,108 (9%)	11,313 (9%)	0.006	4,318 (2%)	4,619 (2%)	0.011
Hypothyroidism	3,151 (8%)	3,155 (8%)	0.001	6,321 (6%)	6,361 (6%)	0.002	4,134 (3%)	4,055 (3%)	0.004	2,475 (1%)	2,621 (1%)	0.007
Malignant neoplastic disease	8,302 (21%)	8,283 (21%)	0.000	8,661 (8%)	10,177 (9%)	0.050	3,813 (3%)	3,777 (3%)	0.002	1,614 (1%)	1,676 (1%)	0.004

	Cohort 1			Cohort 2			Cohort 3			Cohort 4		
	Unvaccinated	Vaccinated	ASMD	Unvaccinated	Vaccinated	ASMD	Unvaccinated	Vaccinated	ASMD	Unvaccinated	Vaccinated	ASMD
Myocardial infarction	2,119 (5%)	1,984 (5%)	0.015	3,308 (3%)	3,740 (3%)	0.023	1,193 (1%)	1,267 (1%)	0.006	430 (0%)	343 (0%)	0.010
Osteoporosis	3,702 (9%)	3,670 (9%)	0.002	3,154 (3%)	3,179 (3%)	0.002	1,038 (1%)	1,030 (1%)	0.001	363 (0%)	375 (0%)	0.002
Pneumonia	1,654 (4%)	1,452 (4%)	0.026	2,424 (2%)	2,211 (2%)	0.013	1,401 (1%)	1,314 (1%)	0.007	1,035 (1%)	1,055 (1%)	0.002
Rheumatoid arthritis	637 (2%)	624 (2%)	0.002	1,618 (1%)	1,818 (2%)	0.015	551 (0%)	760 (1%)	0.023	280 (0%)	157 (0%)	0.019
Stroke	2,103 (5%)	1,866 (5%)	0.027	2,468 (2%)	2,512 (2%)	0.003	916 (1%)	981 (1%)	0.006	385 (0%)	356 (0%)	0.003
Venous thromboembolism	1,732 (4%)	1,648 (4%)	0.010	2,639 (2%)	2,596 (2%)	0.002	1,466 (1%)	1,638 (1%)	0.012	959 (0%)	518 (0%)	0.036

The 4 cohorts represent vaccine rollout periods. *Calculated as the days of previous observation in the database before index date. **Assessed anytime before index date. ASMD = Absolute standardized mean difference, COPD = Chronic obstructive pulmonary disease, GERD = Gastro-Esophageal reflux disease

Table S8: Characteristics of unweighted populations in CPRD GOLD, database, stratified by staggered cohort and exposure status. Exposure is any COVID-19 vaccine.

	Cohort 1			Cohort 2			Cohort 3			Cohort 4		
	Unvaccinated	Vaccinated	ASMD	Unvaccinated	Vaccinated	ASMD	Unvaccinated	Vaccinated	ASMD	Unvaccinated	Vaccinated	ASMD
N (individuals)	169,100	118,507		583,399	486,619		417,996	462,832		469,876	550,437	
Age, median [Q25-Q75]	78 [76-82]	84 [81-87]	0.550	45 [33-58]	71 [66-75]	1.117	42 [31-55]	56 [52-61]	0.546	37 [28-49]	35 [27-43]	0.250
Sex: Female, N(%)	93,719 (55%)	68,258 (58%)	0.044	344,747 (59%)	262,113 (54%)	0.106	230,567 (55%)	230,957 (50%)	0.105	208,184 (44%)	249,603 (45%)	0.021
Years of prior history*, median [Q25-Q75]	17 [13-20]	18 [14-20]	0.023	17 [10-19]	17 [13-20]	0.085	17 [9-19]	17 [10-19]	0.055	13 [6-18]	14 [6-18]	0.020
Number visits, median [Q25-Q75]	11 [6-18]	14 [9-21]		5 [1-11]	11 [6-17]		3 [0-8]	6 [2-12]		0 [0-4]	2 [0-6]	
Number pcrs, median [Q25-Q75]	0[0-0]	0[0-0]		0[0-0]	0[0-0]		0[0-0]	0[0-0]		0[0-0]	0[0-0]	
Comorbidities**, N(%)												
Anxiety	20,097 (12%)	14,878 (13%)	0.020	132,282 (23%)	78,442 (16%)	0.166	83,022 (20%)	83,629 (18%)	0.046	65,306 (14%)	88,512 (16%)	0.061
Asthma	15,573 (9%)	12,090 (10%)	0.034	119,520 (20%)	61,821 (13%)	0.210	68,746 (16%)	52,312 (11%)	0.149	30,811 (7%)	46,774 (8%)	0.074
Chronic kidney disease	29,343 (17%)	29,934 (25%)	0.194	15,484 (3%)	49,550 (10%)	0.311	6,676 (2%)	8,145 (2%)	0.013	4,746 (1%)	1,376 (0%)	0.096
COPD	14,248 (8%)	9,602 (8%)	0.012	12,247 (2%)	39,371 (8%)	0.275	5,114 (1%)	6,699 (1%)	0.020	3,716 (1%)	953 (0%)	0.089
Dementia	6,678 (4%)	6,860 (6%)	0.086	1,986 (0%)	6,557 (1%)	0.110	1,188 (0%)	636 (0%)	0.032	774 (0%)	159 (0%)	0.044
Depressive disorder	16,339 (10%)	10,720 (9%)	0.021	111,568 (19%)	72,063 (15%)	0.115	66,705 (16%)	77,560 (17%)	0.022	50,341 (11%)	64,215 (12%)	0.030
Diabetes	23,579 (14%)	17,895 (15%)	0.033	29,125 (5%)	66,688 (14%)	0.303	12,407 (3%)	25,465 (6%)	0.126	9,225 (2%)	5,012 (1%)	0.089
GERD	7,610 (5%)	6,174 (5%)	0.033	18,053 (3%)	22,884 (5%)	0.083	8,864 (2%)	15,586 (3%)	0.076	5,920 (1%)	8,482 (2%)	0.024
Heart failure	7,475 (4%)	7,118 (6%)	0.071	4,013 (1%)	12,939 (3%)	0.154	1,732 (0%)	2,410 (1%)	0.016	1,274 (0%)	293 (0%)	0.054
Hypertension	56,298 (33%)	44,709 (38%)	0.093	58,662 (10%)	139,644 (29%)	0.485	24,457 (6%)	64,451 (14%)	0.273	16,440 (3%)	11,991 (2%)	0.080
Hypothyroidism	12,126 (7%)	9,825 (8%)	0.042	22,026 (4%)	31,923 (7%)	0.126	10,616 (3%)	19,001 (4%)	0.087	6,676 (1%)	7,790 (1%)	0.000
Malignant neoplastic disease	30,687 (18%)	26,725 (23%)	0.110	19,781 (3%)	65,779 (14%)	0.370	8,870 (2%)	19,474 (4%)	0.119	5,916 (1%)	4,164 (1%)	0.050

	Cohort 1			Cohort 2			Cohort 3			Cohort 4		
	Unvaccinated	Vaccinated	ASMD	Unvaccinated	Vaccinated	ASMD	Unvaccinated	Vaccinated	ASMD	Unvaccinated	Vaccinated	ASMD
Myocardial infarction	7,707 (5%)	6,298 (5%)	0.035	8,409 (1%)	20,200 (4%)	0.165	2,665 (1%)	5,556 (1%)	0.059	2,003 (0%)	501 (0%)	0.066
Osteoporosis	12,736 (8%)	11,677 (10%)	0.082	5,836 (1%)	23,843 (5%)	0.232	2,580 (1%)	4,797 (1%)	0.046	1,855 (0%)	637 (0%)	0.055
Pneumonia	5,401 (3%)	4,381 (4%)	0.028	7,250 (1%)	12,120 (2%)	0.092	3,822 (1%)	4,889 (1%)	0.014	2,522 (1%)	2,797 (1%)	0.004
Rheumatoid arthritis	2,565 (2%)	1,833 (2%)	0.002	4,013 (1%)	9,000 (2%)	0.104	1,294 (0%)	2,566 (1%)	0.037	877 (0%)	316 (0%)	0.037
Stroke	7,214 (4%)	5,843 (5%)	0.032	5,886 (1%)	14,921 (3%)	0.146	2,170 (1%)	3,998 (1%)	0.042	1,591 (0%)	620 (0%)	0.048
Venous thromboembolism	6,188 (4%)	5,096 (4%)	0.033	7,342 (1%)	14,077 (3%)	0.115	3,067 (1%)	6,732 (1%)	0.069	2,611 (1%)	1,018 (0%)	0.061

The 4 cohorts represent vaccine rollout periods. *Calculated as the days of previous observation in the database before index date. **Assessed anytime before index date. ASMD = Absolute standardized mean difference, COPD = Chronic obstructive pulmonary disease, GERD = Gastro-Esophageal reflux disease

Table S9: Characteristics of weighted populations in CPRD GOLD, database, stratified by staggered cohort and exposure status. Exposure is ChAdOx1 vaccine.

	Cohort 1			Cohort 2			Cohort 3			Cohort 4		
	Unvaccinated	Vaccinated	ASMD	Unvaccinated	Vaccinated	ASMD	Unvaccinated	Vaccinated	ASMD	Unvaccinated	Vaccinated	ASMD
N (individuals)	29,163	29,082		82,091	82,226		116,090	115,912		70,312	70,823	
Age, median [Q25-Q75]	82 [79-87]	82 [80-87]	0.002	64 [53-71]	64 [53-70]	0.001	52 [42-58]	52 [42-58]	0.003	42 [39-48]	42 [38-48]	0.000
Sex: Female, N(%)	17,126 (59%)	17,076 (59%)	0.000	45,269 (55%)	45,487 (55%)	0.003	58,599 (50%)	58,799 (51%)	0.005	29,480 (42%)	29,458 (42%)	0.007
Years of prior history*, median [Q25-Q75]	17 [13-20]	17 [14-20]	0.001	17 [11-19]	17 [11-19]	0.002	17 [9-19]	17 [8-19]	0.001	14 [7-18]	14 [6-18]	0.001
Number visits, median [Q25-Q75]	12 [7-21]	12 [8-20]		8 [3-16]	10 [5-16]		4 [0-10]	4 [1-10]		0 [0-6]	2 [0-6]	
Number pcrs, median [Q25-Q75]	0[0-0]	0[0-0]		0[0-0]	0[0-0]		0[0-0]	0[0-0]		0[0-0]	0[0-0]	
Comorbidities**, N(%)												
Anxiety	3,481 (12%)	3,496 (12%)	0.003	16,202 (20%)	15,970 (19%)	0.008	23,083 (20%)	22,695 (20%)	0.008	12,154 (17%)	11,947 (17%)	0.011
Asthma	2,863 (10%)	2,870 (10%)	0.002	13,358 (16%)	13,192 (16%)	0.006	16,057 (14%)	16,029 (14%)	0.000	4,767 (7%)	4,744 (7%)	0.003
Chronic kidney disease	6,959 (24%)	6,928 (24%)	0.001	5,850 (7%)	6,384 (8%)	0.024	2,031 (2%)	2,104 (2%)	0.005	616 (1%)	517 (1%)	0.016
COPD	2,556 (9%)	2,485 (9%)	0.008	5,069 (6%)	5,523 (7%)	0.022	1,969 (2%)	1,874 (2%)	0.006	539 (1%)	478 (1%)	0.011
Dementia	2,042 (7%)	1,794 (6%)	0.034	1,319 (2%)	826 (1%)	0.053	263 (0%)	265 (0%)	0.000	59 (0%)	111 (0%)	0.021
Depressive disorder	2,641 (9%)	2,608 (9%)	0.003	14,875 (18%)	14,558 (18%)	0.011	20,497 (18%)	20,298 (18%)	0.004	10,492 (15%)	10,218 (14%)	0.014
Diabetes	4,346 (15%)	4,273 (15%)	0.006	8,933 (11%)	9,524 (12%)	0.022	5,139 (4%)	5,350 (5%)	0.009	1,459 (2%)	1,421 (2%)	0.005
GERD	1,366 (5%)	1,380 (5%)	0.003	3,514 (4%)	3,414 (4%)	0.006	3,153 (3%)	3,136 (3%)	0.001	1,258 (2%)	1,297 (2%)	0.003
Heart failure	1,844 (6%)	1,699 (6%)	0.020	1,793 (2%)	1,720 (2%)	0.006	613 (1%)	601 (1%)	0.001	177 (0%)	151 (0%)	0.008
Hypertension	10,466 (36%)	10,581 (36%)	0.010	17,843 (22%)	18,115 (22%)	0.007	10,489 (9%)	10,714 (9%)	0.007	3,119 (4%)	3,233 (5%)	0.006
Hypothyroidism	2,338 (8%)	2,360 (8%)	0.004	4,857 (6%)	4,837 (6%)	0.001	3,897 (3%)	3,742 (3%)	0.007	1,432 (2%)	1,412 (2%)	0.003
Malignant neoplastic disease	6,210 (21%)	6,164 (21%)	0.002	7,090 (9%)	8,270 (10%)	0.049	3,588 (3%)	3,590 (3%)	0.000	1,059 (2%)	1,117 (2%)	0.006
Myocardial infarction	1,569 (5%)	1,500 (5%)	0.010	2,720 (3%)	3,083 (4%)	0.024	1,155 (1%)	1,202 (1%)	0.004	319 (0%)	242 (0%)	0.018

	Cohort 1			Cohort 2			Cohort 3			Cohort 4		
	Unvaccinated	Vaccinated	ASMD	Unvaccinated	Vaccinated	ASMD	Unvaccinated	Vaccinated	ASMD	Unvaccinated	Vaccinated	ASMD
Osteoporosis	2,838 (10%)	2,846 (10%)	0.002	2,715 (3%)	2,668 (3%)	0.004	944 (1%)	986 (1%)	0.004	252 (0%)	281 (0%)	0.006
Pneumonia	1,287 (4%)	1,147 (4%)	0.024	1,997 (2%)	1,883 (2%)	0.009	1,307 (1%)	1,245 (1%)	0.005	487 (1%)	473 (1%)	0.003
Rheumatoid arthritis	464 (2%)	445 (2%)	0.005	1,280 (2%)	1,491 (2%)	0.020	514 (0%)	743 (1%)	0.027	184 (0%)	120 (0%)	0.020
Stroke	1,600 (5%)	1,421 (5%)	0.027	2,073 (3%)	2,122 (3%)	0.003	873 (1%)	963 (1%)	0.009	263 (0%)	257 (0%)	0.002
Venous thromboembolism	1,339 (5%)	1,191 (4%)	0.024	2,112 (3%)	2,219 (3%)	0.008	1,407 (1%)	1,572 (1%)	0.013	590 (1%)	297 (0%)	0.053

The 4 cohorts represent vaccine rollout periods. *Calculated as the days of previous observation in the database before index date. **Assessed anytime before index date. ASMD = Absolute standardized mean difference, COPD = Chronic obstructive pulmonary disease, GERD = Gastro-Esophageal reflux disease

Table S10: Characteristics of unweighted populations in CPRD GOLD, database, stratified by staggered cohort and exposure status. Exposure is ChAdOx1 vaccine.

	Cohort 1			Cohort 2			Cohort 3			Cohort 4		
	Unvaccinated	Vaccinated	ASMD	Unvaccinated	Vaccinated	ASMD	Unvaccinated	Vaccinated	ASMD	Unvaccinated	Vaccinated	ASMD
N (individuals)	168,972	82,406		582,791	302,999		418,184	423,876		485,154	147,744	
Age, median [Q25-Q75]	78 [76-82]	84 [82-88]	0.657	45 [33-58]	71 [66-76]	1.153	42 [31-55]	56 [52-61]	0.560	37 [28-49]	44 [41-48]	0.262
Sex: Female, N(%)	93,648 (55%)	47,915 (58%)	0.055	344,408 (59%)	162,753 (54%)	0.109	230,680 (55%)	210,283 (50%)	0.111	215,080 (44%)	64,999 (44%)	0.007
Years of prior history*, median [Q25-Q75]	17 [13-20]	17 [14-20]	0.016	17 [10-19]	17 [13-19]	0.090	17 [9-19]	17 [10-19]	0.047	13 [6-18]	14 [7-18]	0.054
Number visits, median [Q25-Q75]	11 [6-18]	14 [9-21]		5 [1-11]	11 [7-18]		3 [0-8]	6 [2-12]		0 [0-4]	3 [0-7]	
Number pcrs, median [Q25-Q75]	0[0-0]	0[0-0]		0[0-0]	0[0-0]		0[0-0]	0[0-0]		0[0-0]	0[0-0]	
Comorbidities**, N(%)												
Anxiety	20,087 (12%)	9,923 (12%)	0.005	132,145 (23%)	49,010 (16%)	0.165	83,054 (20%)	75,258 (18%)	0.054	66,918 (14%)	24,601 (17%)	0.080
Asthma	15,567 (9%)	8,491 (10%)	0.037	119,442 (20%)	39,988 (13%)	0.196	68,792 (16%)	48,034 (11%)	0.148	31,538 (7%)	10,517 (7%)	0.025
Chronic kidney disease	29,280 (17%)	21,564 (26%)	0.216	15,435 (3%)	34,168 (11%)	0.344	6,675 (2%)	7,553 (2%)	0.014	4,947 (1%)	739 (1%)	0.060
COPD	14,234 (8%)	6,837 (8%)	0.005	12,242 (2%)	27,472 (9%)	0.307	5,122 (1%)	6,334 (1%)	0.023	3,834 (1%)	640 (0%)	0.046
Dementia	6,664 (4%)	4,773 (6%)	0.086	1,998 (0%)	5,124 (2%)	0.135	1,201 (0%)	548 (0%)	0.035	831 (0%)	126 (0%)	0.024
Depressive disorder	16,333 (10%)	6,998 (8%)	0.041	111,526 (19%)	45,154 (15%)	0.113	66,763 (16%)	70,703 (17%)	0.019	51,687 (11%)	21,711 (15%)	0.122
Diabetes	23,547 (14%)	12,387 (15%)	0.031	29,089 (5%)	43,647 (14%)	0.322	12,392 (3%)	24,219 (6%)	0.135	9,455 (2%)	2,254 (2%)	0.032
GERD	7,613 (5%)	4,054 (5%)	0.020	18,044 (3%)	14,294 (5%)	0.084	8,869 (2%)	14,447 (3%)	0.079	6,051 (1%)	2,883 (2%)	0.056
Heart failure	7,468 (4%)	5,058 (6%)	0.077	4,016 (1%)	9,180 (3%)	0.174	1,738 (0%)	2,308 (1%)	0.019	1,316 (0%)	191 (0%)	0.032
Hypertension	56,262 (33%)	31,217 (38%)	0.096	58,578 (10%)	88,833 (29%)	0.499	24,450 (6%)	59,554 (14%)	0.277	16,971 (3%)	6,761 (5%)	0.055
Hypothyroidism	12,132 (7%)	7,042 (9%)	0.051	21,999 (4%)	20,521 (7%)	0.134	10,622 (3%)	17,382 (4%)	0.087	6,848 (1%)	3,245 (2%)	0.059
Malignant neoplastic disease	30,670 (18%)	18,950 (23%)	0.120	19,707 (3%)	42,687 (14%)	0.386	8,893 (2%)	17,903 (4%)	0.120	6,143 (1%)	2,192 (1%)	0.019

	Cohort 1			Cohort 2			Cohort 3			Cohort 4		
	Unvaccinated	Vaccinated	ASMD	Unvaccinated	Vaccinated	ASMD	Unvaccinated	Vaccinated	ASMD	Unvaccinated	Vaccinated	ASMD
Myocardial infarction	7,704 (5%)	4,500 (5%)	0.041	8,413 (1%)	13,456 (4%)	0.178	2,660 (1%)	5,280 (1%)	0.063	2,057 (0%)	330 (0%)	0.035
Osteoporosis	12,732 (8%)	8,564 (10%)	0.100	5,847 (1%)	16,117 (5%)	0.249	2,576 (1%)	4,330 (1%)	0.045	1,923 (0%)	408 (0%)	0.021
Pneumonia	5,401 (3%)	3,231 (4%)	0.039	7,241 (1%)	8,604 (3%)	0.113	3,814 (1%)	4,527 (1%)	0.016	2,615 (1%)	921 (1%)	0.011
Rheumatoid arthritis	2,559 (2%)	1,257 (2%)	0.001	4,017 (1%)	5,999 (2%)	0.113	1,286 (0%)	2,405 (1%)	0.039	918 (0%)	191 (0%)	0.015
Stroke	7,200 (4%)	4,193 (5%)	0.039	5,885 (1%)	10,213 (3%)	0.162	2,167 (1%)	3,789 (1%)	0.045	1,625 (0%)	369 (0%)	0.016
Venous thromboembolism	6,185 (4%)	3,550 (4%)	0.033	7,335 (1%)	9,466 (3%)	0.128	3,072 (1%)	6,339 (1%)	0.073	2,712 (1%)	460 (0%)	0.038

The 4 cohorts represent vaccine rollout periods. *Calculated as the days of previous observation in the database before index date. **Assessed anytime before index date. ASMD = Absolute standardized mean difference, COPD = Chronic obstructive pulmonary disease, GERD = Gastro-Esophageal reflux disease

Table S11: Characteristics of weighted populations in CPRD GOLD, database, stratified by staggered cohort and exposure status. Exposure is BNT162b2 vaccine.

	Cohort 1			Cohort 2			Cohort 3			Cohort 4		
	Unvaccinated	Vaccinated	ASMD	Unvaccinated	Vaccinated	ASMD	Unvaccinated	Vaccinated	ASMD	Unvaccinated	Vaccinated	ASMD
N (individuals)	15,295	15,304		60,813	61,113		24,008	24,157		151,713	152,100	
Age, median [Q25-Q75]	80 [77-85]	80 [77-85]	0.000	64 [53-70]	66 [52-70]	0.008	52 [44-58]	52 [44-58]	0.004	32 [24-38]	32 [24-38]	0.003
Sex: Female, N(%)	8,644 (57%)	8,657 (57%)	0.001	34,612 (57%)	34,776 (57%)	0.000	12,846 (54%)	12,993 (54%)	0.006	66,947 (44%)	67,555 (44%)	0.006
Years of prior history*, median [Q25-Q75]	17 [12-20]	18 [12-21]	0.001	17 [12-19]	17 [11-19]	0.003	17 [11-19]	17 [11-19]	0.004	13 [6-18]	14 [5-18]	0.001
Number visits, median [Q25-Q75]	12 [7-20]	12 [8-20]		8 [3-15]	8 [4-15]		4 [0-10]	4 [1-10]		0 [0-5]	2 [0-5]	
Number pcrs, median [Q25-Q75]	0[0-0]	0[0-0]		0[0-0]	0[0-0]		0[0-0]	0[0-0]		0[0-0]	0[0-0]	
Comorbidities**, N(%)												
Anxiety	1,969 (13%)	1,940 (13%)	0.006	11,790 (19%)	11,914 (19%)	0.003	5,342 (22%)	5,235 (22%)	0.014	24,455 (16%)	23,928 (16%)	0.011
Asthma	1,498 (10%)	1,488 (10%)	0.002	9,126 (15%)	9,093 (15%)	0.004	2,926 (12%)	2,985 (12%)	0.005	12,195 (8%)	11,929 (8%)	0.007
Chronic kidney disease	3,112 (20%)	3,057 (20%)	0.009	3,563 (6%)	3,764 (6%)	0.013	398 (2%)	407 (2%)	0.002	468 (0%)	346 (0%)	0.016
COPD	1,190 (8%)	1,151 (8%)	0.010	3,222 (5%)	3,237 (5%)	0.000	293 (1%)	274 (1%)	0.008	315 (0%)	250 (0%)	0.010
Dementia	1,087 (7%)	864 (6%)	0.060	646 (1%)	355 (1%)	0.053	55 (0%)	80 (0%)	0.019	21 (0%)	28 (0%)	0.004
Depressive disorder	1,527 (10%)	1,496 (10%)	0.007	10,709 (18%)	10,912 (18%)	0.006	4,382 (18%)	4,343 (18%)	0.007	17,112 (11%)	16,594 (11%)	0.012
Diabetes	2,193 (14%)	2,173 (14%)	0.004	6,057 (10%)	6,199 (10%)	0.006	883 (4%)	858 (4%)	0.007	1,609 (1%)	1,271 (1%)	0.023
GERD	880 (6%)	872 (6%)	0.003	2,440 (4%)	2,505 (4%)	0.004	659 (3%)	706 (3%)	0.011	1,935 (1%)	1,961 (1%)	0.001
Heart failure	857 (6%)	748 (5%)	0.032	1,097 (2%)	933 (2%)	0.022	119 (0%)	77 (0%)	0.027	107 (0%)	77 (0%)	0.008
Hypertension	5,338 (35%)	5,312 (35%)	0.004	12,828 (21%)	12,901 (21%)	0.000	2,597 (11%)	2,645 (11%)	0.004	2,260 (1%)	2,369 (2%)	0.006
Hypothyroidism	1,129 (7%)	1,067 (7%)	0.016	3,476 (6%)	3,416 (6%)	0.005	935 (4%)	954 (4%)	0.003	1,772 (1%)	1,653 (1%)	0.008
Malignant neoplastic disease	3,126 (20%)	3,097 (20%)	0.005	5,084 (8%)	5,529 (9%)	0.024	864 (4%)	922 (4%)	0.011	877 (1%)	902 (1%)	0.002
Myocardial infarction	764 (5%)	681 (4%)	0.026	1,797 (3%)	1,853 (3%)	0.005	230 (1%)	186 (1%)	0.020	189 (0%)	128 (0%)	0.013

	Cohort 1			Cohort 2			Cohort 3			Cohort 4		
	Unvaccinated	Vaccinated	ASMD	Unvaccinated	Vaccinated	ASMD	Unvaccinated	Vaccinated	ASMD	Unvaccinated	Vaccinated	ASMD
Osteoporosis	1,312 (9%)	1,225 (8%)	0.021	1,775 (3%)	1,805 (3%)	0.002	251 (1%)	282 (1%)	0.012	154 (0%)	135 (0%)	0.004
Pneumonia	573 (4%)	475 (3%)	0.035	1,232 (2%)	1,107 (2%)	0.016	256 (1%)	244 (1%)	0.005	744 (0%)	698 (0%)	0.005
Rheumatoid arthritis	248 (2%)	234 (2%)	0.008	854 (1%)	945 (2%)	0.012	113 (0%)	102 (0%)	0.007	165 (0%)	62 (0%)	0.025
Stroke	739 (5%)	650 (4%)	0.028	1,291 (2%)	1,297 (2%)	0.000	172 (1%)	129 (1%)	0.023	204 (0%)	138 (0%)	0.013
Venous thromboembolism	640 (4%)	622 (4%)	0.006	1,355 (2%)	1,347 (2%)	0.002	273 (1%)	256 (1%)	0.008	604 (0%)	288 (0%)	0.039

The 4 cohorts represent vaccine rollout periods. *Calculated as the days of previous observation in the database before index date. **Assessed anytime before index date. ASMD = Absolute standardized mean difference, COPD = Chronic obstructive pulmonary disease, GERD = Gastro-Esophageal reflux disease

Table S12: Characteristics of unweighted populations in CPRD GOLD, database, stratified by staggered cohort and exposure status. Exposure is BNT162b2 vaccine.

	Cohort 1			Cohort 2			Cohort 3			Cohort 4		
	Unvaccinated	Vaccinated	ASMD	Unvaccinated	Vaccinated	ASMD	Unvaccinated	Vaccinated	ASMD	Unvaccinated	Vaccinated	ASMD
N (individuals)	169,459	32,755		584,309	180,670		416,549	36,748		465,326	365,096	
Age, median [Q25-Q75]	78 [76-82]	81 [79-86]	0.306	45 [33-58]	70 [66-74]	1.059	42 [31-55]	54 [50-60]	0.407	37 [28-49]	31 [24-37]	0.445
Sex: Female, N(%)	93,939 (55%)	18,415 (56%)	0.016	345,249 (59%)	97,747 (54%)	0.101	229,807 (55%)	19,649 (53%)	0.034	206,080 (44%)	167,510 (46%)	0.032
Years of prior history*, median [Q25-Q75]	17 [13-20]	18 [13-21]	0.017	17 [10-19]	17 [12-19]	0.076	17 [9-19]	18 [12-20]	0.153	13 [6-18]	15 [6-18]	0.018
Number visits, median [Q25-Q75]	11 [6-18]	14 [9-21]		5 [1-11]	10 [6-16]		3 [0-8]	6 [2-11]		0 [0-4]	2 [0-6]	
Number pcrs, median [Q25-Q75]	0[0-0]	0[0-0]		0[0-0]	0[0-0]		0[0-0]	0[0-0]		0[0-0]	0[0-0]	
Comorbidities**, N(%)												
Anxiety	20,145 (12%)	4,336 (13%)	0.041	132,397 (23%)	28,697 (16%)	0.172	82,752 (20%)	8,004 (22%)	0.047	64,849 (14%)	59,094 (16%)	0.063
Asthma	15,611 (9%)	3,250 (10%)	0.024	119,679 (20%)	21,396 (12%)	0.236	68,556 (16%)	4,053 (11%)	0.158	30,579 (7%)	33,240 (9%)	0.094
Chronic kidney disease	29,378 (17%)	7,430 (23%)	0.134	15,504 (3%)	15,033 (8%)	0.251	6,636 (2%)	566 (2%)	0.004	4,692 (1%)	578 (0%)	0.112
COPD	14,265 (8%)	2,417 (7%)	0.039	12,276 (2%)	11,545 (6%)	0.214	5,085 (1%)	348 (1%)	0.026	3,657 (1%)	285 (0%)	0.108
Dementia	6,705 (4%)	1,895 (6%)	0.085	2,008 (0%)	1,375 (1%)	0.056	1,168 (0%)	87 (0%)	0.009	746 (0%)	29 (0%)	0.053
Depressive disorder	16,385 (10%)	3,310 (10%)	0.015	111,708 (19%)	26,294 (15%)	0.122	66,510 (16%)	6,569 (18%)	0.051	49,969 (11%)	39,181 (11%)	0.000
Diabetes	23,614 (14%)	4,882 (15%)	0.028	29,200 (5%)	22,552 (12%)	0.267	12,338 (3%)	1,191 (3%)	0.016	9,143 (2%)	2,507 (1%)	0.112
GERD	7,655 (5%)	2,012 (6%)	0.072	18,069 (3%)	8,525 (5%)	0.084	8,839 (2%)	1,093 (3%)	0.054	5,864 (1%)	5,213 (1%)	0.015
Heart failure	7,502 (4%)	1,782 (5%)	0.047	4,026 (1%)	3,669 (2%)	0.116	1,715 (0%)	100 (0%)	0.024	1,236 (0%)	98 (0%)	0.063
Hypertension	56,411 (33%)	11,995 (37%)	0.070	58,749 (10%)	49,763 (28%)	0.459	24,301 (6%)	4,679 (13%)	0.239	16,363 (4%)	4,776 (1%)	0.144
Hypothyroidism	12,163 (7%)	2,373 (7%)	0.003	22,061 (4%)	11,106 (6%)	0.109	10,565 (3%)	1,553 (4%)	0.094	6,617 (1%)	4,180 (1%)	0.025
Malignant neoplastic disease	30,728 (18%)	6,972 (21%)	0.079	19,832 (3%)	22,617 (13%)	0.342	8,827 (2%)	1,522 (4%)	0.116	5,804 (1%)	1,796 (0%)	0.081

	Cohort 1			Cohort 2			Cohort 3			Cohort 4		
	Unvaccinated	Vaccinated	ASMD	Unvaccinated	Vaccinated	ASMD	Unvaccinated	Vaccinated	ASMD	Unvaccinated	Vaccinated	ASMD
Myocardial infarction	7,716 (5%)	1,603 (5%)	0.016	8,437 (1%)	6,621 (4%)	0.141	2,644 (1%)	271 (1%)	0.012	1,985 (0%)	154 (0%)	0.080
Osteoporosis	12,776 (8%)	2,770 (8%)	0.034	5,867 (1%)	7,531 (4%)	0.200	2,558 (1%)	458 (1%)	0.066	1,841 (0%)	205 (0%)	0.072
Pneumonia	5,415 (3%)	1,032 (3%)	0.003	7,266 (1%)	3,418 (2%)	0.052	3,790 (1%)	345 (1%)	0.003	2,512 (1%)	1,696 (0%)	0.011
Rheumatoid arthritis	2,566 (2%)	512 (2%)	0.004	4,018 (1%)	2,929 (2%)	0.087	1,276 (0%)	154 (0%)	0.019	881 (0%)	111 (0%)	0.048
Stroke	7,203 (4%)	1,490 (5%)	0.015	5,907 (1%)	4,632 (3%)	0.117	2,152 (1%)	199 (1%)	0.003	1,578 (0%)	225 (0%)	0.062
Venous thromboembolism	6,198 (4%)	1,389 (4%)	0.030	7,333 (1%)	4,490 (2%)	0.091	3,056 (1%)	370 (1%)	0.029	2,585 (1%)	496 (0%)	0.072

The 4 cohorts represent vaccine rollout periods. *Calculated as the days of previous observation in the database before index date. **Assessed anytime before index date. ASMD = Absolute standardized mean difference, COPD = Chronic obstructive pulmonary disease, GERD = Gastro-Esophageal reflux disease

Table S13: Characteristics of weighted populations in SIDIAP, database, stratified by staggered cohort and exposure status. Exposure is any COVID-19 vaccine.

	Cohort 1			Cohort 2			Cohort 3			Cohort 4		
	Unvaccinated	Vaccinated	ASMD	Unvaccinated	Vaccinated	ASMD	Unvaccinated	Vaccinated	ASMD	Unvaccinated	Vaccinated	ASMD
N (individuals)	58,342	58,535		235,543	235,780		344,520	342,678		413,428	412,893	
Age, median [Q25-Q75]	86 [83-89]	86 [82-89]	0.002	68 [63-73]	68 [63-74]	0.003	52 [46-58]	52 [46-59]	0.000	36 [28-44]	36 [28-44]	0.002
Sex: Female, N(%)	36,115 (62%)	36,214 (62%)	0.001	128,806 (55%)	129,053 (55%)	0.001	164,316 (48%)	163,188 (48%)	0.001	188,426 (46%)	188,471 (46%)	0.001
Years of prior history*, median [Q25-Q75]	15 [15-15]	15 [15-15]	0.001	15 [15-15]	15 [15-15]	0.000	15 [15-15]	15 [15-15]	0.003	15 [13-16]	15 [13-16]	0.004
Number visits, median [Q25-Q75]	8 [3-15]	8 [4-15]		4 [0-9]	4 [1-9]		0 [0-6]	2 [0-6]		0 [0-4]	0 [0-5]	
Number pcrs, median [Q25-Q75]	0[0-0]	0[0-0]		0[0-0]	0[0-0]		0[0-0]	0[0-0]		0[0-0]	0[0-0]	
Comorbidities**, N(%)												
Anxiety	11,384 (20%)	11,467 (20%)	0.002	52,314 (22%)	52,262 (22%)	0.001	81,514 (24%)	80,775 (24%)	0.002	84,856 (21%)	83,145 (20%)	0.010
Asthma	3,708 (6%)	3,627 (6%)	0.007	10,973 (5%)	10,703 (5%)	0.006	14,915 (4%)	14,492 (4%)	0.005	19,969 (5%)	19,628 (5%)	0.004
Chronic kidney disease	18,755 (32%)	18,803 (32%)	0.001	21,147 (9%)	21,249 (9%)	0.001	7,411 (2%)	7,335 (2%)	0.001	3,293 (1%)	2,846 (1%)	0.012
COPD	7,008 (12%)	6,983 (12%)	0.002	17,160 (7%)	16,784 (7%)	0.006	8,852 (3%)	8,622 (3%)	0.003	3,210 (1%)	3,215 (1%)	0.000
Dementia	5,686 (10%)	5,812 (10%)	0.006	4,628 (2%)	4,425 (2%)	0.006	1,247 (0%)	1,229 (0%)	0.001	673 (0%)	689 (0%)	0.001
Depressive disorder	10,960 (19%)	11,020 (19%)	0.001	34,232 (15%)	34,571 (15%)	0.004	34,243 (10%)	32,427 (9%)	0.016	23,679 (6%)	23,024 (6%)	0.007
Diabetes	14,529 (25%)	14,269 (24%)	0.012	39,335 (17%)	39,133 (17%)	0.003	25,964 (8%)	26,135 (8%)	0.003	14,136 (3%)	14,091 (3%)	0.000
GERD	6,898 (12%)	6,871 (12%)	0.003	21,088 (9%)	21,212 (9%)	0.002	16,959 (5%)	17,024 (5%)	0.002	10,569 (3%)	10,903 (3%)	0.005
Heart failure	9,320 (16%)	9,141 (16%)	0.010	10,251 (4%)	10,196 (4%)	0.001	4,001 (1%)	3,743 (1%)	0.007	1,606 (0%)	1,565 (0%)	0.002
Hypertension	38,140 (65%)	37,917 (65%)	0.013	96,384 (41%)	96,118 (41%)	0.003	58,596 (17%)	57,241 (17%)	0.008	22,160 (5%)	22,739 (6%)	0.006
Hypothyroidism	7,350 (13%)	7,236 (12%)	0.007	24,054 (10%)	24,260 (10%)	0.003	21,956 (6%)	21,573 (6%)	0.003	17,452 (4%)	17,758 (4%)	0.004
Malignant neoplastic disease	15,402 (26%)	15,230 (26%)	0.009	37,052 (16%)	38,490 (16%)	0.016	19,765 (6%)	19,599 (6%)	0.001	9,413 (2%)	8,865 (2%)	0.009

	Cohort 1			Cohort 2			Cohort 3			Cohort 4		
	Unvaccinated	Vaccinated	ASMD	Unvaccinated	Vaccinated	ASMD	Unvaccinated	Vaccinated	ASMD	Unvaccinated	Vaccinated	ASMD
Myocardial infarction	2,258 (4%)	2,235 (4%)	0.003	5,972 (3%)	5,812 (2%)	0.005	3,615 (1%)	3,448 (1%)	0.004	1,362 (0%)	1,364 (0%)	0.000
Osteoporosis	9,270 (16%)	9,151 (16%)	0.007	18,870 (8%)	19,036 (8%)	0.002	7,126 (2%)	7,039 (2%)	0.001	2,254 (1%)	2,040 (0%)	0.007
Pneumonia	6,643 (11%)	6,563 (11%)	0.005	15,630 (7%)	15,557 (7%)	0.002	14,821 (4%)	14,580 (4%)	0.002	14,171 (3%)	14,083 (3%)	0.001
Rheumatoid arthritis	765 (1%)	727 (1%)	0.006	2,274 (1%)	2,286 (1%)	0.000	1,544 (0%)	1,592 (0%)	0.002	754 (0%)	646 (0%)	0.006
Stroke	5,119 (9%)	5,043 (9%)	0.006	8,750 (4%)	7,706 (3%)	0.024	4,343 (1%)	4,147 (1%)	0.005	1,828 (0%)	1,840 (0%)	0.001
Venous thromboembolism	2,469 (4%)	2,418 (4%)	0.005	4,745 (2%)	4,419 (2%)	0.010	3,365 (1%)	2,982 (1%)	0.011	1,931 (0%)	1,777 (0%)	0.005

The 4 cohorts represent vaccine rollout periods. *Calculated as the days of previous observation in the database before index date. **Assessed anytime before index date. ASMD = Absolute standardized mean difference, COPD = Chronic obstructive pulmonary disease, GERD = Gastro-Esophageal reflux disease

Table S14: Characteristics of unweighted populations in SIDIAP, database, stratified by staggered cohort and exposure status. Exposure is any COVID-19 vaccine.

	Cohort 1			Cohort 2			Cohort 3			Cohort 4		
	Unvaccinated	Vaccinated	ASMD	Unvaccinated	Vaccinated	ASMD	Unvaccinated	Vaccinated	ASMD	Unvaccinated	Vaccinated	ASMD
N (individuals)	223,962	89,941		433,151	819,590		869,497	954,232		1,061,634	880,950	
Age, median [Q25-Q75]	85 [82-88]	87 [83-90]	0.253	67 [62-72]	72 [65-78]	0.391	48 [43-57]	54 [49-58]	0.192	38 [28-51]	37 [29-43]	0.246
Sex: Female, N(%)	136,888 (61%)	56,235 (63%)	0.029	237,494 (55%)	443,019 (54%)	0.016	409,207 (47%)	462,599 (48%)	0.028	488,499 (46%)	408,555 (46%)	0.007
Years of prior history*, median [Q25-Q75]	15 [15-15]	15 [15-15]	0.051	15 [15-15]	15 [15-15]	0.185	15 [15-15]	15 [15-15]	0.246	15 [10-16]	15 [15-16]	0.195
Number visits, median [Q25-Q75]	7 [2-13]	10 [5-18]		3 [0-8]	6 [2-11]		1 [0-5]	2 [0-7]		0 [0-4]	2 [0-6]	
Number pcrs, median [Q25-Q75]	0[0-0]	0[0-1]		0[0-0]	0[0-1]		0[0-0]	0[0-1]		0[0-0]	0[0-1]	
Comorbidities**, N(%)												
Anxiety	41,908 (19%)	18,117 (20%)	0.036	97,857 (23%)	181,286 (22%)	0.011	197,922 (23%)	233,123 (24%)	0.039	203,019 (19%)	186,562 (21%)	0.051
Asthma	13,371 (6%)	5,841 (6%)	0.022	19,809 (5%)	41,966 (5%)	0.025	36,811 (4%)	42,221 (4%)	0.009	45,374 (4%)	46,776 (5%)	0.049
Chronic kidney disease	63,041 (28%)	31,132 (35%)	0.140	32,450 (7%)	101,792 (12%)	0.165	22,454 (3%)	20,303 (2%)	0.030	20,368 (2%)	5,314 (1%)	0.118
COPD	24,459 (11%)	11,292 (13%)	0.051	28,780 (7%)	67,795 (8%)	0.062	19,020 (2%)	27,451 (3%)	0.044	15,415 (1%)	5,836 (1%)	0.077
Dementia	16,743 (7%)	10,455 (12%)	0.142	7,404 (2%)	19,153 (2%)	0.045	6,009 (1%)	2,787 (0%)	0.057	5,866 (1%)	1,310 (0%)	0.068
Depressive disorder	38,148 (17%)	18,040 (20%)	0.078	61,308 (14%)	124,929 (15%)	0.031	77,039 (9%)	98,723 (10%)	0.050	66,864 (6%)	49,608 (6%)	0.028
Diabetes	51,964 (23%)	22,968 (26%)	0.054	65,572 (15%)	155,362 (19%)	0.102	60,254 (7%)	78,356 (8%)	0.048	49,331 (5%)	29,768 (3%)	0.065
GERD	25,376 (11%)	10,728 (12%)	0.019	34,715 (8%)	87,626 (11%)	0.092	37,828 (4%)	53,565 (6%)	0.058	31,600 (3%)	23,657 (3%)	0.018
Heart failure	28,538 (13%)	16,202 (18%)	0.147	16,697 (4%)	42,924 (5%)	0.066	11,909 (1%)	10,469 (1%)	0.025	10,738 (1%)	2,776 (0%)	0.086
Hypertension	138,631 (62%)	60,128 (67%)	0.104	157,290 (36%)	390,610 (48%)	0.231	125,239 (14%)	188,390 (20%)	0.142	97,835 (9%)	43,351 (5%)	0.168

	Cohort 1			Cohort 2			Cohort 3			Cohort 4		
	Unvaccinated	Vaccinated	ASMD	Unvaccinated	Vaccinated	ASMD	Unvaccinated	Vaccinated	ASMD	Unvaccinated	Vaccinated	ASMD
Hypothyroidism	26,875 (12%)	11,473 (13%)	0.023	42,245 (10%)	89,496 (11%)	0.038	50,396 (6%)	64,873 (7%)	0.041	49,279 (5%)	38,477 (4%)	0.013
Malignant neoplastic disease	54,714 (24%)	24,173 (27%)	0.056	81,394 (19%)	151,745 (19%)	0.007	48,971 (6%)	59,566 (6%)	0.026	37,755 (4%)	18,021 (2%)	0.092
Myocardial infarction	7,886 (4%)	3,642 (4%)	0.028	9,894 (2%)	22,773 (3%)	0.031	7,570 (1%)	11,483 (1%)	0.033	6,171 (1%)	2,459 (0%)	0.046
Osteoporosis	32,239 (14%)	14,846 (17%)	0.058	29,512 (7%)	81,707 (10%)	0.114	16,393 (2%)	21,679 (2%)	0.027	14,373 (1%)	3,343 (0%)	0.105
Pneumonia	22,254 (10%)	10,959 (12%)	0.072	27,837 (6%)	61,325 (7%)	0.042	34,513 (4%)	44,236 (5%)	0.033	36,413 (3%)	32,657 (4%)	0.015
Rheumatoid arthritis	2,666 (1%)	1,204 (1%)	0.013	3,771 (1%)	8,890 (1%)	0.022	3,239 (0%)	4,770 (0%)	0.019	2,706 (0%)	1,281 (0%)	0.024
Stroke	16,690 (7%)	8,542 (9%)	0.073	14,256 (3%)	32,612 (4%)	0.037	10,877 (1%)	12,068 (1%)	0.001	9,400 (1%)	3,384 (0%)	0.063
Venous thromboembolism	8,014 (4%)	4,126 (5%)	0.051	8,172 (2%)	17,846 (2%)	0.021	7,747 (1%)	8,920 (1%)	0.005	6,632 (1%)	3,768 (0%)	0.027

The 4 cohorts represent vaccine rollout periods. *Calculated as the days of previous observation in the database before index date. **Assessed anytime before index date. ASMD = Absolute standardized mean difference, COPD = Chronic obstructive pulmonary disease, GERD = Gastro-Esophageal reflux disease

Table S15: Characteristics of weighted populations in SIDIAP, database, stratified by staggered cohort and exposure status. Exposure is BNT162b2 vaccine.

	Cohort 1			Cohort 2			Cohort 3			Cohort 4		
	Unvaccinated	Vaccinated	ASMD	Unvaccinated	Vaccinated	ASMD	Unvaccinated	Vaccinated	ASMD	Unvaccinated	Vaccinated	ASMD
N (individuals)	57,981	57,843		99,838	99,488		276,241	273,593		312,492	313,346	
Age, median [Q25-Q75]	86 [83-89]	86 [82-89]	0.000	74 [71-81]	74 [72-81]	0.006	50 [45-56]	50 [45-56]	0.003	36 [29-43]	36 [29-43]	0.004
Sex: Female, N(%)	35,828 (62%)	35,895 (62%)	0.005	58,343 (58%)	57,844 (58%)	0.006	130,375 (47%)	129,701 (47%)	0.004	145,270 (46%)	144,384 (46%)	0.008
Years of prior history*, median [Q25-Q75]	15 [15-15]	15 [15-15]	0.002	15 [15-15]	15 [15-15]	0.005	15 [15-15]	15 [15-15]	0.001	15 [13-16]	15 [14-16]	0.004
Number visits, median [Q25-Q75]	8 [3-15]	8 [4-15]		4 [0-10]	6 [2-10]		0 [0-5]	2 [0-6]		0 [0-4]	0 [0-5]	
Number pcrs, median [Q25-Q75]	0[0-0]	0[0-0]		0[0-0]	0[0-0]		0[0-0]	0[0-0]		0[0-0]	0[0-0]	
Comorbidities**, N(%)												
Anxiety	11,327 (20%)	11,359 (20%)	0.003	20,281 (20%)	20,181 (20%)	0.001	67,000 (24%)	63,263 (23%)	0.027	65,060 (21%)	64,616 (21%)	0.005
Asthma	3,734 (6%)	3,583 (6%)	0.010	5,213 (5%)	5,179 (5%)	0.001	12,220 (4%)	11,760 (4%)	0.006	15,491 (5%)	15,211 (5%)	0.005
Chronic kidney disease	18,610 (32%)	18,576 (32%)	0.000	15,548 (16%)	15,607 (16%)	0.003	5,583 (2%)	5,399 (2%)	0.003	1,999 (1%)	2,008 (1%)	0.000
COPD	6,980 (12%)	6,907 (12%)	0.003	9,163 (9%)	9,045 (9%)	0.003	6,020 (2%)	6,047 (2%)	0.002	1,998 (1%)	2,000 (1%)	0.000
Dementia	5,678 (10%)	5,771 (10%)	0.006	4,152 (4%)	3,716 (4%)	0.022	1,037 (0%)	980 (0%)	0.003	502 (0%)	506 (0%)	0.000
Depressive disorder	10,920 (19%)	10,923 (19%)	0.001	15,653 (16%)	15,532 (16%)	0.002	26,419 (10%)	24,357 (9%)	0.023	17,262 (6%)	17,507 (6%)	0.003
Diabetes	14,416 (25%)	14,096 (24%)	0.011	20,461 (20%)	20,645 (21%)	0.006	19,302 (7%)	18,543 (7%)	0.008	10,119 (3%)	10,440 (3%)	0.005
GERD	6,784 (12%)	6,826 (12%)	0.003	10,187 (10%)	10,088 (10%)	0.002	12,811 (5%)	12,805 (5%)	0.002	7,750 (2%)	8,224 (3%)	0.009
Heart failure	9,390 (16%)	8,983 (16%)	0.018	7,563 (8%)	7,296 (7%)	0.009	3,044 (1%)	2,699 (1%)	0.011	1,069 (0%)	1,049 (0%)	0.001
Hypertension	37,879 (65%)	37,465 (65%)	0.012	51,262 (51%)	50,608 (51%)	0.010	42,266 (15%)	41,291 (15%)	0.006	15,063 (5%)	15,323 (5%)	0.003
Hypothyroidism	7,310 (13%)	7,166 (12%)	0.007	11,611 (12%)	11,249 (11%)	0.010	16,597 (6%)	16,509 (6%)	0.001	13,155 (4%)	13,617 (4%)	0.007
Malignant neoplastic disease	15,302 (26%)	14,971 (26%)	0.012	19,393 (19%)	18,719 (19%)	0.015	14,311 (5%)	13,981 (5%)	0.003	6,555 (2%)	6,398 (2%)	0.004
Myocardial infarction	2,286 (4%)	2,182 (4%)	0.009	3,130 (3%)	2,924 (3%)	0.011	2,569 (1%)	2,451 (1%)	0.004	875 (0%)	880 (0%)	0.000

	Cohort 1			Cohort 2			Cohort 3			Cohort 4		
	Unvaccinated	Vaccinated	ASMD	Unvaccinated	Vaccinated	ASMD	Unvaccinated	Vaccinated	ASMD	Unvaccinated	Vaccinated	ASMD
Osteoporosis	9,170 (16%)	9,085 (16%)	0.003	11,182 (11%)	11,201 (11%)	0.002	4,764 (2%)	4,639 (2%)	0.002	1,344 (0%)	1,306 (0%)	0.002
Pneumonia	6,588 (11%)	6,476 (11%)	0.005	7,945 (8%)	7,918 (8%)	0.000	11,759 (4%)	11,273 (4%)	0.007	10,730 (3%)	10,798 (3%)	0.001
Rheumatoid arthritis	755 (1%)	718 (1%)	0.006	1,064 (1%)	1,111 (1%)	0.005	1,113 (0%)	1,026 (0%)	0.004	536 (0%)	461 (0%)	0.006
Stroke	5,070 (9%)	5,006 (9%)	0.003	5,363 (5%)	5,086 (5%)	0.012	3,121 (1%)	3,043 (1%)	0.002	1,199 (0%)	1,253 (0%)	0.003
Venous thromboembolism	2,452 (4%)	2,378 (4%)	0.006	2,660 (3%)	2,526 (3%)	0.008	2,527 (1%)	2,211 (1%)	0.012	1,394 (0%)	1,327 (0%)	0.003

The 4 cohorts represent vaccine rollout periods. *Calculated as the days of previous observation in the database before index date. **Assessed anytime before index date. ASMD = Absolute standardized mean difference, COPD = Chronic obstructive pulmonary disease, GERD = Gastro-Esophageal reflux disease

Table S16: Characteristics of unweighted populations in SIDIAP, database, stratified by staggered cohort and exposure status. Exposure is BNT162b2 vaccine.

	Cohort 1			Cohort 2			Cohort 3			Cohort 4		
	Unvaccinated	Vaccinated	ASMD	Unvaccinated	Vaccinated	ASMD	Unvaccinated	Vaccinated	ASMD	Unvaccinated	Vaccinated	ASMD
N (individuals)	223,960	88,896		433,111	445,581		869,109	706,435		1,068,043	580,329	
Age, median [Q25-Q75]	85 [82-88]	87 [84-90]	0.258	67 [62-72]	78 [74-83]	0.943	48 [43-57]	53 [48-57]	0.127	38 [28-51]	38 [31-43]	0.231
Sex: Female, N(%)	136,891 (61%)	55,704 (63%)	0.032	237,440 (55%)	254,378 (57%)	0.046	409,076 (47%)	341,289 (48%)	0.025	491,528 (46%)	274,150 (47%)	0.024
Years of prior history*, median [Q25-Q75]	15 [15-15]	15 [15-15]	0.051	15 [15-15]	15 [15-15]	0.206	15 [15-15]	15 [15-15]	0.244	15 [10-16]	15 [15-16]	0.211
Number visits, median [Q25-Q75]	7 [2-13]	10 [5-18]		3 [0-8]	7 [3-12]		1 [0-5]	2 [0-7]		0 [0-4]	2 [0-6]	
Number pcrs, median [Q25-Q75]	0[0-0]	0[0-1]		0[0-0]	0[0-1]		0[0-0]	0[0-1]		0[0-0]	0[0-1]	
Comorbidities**, N(%)												
Anxiety	41,914 (19%)	17,962 (20%)	0.038	97,901 (23%)	91,620 (21%)	0.050	197,933 (23%)	172,434 (24%)	0.039	204,108 (19%)	125,466 (22%)	0.062
Asthma	13,370 (6%)	5,796 (7%)	0.023	19,824 (5%)	25,291 (6%)	0.050	36,788 (4%)	31,586 (4%)	0.012	45,747 (4%)	30,865 (5%)	0.048
Chronic kidney disease	63,046 (28%)	30,745 (35%)	0.139	32,447 (7%)	83,968 (19%)	0.341	22,494 (3%)	13,920 (2%)	0.041	20,416 (2%)	3,171 (1%)	0.124
COPD	24,471 (11%)	11,169 (13%)	0.051	28,773 (7%)	44,207 (10%)	0.119	19,028 (2%)	17,815 (3%)	0.022	15,424 (1%)	3,218 (1%)	0.090
Dementia	16,748 (7%)	10,393 (12%)	0.143	7,389 (2%)	17,606 (4%)	0.136	6,003 (1%)	2,033 (0%)	0.058	5,878 (1%)	856 (0%)	0.068
Depressive disorder	38,161 (17%)	17,894 (20%)	0.079	61,309 (14%)	72,447 (16%)	0.059	77,050 (9%)	69,517 (10%)	0.033	67,070 (6%)	32,476 (6%)	0.029
Diabetes	51,948 (23%)	22,682 (26%)	0.054	65,583 (15%)	99,692 (22%)	0.186	60,242 (7%)	53,330 (8%)	0.024	49,433 (5%)	19,502 (3%)	0.065
GERD	25,370 (11%)	10,611 (12%)	0.019	34,704 (8%)	53,110 (12%)	0.131	37,842 (4%)	37,707 (5%)	0.046	31,662 (3%)	15,544 (3%)	0.017
Heart failure	28,525 (13%)	16,041 (18%)	0.147	16,686 (4%)	34,932 (8%)	0.171	11,920 (1%)	7,057 (1%)	0.034	10,734 (1%)	1,642 (0%)	0.090
Hypertension	138,655 (62%)	59,414 (67%)	0.103	157,291 (36%)	252,365 (57%)	0.416	125,235 (14%)	128,859 (18%)	0.104	97,944 (9%)	26,383 (5%)	0.184

	Cohort 1			Cohort 2			Cohort 3			Cohort 4		
	Unvaccinated	Vaccinated	ASMD	Unvaccinated	Vaccinated	ASMD	Unvaccinated	Vaccinated	ASMD	Unvaccinated	Vaccinated	ASMD
Hypothyroidism	26,868 (12%)	11,363 (13%)	0.024	42,216 (10%)	53,488 (12%)	0.073	50,384 (6%)	46,214 (7%)	0.031	49,424 (5%)	25,961 (4%)	0.007
Malignant neoplastic disease	54,729 (24%)	23,784 (27%)	0.053	81,399 (19%)	96,204 (22%)	0.070	48,967 (6%)	40,510 (6%)	0.004	37,874 (4%)	11,535 (2%)	0.095
Myocardial infarction	7,890 (4%)	3,590 (4%)	0.027	9,892 (2%)	14,140 (3%)	0.055	7,573 (1%)	7,753 (1%)	0.023	6,182 (1%)	1,405 (0%)	0.053
Osteoporosis	32,250 (14%)	14,701 (17%)	0.059	29,528 (7%)	56,885 (13%)	0.201	16,385 (2%)	14,126 (2%)	0.008	14,380 (1%)	1,876 (0%)	0.113
Pneumonia	22,249 (10%)	10,811 (12%)	0.071	27,831 (6%)	38,127 (9%)	0.081	34,511 (4%)	31,972 (5%)	0.028	36,645 (3%)	21,355 (4%)	0.013
Rheumatoid arthritis	2,666 (1%)	1,189 (1%)	0.013	3,769 (1%)	5,143 (1%)	0.028	3,242 (0%)	2,843 (0%)	0.005	2,700 (0%)	812 (0%)	0.026
Stroke	16,693 (7%)	8,475 (10%)	0.075	14,244 (3%)	24,307 (5%)	0.106	10,868 (1%)	8,114 (1%)	0.009	9,394 (1%)	2,033 (0%)	0.068
Venous thromboembolism	8,023 (4%)	4,072 (5%)	0.050	8,162 (2%)	12,564 (3%)	0.062	7,738 (1%)	6,066 (1%)	0.003	6,658 (1%)	2,434 (0%)	0.028

The 4 cohorts represent vaccine rollout periods. *Calculated as the days of previous observation in the database before index date. **Assessed anytime before index date. ASMD = Absolute standardized mean difference, COPD = Chronic obstructive pulmonary disease, GERD = Gastro-Esophageal reflux disease

Table S17: Characteristics of weighted populations in SIDIAP, database, stratified by staggered cohort and exposure status. Exposure is ChAdOx1 vaccine.

	Cohort 2			Cohort 3		
	Unvaccinated	Vaccinated	ASMD	Unvaccinated	Vaccinated	ASMD
N (individuals)	120,307	120,802		44,033	43,901	
Age, median [Q25-Q75]	64 [61-66]	64 [61-66]	0.000	64 [61-66]	64 [61-67]	0.002
Sex: Female, N(%)	62,434 (52%)	62,425 (52%)	0.004	23,009 (52%)	22,980 (52%)	0.002
Years of prior history*, median [Q25-Q75]	15 [15-15]	15 [15-15]	0.003	15 [15-15]	15 [15-15]	0.005
Number visits, median [Q25-Q75]	2 [0-7]	4 [1-8]		2 [0-7]	2 [0-7]	
Number pcrs, median [Q25-Q75]	0[0-0]	0[0-0]		0[0-0]	0[0-0]	
Comorbidities**, N(%)						
Anxiety	28,213 (23%)	27,989 (23%)	0.007	10,333 (23%)	9,717 (22%)	0.032
Asthma	4,909 (4%)	4,785 (4%)	0.006	1,664 (4%)	1,639 (4%)	0.002
Chronic kidney disease	4,390 (4%)	4,526 (4%)	0.005	1,556 (4%)	1,597 (4%)	0.006
COPD	6,702 (6%)	6,846 (6%)	0.004	2,405 (5%)	2,350 (5%)	0.005
Dementia	470 (0%)	397 (0%)	0.010	170 (0%)	171 (0%)	0.000
Depressive disorder	16,483 (14%)	16,258 (13%)	0.007	5,940 (13%)	5,813 (13%)	0.007
Diabetes	16,127 (13%)	16,418 (14%)	0.005	5,698 (13%)	5,705 (13%)	0.002
GERD	9,580 (8%)	9,569 (8%)	0.002	3,206 (7%)	3,216 (7%)	0.002
Heart failure	2,268 (2%)	2,236 (2%)	0.003	844 (2%)	847 (2%)	0.001
Hypertension	39,422 (33%)	39,551 (33%)	0.001	13,589 (31%)	13,737 (31%)	0.009
Hypothyroidism	10,965 (9%)	11,173 (9%)	0.005	4,002 (9%)	3,830 (9%)	0.013
Malignant neoplastic disease	12,621 (10%)	12,418 (10%)	0.007	4,304 (10%)	3,910 (9%)	0.030
Myocardial infarction	2,553 (2%)	2,500 (2%)	0.004	888 (2%)	868 (2%)	0.003
Osteoporosis	6,687 (6%)	6,679 (6%)	0.001	2,155 (5%)	2,200 (5%)	0.005
Pneumonia	6,452 (5%)	6,392 (5%)	0.003	2,243 (5%)	2,167 (5%)	0.007
Rheumatoid arthritis	1,009 (1%)	931 (1%)	0.008	337 (1%)	259 (1%)	0.021
Stroke	2,693 (2%)	2,582 (2%)	0.007	965 (2%)	1,000 (2%)	0.006
Venous thromboembolism	1,686 (1%)	1,469 (1%)	0.016	659 (1%)	541 (1%)	0.023

The 4 cohorts represent vaccine rollout periods. *Calculated as the days of previous observation in the database before index date. **Assessed anytime before index date. ASMD = Absolute standardized mean difference, COPD = Chronic obstructive pulmonary disease, GERD = Gastro-Esophageal reflux disease

Table S18: Characteristics of unweighted populations in SIDIAP, database, stratified by staggered cohort and exposure status. Exposure is ChAdOx1 vaccine.

	Cohort 2			Cohort 3		
	Unvaccinated	Vaccinated	ASMD	Unvaccinated	Vaccinated	ASMD
N (individuals)	433,636	323,204		873,400	84,204	
Age, median [Q25-Q75]	67 [62-72]	64 [62-67]	0.241	48 [43-57]	64 [61-67]	0.986
Sex: Female, N(%)	237,722 (55%)	162,269 (50%)	0.093	411,107 (47%)	44,374 (53%)	0.113
Years of prior history*, median [Q25-Q75]	15 [15-15]	15 [15-15]	0.158	15 [15-15]	15 [15-15]	0.281
Number visits, median [Q25-Q75]	3 [0-8]	4 [1-9]		1 [0-5]	4 [1-8]	
Number pcrs, median [Q25-Q75]	0[0-0]	0[0-1]		0[0-0]	0[0-0]	
Comorbidities**, N(%)						
Anxiety	97,950 (23%)	77,793 (24%)	0.035	198,282 (23%)	19,626 (23%)	0.014
Asthma	19,861 (5%)	13,894 (4%)	0.014	36,915 (4%)	3,283 (4%)	0.017
Chronic kidney disease	32,497 (7%)	12,206 (4%)	0.162	22,570 (3%)	3,199 (4%)	0.069
COPD	28,826 (7%)	18,658 (6%)	0.036	19,103 (2%)	4,996 (6%)	0.191
Dementia	7,407 (2%)	1,009 (0%)	0.140	6,041 (1%)	345 (0%)	0.038
Depressive disorder	61,377 (14%)	44,463 (14%)	0.011	77,249 (9%)	11,874 (14%)	0.166
Diabetes	65,666 (15%)	45,453 (14%)	0.031	60,383 (7%)	12,142 (14%)	0.245
GERD	34,755 (8%)	28,610 (9%)	0.030	37,840 (4%)	6,754 (8%)	0.154
Heart failure	16,741 (4%)	5,636 (2%)	0.129	11,981 (1%)	1,703 (2%)	0.050
Hypertension	157,484 (36%)	114,179 (35%)	0.021	125,527 (14%)	28,314 (34%)	0.463
Hypothyroidism	42,257 (10%)	30,350 (9%)	0.012	50,476 (6%)	7,763 (9%)	0.131
Malignant neoplastic disease	81,510 (19%)	36,352 (11%)	0.212	49,066 (6%)	7,842 (9%)	0.141
Myocardial infarction	9,910 (2%)	7,242 (2%)	0.003	7,561 (1%)	1,784 (2%)	0.103
Osteoporosis	29,546 (7%)	19,864 (6%)	0.027	16,434 (2%)	4,382 (5%)	0.180
Pneumonia	27,865 (6%)	18,329 (6%)	0.032	34,617 (4%)	4,445 (5%)	0.063
Rheumatoid arthritis	3,762 (1%)	2,557 (1%)	0.008	3,246 (0%)	535 (1%)	0.037
Stroke	14,284 (3%)	6,369 (2%)	0.083	10,884 (1%)	1,915 (2%)	0.078
Venous thromboembolism	8,163 (2%)	3,613 (1%)	0.063	7,746 (1%)	1,110 (1%)	0.041

The 4 cohorts represent vaccine rollout periods. *Calculated as the days of previous observation in the database before index date. **Assessed anytime before index date. ASMD = Absolute standardized mean difference, COPD = Chronic obstructive pulmonary disease, GERD = Gastro-Esophageal reflux disease

Table S19: Characteristics of weighted populations in CORIVA, database, stratified by staggered cohort and exposure status. Exposure is any COVID-19 vaccine.

	Cohort 1			Cohort 2			Cohort 3			Cohort 4		
	Unvaccinated	Vaccinated	ASMD	Unvaccinated	Vaccinated	ASMD	Unvaccinated	Vaccinated	ASMD	Unvaccinated	Vaccinated	ASMD
N (individuals)	10,630	10,630		3,863	3,863		17,929	17,929		18,740	18,740	
Age, median [Q25-Q75]	78 [72-83]	78 [72-83]	0.000	70 [65-75]	70 [65-75]	0.000	52 [45-59]	50 [45-59]	0.000	40 [30-51]	40 [30-51]	0.000
Sex: Female, N(%)	7,165 (67%)	7,165 (67%)	0.000	2,439 (63%)	2,439 (63%)	0.000	9,054 (50%)	9,054 (50%)	0.000	8,493 (45%)	8,493 (45%)	0.000
Years of prior history*, median [Q25-Q75]	4 [4-4]	4 [4-4]	0.000	4 [4-4]	4 [4-4]	0.000	4 [4-4]	4 [4-4]	0.000	5 [4-5]	5 [4-5]	0.000
Number visits, median [Q25-Q75]	14 [4-24]	14 [6-23]		12 [3-23]	12 [5-22]		2 [0-11]	4 [1-10]		2 [0-8]	2 [0-8]	
Number pcrs, median [Q25-Q75]	0[0-0]	0[0-0]		0[0-0]	0[0-0]		0[0-0]	0[0-0]		0[0-0]	0[0-0]	
Comorbidities**, N(%)												
Anxiety	1,060 (10%)	1,076 (10%)	0.005	405 (10%)	415 (11%)	0.008	1,545 (9%)	1,500 (8%)	0.009	1,552 (8%)	1,495 (8%)	0.011
Asthma	996 (9%)	917 (9%)	0.026	372 (10%)	365 (9%)	0.006	936 (5%)	894 (5%)	0.011	845 (5%)	782 (4%)	0.016
Chronic kidney disease	1,015 (10%)	999 (9%)	0.005	336 (9%)	309 (8%)	0.025	347 (2%)	339 (2%)	0.003	212 (1%)	194 (1%)	0.009
COPD	757 (7%)	723 (7%)	0.012	264 (7%)	258 (7%)	0.006	442 (2%)	417 (2%)	0.009	318 (2%)	249 (1%)	0.030
Dementia	438 (4%)	412 (4%)	0.013	106 (3%)	90 (2%)	0.027	120 (1%)	131 (1%)	0.008	71 (0%)	70 (0%)	0.001
Depressive disorder	1,076 (10%)	1,083 (10%)	0.002	462 (12%)	433 (11%)	0.023	1,787 (10%)	1,764 (10%)	0.004	1,679 (9%)	1,739 (9%)	0.011
Diabetes	1,861 (18%)	1,833 (17%)	0.007	640 (17%)	588 (15%)	0.037	1,012 (6%)	963 (5%)	0.012	814 (4%)	764 (4%)	0.014
GERD	1,416 (13%)	1,458 (14%)	0.011	523 (14%)	531 (14%)	0.006	1,562 (9%)	1,600 (9%)	0.007	1,166 (6%)	1,172 (6%)	0.001
Heart failure	3,898 (37%)	3,839 (36%)	0.011	1,003 (26%)	970 (25%)	0.020	1,348 (8%)	1,324 (7%)	0.005	781 (4%)	737 (4%)	0.012
Hypertension	8,016 (75%)	8,221 (77%)	0.045	2,569 (67%)	2,641 (68%)	0.040	5,521 (31%)	5,643 (31%)	0.015	3,359 (18%)	3,538 (19%)	0.025
Hypothyroidism	1,218 (11%)	1,160 (11%)	0.017	419 (11%)	428 (11%)	0.007	981 (5%)	948 (5%)	0.008	654 (3%)	675 (4%)	0.006
Malignant neoplastic disease	1,655 (16%)	1,732 (16%)	0.020	640 (17%)	659 (17%)	0.013	771 (4%)	782 (4%)	0.003	455 (2%)	453 (2%)	0.001
Myocardial infarction	269 (3%)	264 (2%)	0.003	86 (2%)	71 (2%)	0.026	127 (1%)	116 (1%)	0.008	81 (0%)	75 (0%)	0.005
Osteoporosis	675 (6%)	685 (6%)	0.004	187 (5%)	176 (5%)	0.013	233 (1%)	230 (1%)	0.001	131 (1%)	146 (1%)	0.009
Pneumonia	771 (7%)	768 (7%)	0.001	249 (6%)	244 (6%)	0.005	657 (4%)	670 (4%)	0.004	567 (3%)	562 (3%)	0.002
Rheumatoid arthritis	268 (3%)	273 (3%)	0.003	139 (4%)	122 (3%)	0.024	209 (1%)	187 (1%)	0.012	130 (1%)	116 (1%)	0.009

	Cohort 1			Cohort 2			Cohort 3			Cohort 4		
	Unvaccinated	Vaccinated	ASMD	Unvaccinated	Vaccinated	ASMD	Unvaccinated	Vaccinated	ASMD	Unvaccinated	Vaccinated	ASMD
Stroke	460 (4%)	461 (4%)	0.001	147 (4%)	144 (4%)	0.004	179 (1%)	189 (1%)	0.006	112 (1%)	116 (1%)	0.003
Venous thromboembolism	469 (4%)	472 (4%)	0.001	171 (4%)	123 (3%)	0.064	306 (2%)	301 (2%)	0.002	219 (1%)	201 (1%)	0.009

The 4 cohorts represent vaccine rollout periods. *Calculated as the days of previous observation in the database before index date. **Assessed anytime before index date. ASMD = Absolute standardized mean difference, COPD = Chronic obstructive pulmonary disease, GERD = Gastro-Esophageal reflux disease

Table S20: Characteristics of unweighted populations in CORIVA, database, stratified by staggered cohort and exposure status. Exposure is any COVID-19 vaccine.

	Cohort 1			Cohort 2			Cohort 3			Cohort 4		
	Unvaccinated	Vaccinated	ASMD	Unvaccinated	Vaccinated	ASMD	Unvaccinated	Vaccinated	ASMD	Unvaccinated	Vaccinated	ASMD
N (individuals)	23,982	26,736		34,317	4,572		96,423	24,050		147,545	22,245	
Age, median [Q25-Q75]	79 [73-85]	77 [73-82]	0.127	72 [67-81]	70 [66-75]	0.177	54 [46-66]	51 [45-59]	0.227	42 [32-58]	40 [30-51]	0.186
Sex: Female, N(%)	16,532 (69%)	17,342 (65%)	0.087	21,862 (64%)	2,891 (63%)	0.010	48,984 (51%)	12,233 (51%)	0.001	72,057 (49%)	10,026 (45%)	0.076
Years of prior history*, median [Q25-Q75]	4 [4-4]	4 [4-4]	0.019	4 [4-4]	4 [4-4]	0.002	4 [4-4]	4 [4-4]	0.002	5 [4-5]	5 [4-5]	0.003
Number visits, median [Q25-Q75]	11 [1-22]	16 [8-26]		9 [1-20]	13 [6-23]		2 [0-10]	5 [1-11]		1 [0-6]	3 [1-8]	
Number pcrs, median [Q25-Q75]	0[0-0]	0[0-0]		0[0-0]	0[0-0]		0[0-0]	0[0-0]		0[0-0]	0[0-0]	
Comorbidities**, N(%)												
Anxiety	1,966 (8%)	3,238 (12%)	0.130	2,817 (8%)	513 (11%)	0.102	6,406 (7%)	2,162 (9%)	0.087	9,287 (6%)	1,847 (8%)	0.077
Asthma	1,986 (8%)	2,668 (10%)	0.059	2,653 (8%)	447 (10%)	0.072	4,385 (5%)	1,250 (5%)	0.030	5,405 (4%)	968 (4%)	0.035
Chronic kidney disease	2,270 (9%)	2,507 (9%)	0.003	2,939 (9%)	367 (8%)	0.019	2,523 (3%)	415 (2%)	0.061	2,335 (2%)	221 (1%)	0.052
COPD	1,569 (7%)	1,976 (7%)	0.033	2,015 (6%)	312 (7%)	0.039	2,743 (3%)	529 (2%)	0.041	2,558 (2%)	294 (1%)	0.034
Dementia	1,152 (5%)	819 (3%)	0.090	1,297 (4%)	100 (2%)	0.094	1,147 (1%)	151 (1%)	0.059	1,067 (1%)	76 (0%)	0.052
Depressive disorder	2,066 (9%)	3,233 (12%)	0.114	3,189 (9%)	535 (12%)	0.079	7,286 (8%)	2,561 (11%)	0.108	10,034 (7%)	2,152 (10%)	0.105
Diabetes	3,971 (17%)	4,734 (18%)	0.030	4,818 (14%)	712 (16%)	0.043	6,065 (6%)	1,228 (5%)	0.051	6,594 (4%)	901 (4%)	0.021
GERD	2,533 (11%)	4,585 (17%)	0.192	3,364 (10%)	667 (15%)	0.147	6,287 (7%)	2,322 (10%)	0.115	7,455 (5%)	1,427 (6%)	0.059
Heart failure	8,724 (36%)	9,642 (36%)	0.007	9,570 (28%)	1,139 (25%)	0.068	9,982 (10%)	1,607 (7%)	0.132	9,182 (6%)	828 (4%)	0.115
Hypertension	16,651 (69%)	21,677 (81%)	0.272	20,654 (60%)	3,167 (69%)	0.191	29,974 (31%)	7,555 (31%)	0.007	27,992 (19%)	4,172 (19%)	0.006
Hypothyroidism	2,496 (10%)	3,094 (12%)	0.037	3,198 (9%)	515 (11%)	0.064	4,725 (5%)	1,309 (5%)	0.025	5,180 (4%)	799 (4%)	0.004
Malignant neoplastic disease	3,194 (13%)	5,044 (19%)	0.151	5,061 (15%)	782 (17%)	0.064	4,587 (5%)	1,011 (4%)	0.027	4,134 (3%)	523 (2%)	0.028
Myocardial infarction	548 (2%)	743 (3%)	0.031	696 (2%)	86 (2%)	0.011	840 (1%)	146 (1%)	0.031	777 (1%)	87 (0%)	0.020
Osteoporosis	1,273 (5%)	2,015 (8%)	0.091	1,446 (4%)	212 (5%)	0.021	1,545 (2%)	289 (1%)	0.034	1,408 (1%)	164 (1%)	0.024
Pneumonia	1,611 (7%)	2,046 (8%)	0.036	2,081 (6%)	291 (6%)	0.012	3,342 (3%)	898 (4%)	0.014	3,919 (3%)	683 (3%)	0.025

	Cohort 1			Cohort 2			Cohort 3			Cohort 4		
	Unvaccinated	Vaccinated	ASMD	Unvaccinated	Vaccinated	ASMD	Unvaccinated	Vaccinated	ASMD	Unvaccinated	Vaccinated	ASMD
Rheumatoid arthritis	493 (2%)	817 (3%)	0.063	891 (3%)	153 (3%)	0.044	1,022 (1%)	250 (1%)	0.002	987 (1%)	137 (1%)	0.007
Stroke	1,137 (5%)	1,011 (4%)	0.048	1,450 (4%)	169 (4%)	0.027	1,359 (1%)	232 (1%)	0.041	1,256 (1%)	133 (1%)	0.030
Venous thromboembolism	1,058 (4%)	1,207 (5%)	0.005	1,349 (4%)	149 (3%)	0.036	1,808 (2%)	387 (2%)	0.020	1,788 (1%)	235 (1%)	0.015

The 4 cohorts represent vaccine rollout periods. *Calculated as the days of previous observation in the database before index date. **Assessed anytime before index date. ASMD = Absolute standardized mean difference, COPD = Chronic obstructive pulmonary disease, GERD = Gastro-Esophageal reflux disease

Table S21: Characteristics of weighted populations in CORIVA, database, stratified by staggered cohort and exposure status. Exposure is BNT162b2 vaccine.

	Cohort 1			Cohort 2			Cohort 3			Cohort 4		
	Unvaccinated	Vaccinated	ASMD	Unvaccinated	Vaccinated	ASMD	Unvaccinated	Vaccinated	ASMD	Unvaccinated	Vaccinated	ASMD
N (individuals)	9,118	9,118		3,465	3,465		14,414	14,414		13,759	13,759	
Age, median [Q25-Q75]	78 [73-83]	78 [73-83]	0.000	70 [65-75]	70 [65-75]	0.000	50 [45-59]	50 [45-59]	0.000	38 [30-50]	38 [30-50]	0.000
Sex: Female, N(%)	6,206 (68%)	6,206 (68%)	0.000	2,197 (63%)	2,197 (63%)	0.000	7,324 (51%)	7,324 (51%)	0.000	6,552 (48%)	6,552 (48%)	0.000
Years of prior history*, median [Q25-Q75]	4 [4-4]	4 [4-4]	0.000	4 [4-4]	4 [4-4]	0.000	4 [4-4]	4 [4-4]	0.000	5 [4-5]	5 [4-5]	0.000
Number visits, median [Q25-Q75]	14 [4-25]	14 [7-24]		12 [3-23]	12 [5-22]		2 [0-10]	4 [1-10]		2 [0-8]	2 [0-8]	
Number pcrs, median [Q25-Q75]	0[0-0]	0[0-0]		0[0-0]	0[0-0]		0[0-0]	0[0-0]		0[0-0]	0[0-0]	
Comorbidities**, N(%)												
Anxiety	935 (10%)	956 (10%)	0.007	367 (11%)	373 (11%)	0.006	1,284 (9%)	1,278 (9%)	0.001	1,206 (9%)	1,170 (9%)	0.009
Asthma	891 (10%)	822 (9%)	0.026	340 (10%)	333 (10%)	0.007	747 (5%)	718 (5%)	0.009	644 (5%)	615 (4%)	0.010
Chronic kidney disease	939 (10%)	905 (10%)	0.012	302 (9%)	278 (8%)	0.025	225 (2%)	220 (2%)	0.003	144 (1%)	132 (1%)	0.008
COPD	666 (7%)	639 (7%)	0.011	238 (7%)	227 (7%)	0.013	333 (2%)	316 (2%)	0.008	223 (2%)	171 (1%)	0.032
Dementia	403 (4%)	377 (4%)	0.014	91 (3%)	81 (2%)	0.018	75 (1%)	72 (0%)	0.002	46 (0%)	38 (0%)	0.012
Depressive disorder	960 (11%)	966 (11%)	0.002	420 (12%)	411 (12%)	0.008	1,472 (10%)	1,485 (10%)	0.003	1,311 (10%)	1,367 (10%)	0.014
Diabetes	1,647 (18%)	1,624 (18%)	0.007	576 (17%)	531 (15%)	0.036	747 (5%)	731 (5%)	0.005	596 (4%)	565 (4%)	0.011
GERD	1,240 (14%)	1,268 (14%)	0.009	476 (14%)	473 (14%)	0.003	1,283 (9%)	1,322 (9%)	0.009	892 (6%)	900 (7%)	0.002
Heart failure	3,527 (39%)	3,470 (38%)	0.013	911 (26%)	877 (25%)	0.022	920 (6%)	899 (6%)	0.006	519 (4%)	484 (4%)	0.014
Hypertension	7,040 (77%)	7,234 (79%)	0.051	2,327 (67%)	2,384 (69%)	0.036	4,296 (30%)	4,340 (30%)	0.007	2,391 (17%)	2,479 (18%)	0.017
Hypothyroidism	1,080 (12%)	1,035 (11%)	0.015	376 (11%)	388 (11%)	0.011	770 (5%)	743 (5%)	0.009	500 (4%)	503 (4%)	0.001
Malignant neoplastic disease	1,485 (16%)	1,565 (17%)	0.023	579 (17%)	594 (17%)	0.012	582 (4%)	606 (4%)	0.008	324 (2%)	317 (2%)	0.003
Myocardial infarction	248 (3%)	234 (3%)	0.010	78 (2%)	68 (2%)	0.020	97 (1%)	88 (1%)	0.008	52 (0%)	52 (0%)	0.000
Osteoporosis	615 (7%)	632 (7%)	0.007	170 (5%)	167 (5%)	0.003	167 (1%)	161 (1%)	0.004	97 (1%)	107 (1%)	0.008
Pneumonia	698 (8%)	696 (8%)	0.001	222 (6%)	222 (6%)	0.001	543 (4%)	505 (4%)	0.014	418 (3%)	429 (3%)	0.005
Rheumatoid arthritis	240 (3%)	239 (3%)	0.001	128 (4%)	110 (3%)	0.028	167 (1%)	148 (1%)	0.013	97 (1%)	88 (1%)	0.008
Stroke	419 (5%)	417 (5%)	0.001	134 (4%)	131 (4%)	0.004	121 (1%)	130 (1%)	0.007	74 (1%)	82 (1%)	0.008

	Cohort 1			Cohort 2			Cohort 3			Cohort 4		
	Unvaccinated	Vaccinated	ASMD	Unvaccinated	Vaccinated	ASMD	Unvaccinated	Vaccinated	ASMD	Unvaccinated	Vaccinated	ASMD
Venous thromboembolism	438 (5%)	416 (5%)	0.011	153 (4%)	117 (3%)	0.053	220 (2%)	214 (1%)	0.003	159 (1%)	138 (1%)	0.015

The 4 cohorts represent vaccine rollout periods. *Calculated as the days of previous observation in the database before index date. **Assessed anytime before index date. ASMD = Absolute standardized mean difference, COPD = Chronic obstructive pulmonary disease, GERD = Gastro-Esophageal reflux disease

Table S22: Characteristics of unweighted populations in CORIVA, database, stratified by staggered cohort and exposure status. Exposure is BNT162b2 vaccine.

	Cohort 1			Cohort 2			Cohort 3			Cohort 4		
	Unvaccinated	Vaccinated	ASMD	Unvaccinated	Vaccinated	ASMD	Unvaccinated	Vaccinated	ASMD	Unvaccinated	Vaccinated	ASMD
N (individuals)	24,073	19,686		34,320	4,067		96,471	18,645		147,553	15,683	
Age, median [Q25-Q75]	79 [73-85]	79 [74-83]	0.040	72 [67-81]	70 [66-75]	0.174	54 [46-66]	51 [45-59]	0.257	42 [32-58]	38 [30-50]	0.216
Sex: Female, N(%)	16,582 (69%)	13,022 (66%)	0.058	21,867 (64%)	2,582 (63%)	0.005	49,023 (51%)	9,570 (51%)	0.010	72,056 (49%)	7,500 (48%)	0.020
Years of prior history*, median [Q25-Q75]	4 [4-4]	4 [4-4]	0.026	4 [4-4]	4 [4-4]	0.000	4 [4-4]	4 [4-4]	0.000	5 [4-5]	5 [4-5]	0.003
Number visits, median [Q25-Q75]	11 [1-22]	17 [9-27]		9 [1-20]	13 [6-23]		2 [0-10]	5 [1-11]		1 [0-6]	4 [1-9]	
Number pcrs, median [Q25-Q75]	0[0-0]	0[0-0]		0[0-0]	0[0-0]		0[0-0]	0[0-0]		0[0-0]	0[0-0]	
Comorbidities**, N(%)												
Anxiety	1,966 (8%)	2,429 (12%)	0.138	2,816 (8%)	458 (11%)	0.103	6,416 (7%)	1,780 (10%)	0.106	9,291 (6%)	1,384 (9%)	0.096
Asthma	2,004 (8%)	2,029 (10%)	0.068	2,653 (8%)	404 (10%)	0.078	4,393 (5%)	969 (5%)	0.030	5,403 (4%)	730 (5%)	0.050
Chronic kidney disease	2,284 (9%)	2,041 (10%)	0.029	2,943 (9%)	326 (8%)	0.020	2,537 (3%)	263 (1%)	0.087	2,339 (2%)	146 (1%)	0.059
COPD	1,587 (7%)	1,501 (8%)	0.040	2,013 (6%)	274 (7%)	0.036	2,746 (3%)	388 (2%)	0.049	2,560 (2%)	193 (1%)	0.042
Dementia	1,162 (5%)	688 (3%)	0.067	1,301 (4%)	90 (2%)	0.093	1,136 (1%)	81 (0%)	0.083	1,062 (1%)	40 (0%)	0.067
Depressive disorder	2,070 (9%)	2,449 (12%)	0.125	3,188 (9%)	502 (12%)	0.098	7,303 (8%)	2,075 (11%)	0.122	10,051 (7%)	1,623 (10%)	0.127
Diabetes	3,964 (16%)	3,599 (18%)	0.048	4,814 (14%)	638 (16%)	0.047	6,071 (6%)	900 (5%)	0.064	6,594 (4%)	644 (4%)	0.018
GERD	2,532 (11%)	3,307 (17%)	0.184	3,364 (10%)	587 (14%)	0.142	6,296 (7%)	1,858 (10%)	0.125	7,446 (5%)	1,050 (7%)	0.070
Heart failure	8,750 (36%)	7,743 (39%)	0.062	9,570 (28%)	1,026 (25%)	0.060	10,000 (10%)	1,057 (6%)	0.174	9,185 (6%)	525 (3%)	0.135
Hypertension	16,718 (69%)	16,325 (83%)	0.321	20,659 (60%)	2,838 (70%)	0.202	29,995 (31%)	5,624 (30%)	0.020	27,979 (19%)	2,798 (18%)	0.029
Hypothyroidism	2,526 (10%)	2,352 (12%)	0.046	3,197 (9%)	464 (11%)	0.069	4,732 (5%)	988 (5%)	0.018	5,173 (4%)	576 (4%)	0.009
Malignant neoplastic disease	3,216 (13%)	3,873 (20%)	0.171	5,060 (15%)	700 (17%)	0.067	4,587 (5%)	764 (4%)	0.032	4,139 (3%)	352 (2%)	0.036
Myocardial infarction	539 (2%)	591 (3%)	0.048	696 (2%)	82 (2%)	0.001	850 (1%)	108 (1%)	0.035	779 (1%)	58 (0%)	0.024
Osteoporosis	1,283 (5%)	1,628 (8%)	0.117	1,447 (4%)	200 (5%)	0.034	1,550 (2%)	197 (1%)	0.048	1,403 (1%)	117 (1%)	0.022
Pneumonia	1,621 (7%)	1,624 (8%)	0.058	2,080 (6%)	264 (6%)	0.018	3,353 (3%)	672 (4%)	0.007	3,920 (3%)	499 (3%)	0.031

	Cohort 1			Cohort 2			Cohort 3			Cohort 4		
	Unvaccinated	Vaccinated	ASMD	Unvaccinated	Vaccinated	ASMD	Unvaccinated	Vaccinated	ASMD	Unvaccinated	Vaccinated	ASMD
Rheumatoid arthritis	491 (2%)	603 (3%)	0.065	892 (3%)	137 (3%)	0.045	1,025 (1%)	190 (1%)	0.004	990 (1%)	99 (1%)	0.005
Stroke	1,129 (5%)	834 (4%)	0.022	1,447 (4%)	152 (4%)	0.025	1,370 (1%)	155 (1%)	0.056	1,254 (1%)	90 (1%)	0.033
Venous thromboembolism	1,067 (4%)	972 (5%)	0.024	1,353 (4%)	140 (3%)	0.027	1,808 (2%)	266 (1%)	0.035	1,785 (1%)	156 (1%)	0.021

The 4 cohorts represent vaccine rollout periods. *Calculated as the days of previous observation in the database before index date. **Assessed anytime before index date. ASMD = Absolute standardized mean difference, COPD = Chronic obstructive pulmonary disease, GERD = Gastro-Esophageal reflux disease

Table S23: Characteristics of weighted populations in CPRD AURUM database, stratified by staggered cohort and vaccine brand.

	Cohort 1			Cohort 2			Cohort 3			Cohort 4		
	ChAdOx1	BNT162b2	ASMD	ChAdOx1	BNT162b2	ASMD	ChAdOx1	BNT162b2	ASMD	ChAdOx1	BNT162b2	ASMD
N (individuals)	48,138	48,432		306,114	307,972		35,517	35,840		117,220	116,722	
Age, median [Q25-Q75]	80 [77-85]	80 [77-85]	0.003	66 [57-72]	66 [57-72]	0.003	54 [46-60]	54 [46-60]	0.000	42 [39-46]	42 [39-46]	0.004
Sex: Female, N(%)	27,920 (58%)	27,962 (58%)	0.005	167,623 (55%)	168,473 (55%)	0.001	21,299 (60%)	21,484 (60%)	0.000	54,350 (46%)	54,304 (47%)	0.003
Years of prior history*, median [Q25-Q75]	24 [9-36]	25 [11-36]	0.011	21 [9-32]	21 [9-32]	0.000	17 [8-27]	17 [7-27]	0.007	9 [4-17]	9 [4-17]	0.001
Number visits, median [Q25-Q75]	12 [6-19]	12 [6-19]		10 [5-16]	10 [6-16]		8 [4-14]	8 [4-14]		4 [1-8]	4 [1-8]	
Number pcrs, median [Q25-Q75]	0[0-0]	0[0-0]		0[0-0]	0[0-0]		0[0-0]	0[0-0]		0[0-0]	0[0-0]	
Comorbidities**, N(%)												
Anxiety	7,101 (15%)	7,442 (15%)	0.017	62,230 (20%)	61,892 (20%)	0.006	7,419 (21%)	7,362 (21%)	0.009	19,086 (16%)	19,543 (17%)	0.012
Asthma	5,241 (11%)	5,396 (11%)	0.008	57,043 (19%)	56,551 (18%)	0.007	6,365 (18%)	6,097 (17%)	0.024	9,186 (8%)	9,059 (8%)	0.003
Chronic kidney disease	11,403 (24%)	11,809 (24%)	0.016	28,219 (9%)	29,790 (10%)	0.016	1,565 (4%)	1,700 (5%)	0.016	793 (1%)	897 (1%)	0.011
COPD	4,080 (8%)	4,014 (8%)	0.007	20,765 (7%)	20,456 (7%)	0.006	661 (2%)	669 (2%)	0.000	424 (0%)	471 (0%)	0.007
Dementia	3,667 (8%)	3,510 (7%)	0.014	2,733 (1%)	2,137 (1%)	0.022	419 (1%)	288 (1%)	0.038	109 (0%)	60 (0%)	0.016
Depressive disorder	5,666 (12%)	5,885 (12%)	0.012	56,642 (19%)	57,377 (19%)	0.003	6,508 (18%)	6,556 (18%)	0.001	16,027 (14%)	16,191 (14%)	0.006
Diabetes	8,849 (18%)	9,020 (19%)	0.006	50,019 (16%)	50,218 (16%)	0.001	2,560 (7%)	2,850 (8%)	0.028	3,231 (3%)	3,106 (3%)	0.006
GERD	2,637 (5%)	2,694 (6%)	0.004	16,666 (5%)	16,658 (5%)	0.002	1,479 (4%)	1,443 (4%)	0.007	3,087 (3%)	3,046 (3%)	0.001
Heart failure	2,843 (6%)	2,904 (6%)	0.004	6,822 (2%)	6,936 (2%)	0.002	443 (1%)	361 (1%)	0.023	204 (0%)	202 (0%)	0.000
Hypertension	25,422 (53%)	26,106 (54%)	0.022	103,545 (34%)	105,521 (34%)	0.009	6,295 (18%)	6,514 (18%)	0.012	6,692 (6%)	6,522 (6%)	0.005
Hypothyroidism	4,806 (10%)	4,978 (10%)	0.010	22,667 (7%)	23,290 (8%)	0.006	1,845 (5%)	1,886 (5%)	0.003	2,985 (3%)	3,025 (3%)	0.003
Malignant neoplastic disease	10,958 (23%)	11,284 (23%)	0.013	38,507 (13%)	40,499 (13%)	0.017	2,019 (6%)	2,152 (6%)	0.014	1,504 (1%)	1,576 (1%)	0.006
Myocardial infarction	2,481 (5%)	2,516 (5%)	0.002	11,083 (4%)	11,197 (4%)	0.001	425 (1%)	521 (1%)	0.022	256 (0%)	349 (0%)	0.016
Osteoporosis	5,117 (11%)	5,335 (11%)	0.012	11,759 (4%)	11,858 (4%)	0.000	719 (2%)	667 (2%)	0.012	344 (0%)	372 (0%)	0.004
Pneumonia	2,576 (5%)	2,527 (5%)	0.006	9,543 (3%)	9,423 (3%)	0.003	808 (2%)	692 (2%)	0.024	979 (1%)	904 (1%)	0.007

	Cohort 1			Cohort 2			Cohort 3			Cohort 4		
	ChAdOx1	BNT162b2	ASMD	ChAdOx1	BNT162b2	ASMD	ChAdOx1	BNT162b2	ASMD	ChAdOx1	BNT162b2	ASMD
Rheumatoid arthritis	935 (2%)	1,005 (2%)	0.010	6,476 (2%)	6,640 (2%)	0.003	284 (1%)	344 (1%)	0.017	216 (0%)	258 (0%)	0.008
Stroke	2,314 (5%)	2,418 (5%)	0.009	7,284 (2%)	7,949 (3%)	0.013	446 (1%)	414 (1%)	0.009	294 (0%)	336 (0%)	0.007
Venous thromboembolism	3,001 (6%)	3,101 (6%)	0.007	11,833 (4%)	12,315 (4%)	0.007	812 (2%)	853 (2%)	0.006	601 (1%)	765 (1%)	0.019

The 4 cohorts represent vaccine rollout periods. *Calculated as the days of previous observation in the database before index date. **Assessed anytime before index date. ASMD = Absolute standardized mean difference, COPD = Chronic obstructive pulmonary disease, GERD = Gastro-Esophageal reflux disease

Table S24: Characteristics of unweighted populations in CPRD AURUM database, stratified by staggered cohort and vaccine brand.

	Cohort 1			Cohort 2			Cohort 3			Cohort 4		
	ChAdOx1	BNT162b2	ASMD	ChAdOx1	BNT162b2	ASMD	ChAdOx1	BNT162b2	ASMD	ChAdOx1	BNT162b2	ASMD
N (individuals)	219,804	332,790		969,262	594,262		1,473,602	54,102		542,670	1,335,671	
Age, median [Q25-Q75]	80 [77-85]	82 [79-86]	0.129	69 [63-73]	67 [56-73]	0.148	55 [51-60]	58 [50-82]	0.381	45 [42-48]	31 [25-37]	1.319
Sex: Female, N(%)	127,656 (58%)	186,481 (56%)	0.041	528,692 (55%)	324,259 (55%)	0.000	739,444 (50%)	32,310 (60%)	0.193	242,758 (45%)	625,195 (47%)	0.042
Years of prior history*, median [Q25-Q75]	24 [9-36]	26 [13-38]	0.059	21 [9-33]	21 [9-32]	0.028	17 [8-27]	19 [8-30]	0.116	10 [5-18]	7 [3-19]	0.146
Number visits, median [Q25-Q75]	12 [6-19]	11 [6-18]		10 [6-17]	11 [6-17]		7 [3-12]	10 [5-17]		3 [1-8]	3 [1-7]	
Number pcrs, median [Q25-Q75]	0[0-0]	0[0-0]		0[0-0]	0[0-0]		0[0-0]	0[0-0]		0[0-0]	0[0-0]	
Comorbidities**, N(%)												
Anxiety	33,355 (15%)	49,410 (15%)	0.009	187,469 (19%)	122,087 (21%)	0.030	281,846 (19%)	10,441 (19%)	0.004	86,805 (16%)	218,144 (16%)	0.009
Asthma	24,009 (11%)	37,889 (11%)	0.015	159,162 (16%)	116,596 (20%)	0.083	200,995 (14%)	8,668 (16%)	0.067	41,393 (8%)	114,378 (9%)	0.034
Chronic kidney disease	51,053 (23%)	86,899 (26%)	0.067	97,339 (10%)	56,923 (10%)	0.016	24,198 (2%)	6,692 (12%)	0.430	2,879 (1%)	2,664 (0%)	0.055
COPD	19,105 (9%)	28,317 (9%)	0.007	67,700 (7%)	39,595 (7%)	0.013	13,621 (1%)	2,063 (4%)	0.191	1,510 (0%)	942 (0%)	0.050
Dementia	16,795 (8%)	16,138 (5%)	0.116	12,106 (1%)	3,720 (1%)	0.065	1,896 (0%)	1,323 (2%)	0.207	447 (0%)	119 (0%)	0.034
Depressive disorder	27,009 (12%)	37,831 (11%)	0.028	170,626 (18%)	112,753 (19%)	0.035	256,789 (17%)	9,046 (17%)	0.019	74,210 (14%)	155,037 (12%)	0.062
Diabetes	39,751 (18%)	61,929 (19%)	0.014	154,348 (16%)	98,676 (17%)	0.018	78,394 (5%)	5,817 (11%)	0.201	9,729 (2%)	12,040 (1%)	0.077
GERD	12,156 (6%)	20,204 (6%)	0.023	52,694 (5%)	32,288 (5%)	0.000	56,444 (4%)	2,506 (5%)	0.040	13,807 (3%)	21,599 (2%)	0.065
Heart failure	13,147 (6%)	20,430 (6%)	0.007	24,276 (3%)	13,120 (2%)	0.020	5,673 (0%)	1,529 (3%)	0.195	681 (0%)	448 (0%)	0.033
Hypertension	114,922 (52%)	186,367 (56%)	0.075	345,014 (36%)	200,762 (34%)	0.038	224,543 (15%)	15,536 (29%)	0.330	31,330 (6%)	19,649 (1%)	0.232
Hypothyroidism	21,855 (10%)	34,512 (10%)	0.014	73,992 (8%)	44,456 (7%)	0.006	64,026 (4%)	3,642 (7%)	0.104	13,920 (3%)	18,516 (1%)	0.085
Malignant neoplastic disease	49,023 (22%)	82,610 (25%)	0.059	131,135 (14%)	76,103 (13%)	0.021	55,601 (4%)	6,311 (12%)	0.299	7,505 (1%)	5,104 (0%)	0.107
Myocardial infarction	11,236 (5%)	18,289 (5%)	0.017	33,142 (3%)	23,019 (4%)	0.024	11,237 (1%)	1,464 (3%)	0.149	861 (0%)	715 (0%)	0.032
Osteoporosis	22,986 (10%)	36,535 (11%)	0.017	42,319 (4%)	21,789 (4%)	0.036	12,455 (1%)	2,632 (5%)	0.243	1,380 (0%)	1,028 (0%)	0.044

	Cohort 1			Cohort 2			Cohort 3			Cohort 4		
	ChAdOx1	BNT162b2	ASMD	ChAdOx1	BNT162b2	ASMD	ChAdOx1	BNT162b2	ASMD	ChAdOx1	BNT162b2	ASMD
Pneumonia	12,101 (6%)	16,297 (5%)	0.027	33,170 (3%)	17,567 (3%)	0.027	20,399 (1%)	1,658 (3%)	0.114	4,297 (1%)	7,793 (1%)	0.025
Rheumatoid arthritis	4,544 (2%)	6,693 (2%)	0.004	20,294 (2%)	12,878 (2%)	0.005	8,463 (1%)	667 (1%)	0.070	821 (0%)	891 (0%)	0.026
Stroke	10,876 (5%)	15,601 (5%)	0.012	24,851 (3%)	15,056 (3%)	0.002	9,547 (1%)	1,281 (2%)	0.141	1,153 (0%)	1,022 (0%)	0.036
Venous thromboembolism	13,782 (6%)	21,549 (6%)	0.008	39,415 (4%)	23,632 (4%)	0.005	24,312 (2%)	1,980 (4%)	0.125	1,936 (0%)	2,541 (0%)	0.032

The 4 cohorts represent vaccine rollout periods. *Calculated as the days of previous observation in the database before index date. **Assessed anytime before index date. ASMD = Absolute standardized mean difference, COPD = Chronic obstructive pulmonary disease, GERD = Gastro-Esophageal reflux disease

Table S25: Characteristics of weighted populations in CPRD GOLD database, stratified by staggered cohort and vaccine brand.

	Cohort 1			Cohort 2			Cohort 3			Cohort 4		
	ChAdOx1	BNT162b2	ASMD	ChAdOx1	BNT162b2	ASMD	ChAdOx1	BNT162b2	ASMD	ChAdOx1	BNT162b2	ASMD
N (individuals)	7,490	7,490		77,012	76,978		24,590	24,597		49,538	49,577	
Age, median [Q25-Q75]	82 [78-86]	80 [78-86]	0.000	70 [65-74]	70 [65-74]	0.004	54 [49-59]	54 [49-59]	0.009	42 [37-46]	42 [37-47]	0.003
Sex: Female, N(%)	4,266 (57%)	4,266 (57%)	0.000	41,394 (54%)	41,607 (54%)	0.006	13,052 (53%)	13,078 (53%)	0.002	22,308 (45%)	22,520 (45%)	0.008
Years of prior history*, median [Q25-Q75]	18 [12-21]	18 [11-21]	0.000	17 [12-20]	17 [12-20]	0.005	17 [12-20]	17 [12-20]	0.004	14 [6-18]	14 [6-18]	0.005
Number visits, median [Q25-Q75]	14 [9-21]	14 [9-21]		10 [6-16]	10 [6-17]		6 [2-11]	6 [2-11]		2 [0-6]	2 [0-7]	
Number pcrs, median [Q25-Q75]	0[0-0]	0[0-0]		0[0-0]	0[0-0]		0[0-0]	0[0-0]		0[0-0]	0[0-0]	
Comorbidities**, N(%)												
Anxiety	1,008 (13%)	1,015 (14%)	0.002	12,765 (17%)	12,897 (17%)	0.005	5,218 (21%)	5,293 (22%)	0.007	8,501 (17%)	8,578 (17%)	0.004
Asthma	783 (10%)	774 (10%)	0.004	9,867 (13%)	10,028 (13%)	0.006	2,993 (12%)	2,826 (11%)	0.021	3,700 (7%)	3,568 (7%)	0.010
Chronic kidney disease	1,711 (23%)	1,694 (23%)	0.005	7,209 (9%)	7,045 (9%)	0.007	530 (2%)	411 (2%)	0.035	193 (0%)	202 (0%)	0.003
COPD	568 (8%)	583 (8%)	0.008	5,739 (7%)	5,725 (7%)	0.001	321 (1%)	274 (1%)	0.017	170 (0%)	165 (0%)	0.002
Dementia	543 (7%)	495 (7%)	0.025	726 (1%)	737 (1%)	0.001	55 (0%)	74 (0%)	0.015	28 (0%)	21 (0%)	0.006
Depressive disorder	733 (10%)	729 (10%)	0.002	11,461 (15%)	11,746 (15%)	0.011	4,478 (18%)	4,427 (18%)	0.005	7,038 (14%)	7,119 (14%)	0.004
Diabetes	1,114 (15%)	1,107 (15%)	0.003	10,260 (13%)	10,130 (13%)	0.005	1,051 (4%)	963 (4%)	0.018	768 (2%)	654 (1%)	0.019
GERD	451 (6%)	447 (6%)	0.002	3,691 (5%)	3,753 (5%)	0.004	763 (3%)	770 (3%)	0.001	975 (2%)	978 (2%)	0.000
Heart failure	395 (5%)	411 (5%)	0.009	1,763 (2%)	1,819 (2%)	0.005	125 (1%)	81 (0%)	0.028	50 (0%)	54 (0%)	0.002
Hypertension	2,761 (37%)	2,754 (37%)	0.002	21,627 (28%)	21,686 (28%)	0.002	3,184 (13%)	3,261 (13%)	0.009	1,842 (4%)	1,975 (4%)	0.014
Hypothyroidism	579 (8%)	566 (8%)	0.007	4,932 (6%)	4,869 (6%)	0.003	1,064 (4%)	1,065 (4%)	0.000	979 (2%)	1,028 (2%)	0.007
Malignant neoplastic disease	1,632 (22%)	1,744 (23%)	0.036	10,682 (14%)	9,986 (13%)	0.026	1,007 (4%)	1,089 (4%)	0.017	598 (1%)	660 (1%)	0.011
Myocardial infarction	330 (4%)	325 (4%)	0.004	2,919 (4%)	2,943 (4%)	0.002	239 (1%)	217 (1%)	0.010	90 (0%)	85 (0%)	0.002
Osteoporosis	665 (9%)	638 (9%)	0.013	3,388 (4%)	3,496 (5%)	0.007	323 (1%)	314 (1%)	0.003	103 (0%)	92 (0%)	0.005

	Cohort 1			Cohort 2			Cohort 3			Cohort 4		
	ChAdOx1	BNT162b2	ASMD	ChAdOx1	BNT162b2	ASMD	ChAdOx1	BNT162b2	ASMD	ChAdOx1	BNT162b2	ASMD
Pneumonia	286 (4%)	258 (3%)	0.020	1,807 (2%)	1,724 (2%)	0.007	263 (1%)	252 (1%)	0.005	271 (1%)	265 (1%)	0.002
Rheumatoid arthritis	111 (1%)	111 (1%)	0.001	1,437 (2%)	1,460 (2%)	0.002	123 (1%)	115 (0%)	0.005	58 (0%)	40 (0%)	0.011
Stroke	325 (4%)	321 (4%)	0.003	2,134 (3%)	2,072 (3%)	0.005	207 (1%)	148 (1%)	0.028	96 (0%)	91 (0%)	0.002
Venous thromboembolism	306 (4%)	341 (5%)	0.023	2,125 (3%)	2,153 (3%)	0.002	288 (1%)	285 (1%)	0.001	146 (0%)	198 (0%)	0.018

The 4 cohorts represent vaccine rollout periods. *Calculated as the days of previous observation in the database before index date. **Assessed anytime before index date. ASMD = Absolute standardized mean difference, COPD = Chronic obstructive pulmonary disease, GERD = Gastro-Esophageal reflux disease

Table S26: Characteristics of unweighted populations in CPRD GOLD database, stratified by staggered cohort and vaccine brand.

	Cohort 1			Cohort 2			Cohort 3			Cohort 4		
	ChAdOx1	BNT162b2	ASMD	ChAdOx1	BNT162b2	ASMD	ChAdOx1	BNT162b2	ASMD	ChAdOx1	BNT162b2	ASMD
N (individuals)	82,406	32,755		302,999	180,670		423,876	36,748		147,744	365,096	
Age, median [Q25-Q75]	84 [82-88]	81 [79-86]	0.351	71 [66-76]	70 [66-74]	0.132	56 [52-61]	54 [50-60]	0.171	44 [41-48]	31 [24-37]	1.090
Sex: Female, N(%)	47,915 (58%)	18,415 (56%)	0.039	162,753 (54%)	97,747 (54%)	0.008	210,283 (50%)	19,649 (53%)	0.077	64,999 (44%)	167,510 (46%)	0.038
Years of prior history*, median [Q25-Q75]	17 [14-20]	18 [13-21]	0.001	17 [13-19]	17 [12-19]	0.014	17 [10-19]	18 [12-20]	0.107	14 [7-18]	15 [6-18]	0.017
Number visits, median [Q25-Q75]	14 [9-21]	14 [9-21]		11 [7-18]	10 [6-16]		6 [2-12]	6 [2-11]		3 [0-7]	2 [0-6]	
Number pcrs, median [Q25-Q75]	0[0-0]	0[0-0]		0[0-0]	0[0-0]		0[0-0]	0[0-0]		0[0-0]	0[0-0]	
Comorbidities**, N(%)												
Anxiety	9,923 (12%)	4,336 (13%)	0.036	49,010 (16%)	28,697 (16%)	0.008	75,258 (18%)	8,004 (22%)	0.101	24,601 (17%)	59,094 (16%)	0.013
Asthma	8,491 (10%)	3,250 (10%)	0.013	39,988 (13%)	21,396 (12%)	0.041	48,034 (11%)	4,053 (11%)	0.010	10,517 (7%)	33,240 (9%)	0.073
Chronic kidney disease	21,564 (26%)	7,430 (23%)	0.081	34,168 (11%)	15,033 (8%)	0.100	7,553 (2%)	566 (2%)	0.019	739 (1%)	578 (0%)	0.060
COPD	6,837 (8%)	2,417 (7%)	0.034	27,472 (9%)	11,545 (6%)	0.100	6,334 (1%)	348 (1%)	0.050	640 (0%)	285 (0%)	0.070
Dementia	4,773 (6%)	1,895 (6%)	0.000	5,124 (2%)	1,375 (1%)	0.085	548 (0%)	87 (0%)	0.025	126 (0%)	29 (0%)	0.036
Depressive disorder	6,998 (8%)	3,310 (10%)	0.056	45,154 (15%)	26,294 (15%)	0.010	70,703 (17%)	6,569 (18%)	0.032	21,711 (15%)	39,181 (11%)	0.119
Diabetes	12,387 (15%)	4,882 (15%)	0.004	43,647 (14%)	22,552 (12%)	0.056	24,219 (6%)	1,191 (3%)	0.120	2,254 (2%)	2,507 (1%)	0.080
GERD	4,054 (5%)	2,012 (6%)	0.054	14,294 (5%)	8,525 (5%)	0.000	14,447 (3%)	1,093 (3%)	0.025	2,883 (2%)	5,213 (1%)	0.041
Heart failure	5,058 (6%)	1,782 (5%)	0.030	9,180 (3%)	3,669 (2%)	0.064	2,308 (1%)	100 (0%)	0.043	191 (0%)	98 (0%)	0.037
Hypertension	31,217 (38%)	11,995 (37%)	0.026	88,833 (29%)	49,763 (28%)	0.039	59,554 (14%)	4,679 (13%)	0.039	6,761 (5%)	4,776 (1%)	0.194
Hypothyroidism	7,042 (9%)	2,373 (7%)	0.048	20,521 (7%)	11,106 (6%)	0.025	17,382 (4%)	1,553 (4%)	0.006	3,245 (2%)	4,180 (1%)	0.082
Malignant neoplastic disease	18,950 (23%)	6,972 (21%)	0.041	42,687 (14%)	22,617 (13%)	0.046	17,903 (4%)	1,522 (4%)	0.004	2,192 (1%)	1,796 (0%)	0.100
Myocardial infarction	4,500 (5%)	1,603 (5%)	0.026	13,456 (4%)	6,621 (4%)	0.039	5,280 (1%)	271 (1%)	0.051	330 (0%)	154 (0%)	0.050
Osteoporosis	8,564 (10%)	2,770 (8%)	0.066	16,117 (5%)	7,531 (4%)	0.054	4,330 (1%)	458 (1%)	0.021	408 (0%)	205 (0%)	0.054

	Cohort 1			Cohort 2			Cohort 3			Cohort 4		
	ChAdOx1	BNT162b2	ASMD	ChAdOx1	BNT162b2	ASMD	ChAdOx1	BNT162b2	ASMD	ChAdOx1	BNT162b2	ASMD
Pneumonia	3,231 (4%)	1,032 (3%)	0.042	8,604 (3%)	3,418 (2%)	0.062	4,527 (1%)	345 (1%)	0.013	921 (1%)	1,696 (0%)	0.022
Rheumatoid arthritis	1,257 (2%)	512 (2%)	0.003	5,999 (2%)	2,929 (2%)	0.027	2,405 (1%)	154 (0%)	0.021	191 (0%)	111 (0%)	0.035
Stroke	4,193 (5%)	1,490 (5%)	0.025	10,213 (3%)	4,632 (3%)	0.048	3,789 (1%)	199 (1%)	0.042	369 (0%)	225 (0%)	0.048
Venous thromboembolism	3,550 (4%)	1,389 (4%)	0.003	9,466 (3%)	4,490 (2%)	0.039	6,339 (1%)	370 (1%)	0.044	460 (0%)	496 (0%)	0.037

The 4 cohorts represent vaccine rollout periods. *Calculated as the days of previous observation in the database before index date. **Assessed anytime before index date. ASMD = Absolute standardized mean difference, COPD = Chronic obstructive pulmonary disease, GERD = Gastro-Esophageal reflux disease

Table S27: Number of records (and risk per 10,000 individuals) for post COVID-19 cardiac and thromboembolic complications, across cohorts and databases, stratified by exposure status (any COVID-19 vaccine). Follow-up ends at first vaccine dose after index date.

Cohort	Time window	Outcome	AURUM		CORIVA		GOLD		SIDIAP	
			Unvaccinated	Vaccinated	Unvaccinated	Vaccinated	Unvaccinated	Vaccinated	Unvaccinated	Vaccinated
Cohort 1			N = 346,674	N = 552,602	N = 23,982	N = 26,736	N = 169,100	N = 118,507	N = 223,962	N = 89,941
0 to 30 days	VTE	93 (2.68)	45 (0.81)	74 (30.86)	5 (1.87)	8 (0.47)	< 5	75 (3.35)	< 5	
	DVT	22 (0.63)	10 (0.18)	11 (4.59)	< 5	< 5	< 5	19 (0.85)	< 5	
	PE	75 (2.16)	37 (0.67)	66 (27.52)	< 5	7 (0.41)	< 5	60 (2.68)	< 5	
	ATE	22 (0.63)	28 (0.51)	92 (38.36)	5 (1.87)	6 (0.35)	< 5	75 (3.35)	6 (0.67)	
	IS	8 (0.23)	< 5	52 (21.68)	< 5	< 5	< 5	42 (1.88)	< 5	
	TIA	< 5	6 (0.11)	19 (7.92)	< 5	< 5	< 5	7 (0.31)	< 5	
	MI	11 (0.32)	20 (0.36)	29 (12.09)	5 (1.87)	< 5	< 5	28 (1.25)	< 5	
	HF	59 (1.70)	73 (1.32)	349 (145.53)	22 (8.23)	10 (0.59)	< 5	305 (13.62)	23 (2.56)	
	HS	< 5	< 5	< 5	< 5	< 5	< 5	7 (0.31)	< 5	
	MP	< 5	< 5	< 5	< 5	< 5	< 5	< 5	< 5	
31 to 90 days	VTE	19 (0.55)	20 (0.36)	23 (9.59)	< 5	< 5	< 5	16 (0.71)	< 5	
	DVT	10 (0.29)	7 (0.13)	12 (5.00)	< 5	< 5	< 5	10 (0.45)	< 5	
	PE	9 (0.26)	13 (0.24)	14 (5.84)	< 5	< 5	< 5	6 (0.27)	< 5	
	ATE	5 (0.14)	16 (0.29)	20 (8.34)	< 5	< 5	< 5	42 (1.88)	5 (0.56)	
	IS	< 5	< 5	11 (4.59)	< 5	< 5	< 5	20 (0.89)	< 5	
	TIA	< 5	6 (0.11)	6 (2.50)	< 5	< 5	< 5	14 (0.63)	< 5	
	MI	< 5	7 (0.13)	9 (3.75)	< 5	< 5	< 5	11 (0.49)	< 5	
	HF	30 (0.87)	56 (1.01)	109 (45.45)	19 (7.11)	< 5	< 5	87 (3.88)	8 (0.89)	
	HS	< 5	< 5	< 5	< 5	< 5	< 5	< 5	< 5	
	MP	< 5	< 5	< 5	< 5	< 5	< 5	< 5	< 5	
91 to 180 days	VTE	10 (0.29)	9 (0.16)	15 (6.25)	< 5	< 5	< 5	20 (0.89)	< 5	
	DVT	5 (0.14)	< 5	9 (3.75)	< 5	< 5	< 5	9 (0.40)	< 5	
	PE	5 (0.14)	5 (0.09)	8 (3.34)	< 5	< 5	< 5	11 (0.49)	< 5	
	ATE	11 (0.32)	14 (0.25)	21 (8.76)	< 5	< 5	< 5	30 (1.34)	< 5	
	IS	< 5	< 5	11 (4.59)	< 5	< 5	< 5	16 (0.71)	< 5	
	TIA	5 (0.14)	6 (0.11)	5 (2.08)	< 5	< 5	< 5	8 (0.36)	< 5	
	MI	5 (0.14)	< 5	7 (2.92)	< 5	< 5	< 5	7 (0.31)	< 5	
	HF	37 (1.07)	51 (0.92)	126 (52.54)	17 (6.36)	< 5	< 5	86 (3.84)	7 (0.78)	
	HS	< 5	< 5	< 5	< 5	< 5	< 5	< 5	< 5	
	MP	< 5	< 5	< 5	< 5	< 5	< 5	< 5	< 5	
181 to 365 days	VTE	10 (0.29)	8 (0.14)	42 (17.51)	5 (1.87)	< 5	< 5	11 (0.49)	< 5	
	DVT	5 (0.14)	< 5	12 (5.00)	< 5	< 5	< 5	6 (0.27)	< 5	
	PE	5 (0.14)	< 5	35 (14.59)	< 5	< 5	< 5	5 (0.22)	< 5	
	ATE	10 (0.29)	19 (0.34)	44 (18.35)	< 5	< 5	< 5	42 (1.88)	8 (0.89)	
	IS	< 5	6 (0.11)	26 (10.84)	< 5	< 5	< 5	22 (0.98)	5 (0.56)	
	TIA	6 (0.17)	< 5	16 (6.67)	< 5	< 5	< 5	10 (0.45)	< 5	
	MI	< 5	10 (0.18)	10 (4.17)	< 5	< 5	< 5	10 (0.45)	< 5	
	HF	40 (1.15)	53 (0.96)	222 (92.57)	38 (14.21)	< 5	6 (0.51)	85 (3.80)	20 (2.22)	
	HS	< 5	< 5	< 5	< 5	< 5	< 5	< 5	< 5	
	MP	< 5	< 5	< 5	< 5	< 5	< 5	< 5	< 5	
Cohort 2			N = 1,975,726	N = 1,563,569	N = 34,317	N = 4,572	N = 583,399	N = 486,619	N = 433,151	N = 819,590
0 to 30 days	VTE	241 (1.22)	54 (0.35)	71 (20.69)	< 5	31 (0.53)	7 (0.14)	263 (6.07)	27 (0.33)	
	DVT	41 (0.21)	19 (0.12)	10 (2.91)	< 5	8 (0.14)	< 5	65 (1.50)	9 (0.11)	
	PE	204 (1.03)	38 (0.24)	62 (18.07)	< 5	24 (0.41)	6 (0.12)	217 (5.01)	20 (0.24)	

Cohort	Time window	Outcome	AURUM		CORIVA		GOLD		SIDAP		
			Unvaccinated	Vaccinated	Unvaccinated	Vaccinated	Unvaccinated	Vaccinated	Unvaccinated	Vaccinated	
	31 to 90 days	ATE	41 (0.21)	25 (0.16)	90 (26.23)	< 5	< 5	< 5	171 (3.95)	29 (0.35)	
		IS	7 (0.04)	5 (0.03)	52 (15.15)	< 5	< 5	< 5	93 (2.15)	12 (0.15)	
		TIA	8 (0.04)	< 5	17 (4.95)	< 5	< 5	< 5	16 (0.37)	6 (0.07)	
		MI	26 (0.13)	17 (0.11)	27 (7.87)	< 5	< 5	< 5	66 (1.52)	11 (0.13)	
		HF	45 (0.23)	47 (0.30)	314 (91.50)	< 5	5 (0.09)	< 5	379 (8.75)	76 (0.93)	
		HS	6 (0.03)	< 5	< 5	< 5	< 5	< 5	18 (0.42)	< 5	
		MP	12 (0.06)	< 5	< 5	< 5	< 5	< 5	13 (0.30)	< 5	
	91 to 180 days	VTE	43 (0.22)	13 (0.08)	25 (7.29)	< 5	< 5	< 5	62 (1.43)	9 (0.11)	
		DVT	24 (0.12)	6 (0.04)	14 (4.08)	< 5	< 5	< 5	34 (0.78)	5 (0.06)	
		PE	23 (0.12)	8 (0.05)	13 (3.79)	< 5	< 5	< 5	35 (0.81)	< 5	
		ATE	18 (0.09)	18 (0.12)	20 (5.83)	< 5	< 5	< 5	87 (2.01)	14 (0.17)	
		IS	< 5	< 5	13 (3.79)	< 5	< 5	< 5	44 (1.02)	6 (0.07)	
		TIA	< 5	7 (0.04)	< 5	< 5	< 5	< 5	23 (0.53)	5 (0.06)	
		MI	13 (0.07)	10 (0.06)	9 (2.62)	< 5	< 5	< 5	27 (0.62)	< 5	
		HF	27 (0.14)	30 (0.19)	108 (31.47)	< 5	< 5	< 5	140 (3.23)	29 (0.35)	
		HS	< 5	< 5	< 5	< 5	< 5	< 5	8 (0.18)	< 5	
		MP	6 (0.03)	< 5	< 5	< 5	< 5	< 5	< 5	< 5	
	181 to 365 days	VTE	28 (0.14)	15 (0.10)	21 (6.12)	< 5	6 (0.10)	< 5	59 (1.36)	6 (0.07)	
		DVT	13 (0.07)	9 (0.06)	11 (3.21)	< 5	< 5	< 5	32 (0.74)	6 (0.07)	
		PE	15 (0.08)	6 (0.04)	11 (3.21)	< 5	< 5	< 5	30 (0.69)	< 5	
		ATE	17 (0.09)	15 (0.10)	18 (5.25)	< 5	< 5	< 5	88 (2.03)	19 (0.23)	
		IS	< 5	< 5	7 (2.04)	< 5	< 5	< 5	48 (1.11)	9 (0.11)	
		TIA	9 (0.05)	5 (0.03)	6 (1.75)	< 5	< 5	< 5	19 (0.44)	5 (0.06)	
		MI	9 (0.05)	10 (0.06)	7 (2.04)	< 5	< 5	< 5	24 (0.55)	6 (0.07)	
		HF	22 (0.11)	27 (0.17)	129 (37.59)	< 5	< 5	< 5	115 (2.65)	41 (0.50)	
		HS	< 5	< 5	< 5	< 5	< 5	< 5	7 (0.16)	< 5	
	Cohort 3			N = 1,510,401	N = 1,528,031	N = 96,423	N = 24,050	N = 417,996	N = 462,832	N = 869,497	N = 954,232
		0 to 30 days	VTE	245 (1.62)	25 (0.16)	103 (10.68)	< 5	27 (0.65)	< 5	328 (3.77)	27 (0.28)
			DVT	45 (0.30)	< 5	19 (1.97)	< 5	6 (0.14)	< 5	93 (1.07)	7 (0.07)
			PE	209 (1.38)	22 (0.14)	86 (8.92)	< 5	22 (0.53)	< 5	263 (3.02)	22 (0.23)
			ATE	29 (0.19)	10 (0.07)	97 (10.06)	< 5	< 5	< 5	213 (2.45)	14 (0.15)
			IS	< 5	< 5	53 (5.50)	< 5	< 5	< 5	103 (1.18)	5 (0.05)
			TIA	5 (0.03)	< 5	18 (1.87)	< 5	< 5	< 5	20 (0.23)	< 5
			MI	20 (0.13)	8 (0.05)	31 (3.22)	< 5	< 5	< 5	96 (1.10)	7 (0.07)
			HF	31 (0.21)	18 (0.12)	326 (33.81)	13 (5.41)	< 5	< 5	365 (4.20)	23 (0.24)
			HS	< 5	< 5	5 (0.52)	< 5	< 5	< 5	20 (0.23)	< 5
MP	9 (0.06)	< 5	< 5	< 5	< 5	< 5	19 (0.22)	< 5			
31 to 90 days	VTE	44 (0.29)	< 5	32 (3.32)	< 5	< 5	< 5	85 (0.98)	9 (0.09)		

Cohort	Time window	Outcome	AURUM		CORIVA		GOLD		SIDAP	
			Unvaccinated	Vaccinated	Unvaccinated	Vaccinated	Unvaccinated	Vaccinated	Unvaccinated	Vaccinated
		DVT	20 (0.13)	< 5	19 (1.97)	< 5	< 5	< 5	57 (0.66)	5 (0.05)
		PE	27 (0.18)	< 5	16 (1.66)	< 5	< 5	< 5	38 (0.44)	< 5
		ATE	11 (0.07)	7 (0.05)	33 (3.42)	< 5	< 5	< 5	107 (1.23)	10 (0.10)
		IS	< 5	< 5	17 (1.76)	< 5	< 5	< 5	52 (0.60)	6 (0.06)
		TIA	< 5	< 5	5 (0.52)	< 5	< 5	< 5	27 (0.31)	< 5
		MI	9 (0.06)	< 5	15 (1.56)	< 5	< 5	< 5	36 (0.41)	< 5
		HF	15 (0.10)	8 (0.05)	131 (13.59)	5 (2.08)	< 5	< 5	140 (1.61)	13 (0.14)
		HS	< 5	< 5	< 5	< 5	< 5	< 5	7 (0.08)	< 5
		MP	8 (0.05)	< 5	6 (0.62)	< 5	< 5	< 5	7 (0.08)	< 5
	91 to 180 days	VTE	24 (0.16)	8 (0.05)	36 (3.73)	< 5	< 5	< 5	63 (0.72)	8 (0.08)
		DVT	11 (0.07)	6 (0.04)	22 (2.28)	< 5	< 5	< 5	35 (0.40)	7 (0.07)
		PE	14 (0.09)	< 5	15 (1.56)	< 5	< 5	< 5	32 (0.37)	< 5
		ATE	< 5	7 (0.05)	25 (2.59)	< 5	< 5	< 5	115 (1.32)	20 (0.21)
		IS	< 5	< 5	10 (1.04)	< 5	< 5	< 5	58 (0.67)	12 (0.13)
		TIA	< 5	< 5	9 (0.93)	< 5	< 5	< 5	22 (0.25)	< 5
		MI	< 5	< 5	10 (1.04)	< 5	< 5	< 5	38 (0.44)	6 (0.06)
		HF	11 (0.07)	6 (0.04)	162 (16.80)	< 5	< 5	< 5	121 (1.39)	15 (0.16)
		HS	< 5	< 5	< 5	< 5	< 5	< 5	9 (0.10)	< 5
	181 to 365 days	MP	< 5	< 5	< 5	< 5	< 5	< 5	7 (0.08)	< 5
		VTE	< 5	9 (0.06)	59 (6.12)	< 5	< 5	< 5	37 (0.43)	5 (0.05)
DVT		< 5	< 5	30 (3.11)	< 5	< 5	< 5	23 (0.26)	< 5	
PE		< 5	6 (0.04)	32 (3.32)	< 5	< 5	< 5	16 (0.18)	< 5	
ATE		< 5	< 5	60 (6.22)	< 5	< 5	< 5	53 (0.61)	18 (0.19)	
IS		< 5	< 5	30 (3.11)	< 5	< 5	< 5	24 (0.28)	9 (0.09)	
TIA		< 5	< 5	17 (1.76)	< 5	< 5	< 5	12 (0.14)	< 5	
MI		< 5	< 5	20 (2.07)	< 5	< 5	< 5	18 (0.21)	7 (0.07)	
HF		5 (0.03)	< 5	260 (26.96)	6 (2.49)	< 5	< 5	62 (0.71)	13 (0.14)	
HS	< 5	< 5	< 5	< 5	< 5	< 5	< 5	< 5		
MP	< 5	< 5	< 5	< 5	< 5	< 5	< 5	< 5		
Cohort 4		N = 2,027,763	N = 2,085,598	N = 147,545	N = 22,245	N = 469,876	N = 550,437	N = 1,061,634	N = 880,950	
0 to 30 days	VTE	334 (1.65)	19 (0.09)	105 (7.12)	< 5	36 (0.77)	7 (0.13)	349 (3.29)	38 (0.43)	
	DVT	55 (0.27)	6 (0.03)	21 (1.42)	< 5	6 (0.13)	< 5	104 (0.98)	14 (0.16)	
	PE	291 (1.44)	13 (0.06)	86 (5.83)	< 5	31 (0.66)	7 (0.13)	270 (2.54)	25 (0.28)	
	ATE	26 (0.13)	5 (0.02)	93 (6.30)	< 5	< 5	< 5	225 (2.12)	35 (0.40)	
	IS	< 5	< 5	52 (3.52)	< 5	< 5	< 5	111 (1.05)	17 (0.19)	
	TIA	6 (0.03)	< 5	16 (1.08)	< 5	< 5	< 5	27 (0.25)	< 5	
	MI	16 (0.08)	< 5	30 (2.03)	< 5	< 5	< 5	93 (0.88)	15 (0.17)	
	HF	28 (0.14)	< 5	313 (21.21)	6 (2.70)	< 5	< 5	368 (3.47)	28 (0.32)	
	HS	< 5	< 5	< 5	< 5	< 5	< 5	24 (0.23)	< 5	
MP	12 (0.06)	< 5	6 (0.41)	< 5	< 5	< 5	29 (0.27)	9 (0.10)		
31 to 90 days	VTE	58 (0.29)	11 (0.05)	34 (2.30)	< 5	5 (0.11)	< 5	90 (0.85)	12 (0.14)	
	DVT	21 (0.10)	< 5	21 (1.42)	< 5	< 5	< 5	61 (0.57)	7 (0.08)	
	PE	40 (0.20)	7 (0.03)	16 (1.08)	< 5	< 5	< 5	38 (0.36)	6 (0.07)	
	ATE	12 (0.06)	< 5	32 (2.17)	< 5	< 5	< 5	114 (1.07)	18 (0.20)	
	IS	< 5	< 5	16 (1.08)	< 5	< 5	< 5	50 (0.47)	7 (0.08)	
	TIA	< 5	< 5	5 (0.34)	< 5	< 5	< 5	32 (0.30)	7 (0.08)	
	MI	9 (0.04)	< 5	14 (0.95)	< 5	< 5	< 5	40 (0.38)	< 5	
	HF	14 (0.07)	8 (0.04)	126 (8.54)	< 5	< 5	< 5	138 (1.30)	17 (0.19)	
	HS	< 5	< 5	< 5	< 5	< 5	< 5	9 (0.08)	< 5	

Cohort	Time window	Outcome	AURUM		CORIVA		GOLD		SIDIAP	
			Unvaccinated	Vaccinated	Unvaccinated	Vaccinated	Unvaccinated	Vaccinated	Unvaccinated	Vaccinated
91 to 180 days		MP	7 (0.03)	< 5	6 (0.41)	< 5	< 5	< 5	11 (0.10)	< 5
		VTE	26 (0.13)	9 (0.04)	41 (2.78)	< 5	< 5	< 5	72 (0.68)	11 (0.12)
		DVT	10 (0.05)	7 (0.03)	27 (1.83)	< 5	< 5	< 5	42 (0.40)	6 (0.07)
		PE	17 (0.08)	< 5	15 (1.02)	< 5	< 5	< 5	34 (0.32)	6 (0.07)
		ATE	< 5	5 (0.02)	24 (1.63)	< 5	< 5	< 5	129 (1.22)	21 (0.24)
		IS	< 5	< 5	10 (0.68)	< 5	< 5	< 5	62 (0.58)	11 (0.12)
		TIA	< 5	< 5	9 (0.61)	< 5	< 5	< 5	30 (0.28)	< 5
		MI	< 5	< 5	9 (0.61)	< 5	< 5	< 5	40 (0.38)	7 (0.08)
		HF	10 (0.05)	< 5	152 (10.30)	< 5	< 5	< 5	138 (1.30)	19 (0.22)
		HS	< 5	< 5	< 5	< 5	< 5	< 5	14 (0.13)	< 5
181 to 365 days		MP	< 5	< 5	< 5	< 5	< 5	< 5	12 (0.11)	< 5
		VTE	< 5	< 5	64 (4.34)	5 (2.25)	< 5	< 5	48 (0.45)	9 (0.10)
		DVT	< 5	< 5	36 (2.44)	< 5	< 5	< 5	31 (0.29)	5 (0.06)
		PE	< 5	< 5	31 (2.10)	< 5	< 5	< 5	18 (0.17)	< 5
		ATE	< 5	< 5	56 (3.80)	< 5	< 5	< 5	51 (0.48)	22 (0.25)
		IS	< 5	< 5	28 (1.90)	< 5	< 5	< 5	22 (0.21)	15 (0.17)
		TIA	< 5	< 5	15 (1.02)	< 5	< 5	< 5	11 (0.10)	< 5
		MI	< 5	< 5	19 (1.29)	< 5	< 5	< 5	19 (0.18)	7 (0.08)
		HF	< 5	< 5	243 (16.47)	< 5	< 5	< 5	59 (0.56)	11 (0.12)
		HS	< 5	< 5	6 (0.41)	< 5	< 5	< 5	5 (0.05)	< 5
	MP	< 5	< 5	< 5	< 5	< 5	< 5	6 (0.06)	< 5	

VTE = Venous thromboembolism (DVT + PE), DVT = Deep vein thrombosis, PE = Pulmonary embolism, ATE = Arterial thromboembolism (IS + TIA + MI), IS = Ischemic stroke, TIA = Transient ischemic attack, MI = Myocardial infarction, HF = Heart failure, HS = Hemorrhagic stroke, MP = Myocarditis or Pericarditis

Table S28: Number of records (and risk per 10,000 individuals) for post COVID-19 cardiac and thromboembolic complications, across cohorts and databases, stratified by exposure status (any COVID-19 vaccine). Only first outcome after COVID-19 captured.

Cohort	Time window	Outcome	AURUM		CORIVA		GOLD		SIDIAP	
			Unvaccinated	Vaccinated	Unvaccinated	Vaccinated	Unvaccinated	Vaccinated	Unvaccinated	Vaccinated
Cohort 1			N = 346,674	N = 552,602	N = 23,982	N = 26,736	N = 169,100	N = 118,507	N = 223,962	N = 89,941
0 to 30 days	VTE	154 (4.44)	117 (2.12)	93 (38.78)	36 (13.46)	15 (0.89)	8 (0.68)	251 (11.21)	96 (10.67)	
	DVT	40 (1.15)	27 (0.49)	17 (7.09)	8 (2.99)	< 5	< 5	77 (3.44)	29 (3.22)	
	PE	123 (3.55)	95 (1.72)	79 (32.94)	30 (11.22)	13 (0.77)	7 (0.59)	186 (8.30)	77 (8.56)	
	ATE	57 (1.64)	70 (1.27)	128 (53.37)	50 (18.70)	8 (0.47)	7 (0.59)	350 (15.63)	208 (23.13)	
	IS	15 (0.43)	5 (0.09)	79 (32.94)	23 (8.60)	< 5	< 5	192 (8.57)	116 (12.90)	
	TIA	13 (0.37)	18 (0.33)	25 (10.42)	9 (3.37)	< 5	< 5	58 (2.59)	41 (4.56)	
	MI	31 (0.89)	46 (0.83)	36 (15.01)	26 (9.72)	6 (0.35)	5 (0.42)	116 (5.18)	63 (7.00)	
	HF	135 (3.89)	198 (3.58)	439 (183.05)	199 (74.43)	21 (1.24)	9 (0.76)	1,205 (53.80)	640 (71.16)	
	HS	< 5	7 (0.13)	< 5	< 5	< 5	< 5	46 (2.05)	14 (1.56)	
	MP	< 5	< 5	< 5	< 5	< 5	< 5	16 (0.71)	< 5	
31 to 90 days	VTE	32 (0.92)	39 (0.71)	32 (13.34)	12 (4.49)	< 5	< 5	88 (3.93)	45 (5.00)	
	DVT	14 (0.40)	15 (0.27)	19 (7.92)	5 (1.87)	< 5	< 5	53 (2.37)	29 (3.22)	
	PE	18 (0.52)	25 (0.45)	16 (6.67)	7 (2.62)	< 5	< 5	41 (1.83)	20 (2.22)	
	ATE	15 (0.43)	43 (0.78)	30 (12.51)	23 (8.60)	< 5	< 5	216 (9.64)	127 (14.12)	
	IS	< 5	< 5	18 (7.51)	11 (4.11)	< 5	< 5	110 (4.91)	70 (7.78)	
	TIA	6 (0.17)	19 (0.34)	10 (4.17)	8 (2.99)	< 5	< 5	70 (3.13)	32 (3.56)	
	MI	10 (0.29)	20 (0.36)	10 (4.17)	6 (2.24)	< 5	< 5	49 (2.19)	29 (3.22)	
	HF	72 (2.08)	109 (1.97)	134 (55.88)	83 (31.04)	8 (0.47)	8 (0.68)	473 (21.12)	290 (32.24)	
	HS	< 5	< 5	< 5	< 5	< 5	< 5	17 (0.76)	12 (1.33)	
	MP	< 5	< 5	< 5	< 5	< 5	< 5	< 5	< 5	
91 to 180 days	VTE	17 (0.49)	18 (0.33)	19 (7.92)	14 (5.24)	6 (0.35)	< 5	62 (2.77)	35 (3.89)	
	DVT	7 (0.20)	8 (0.14)	9 (3.75)	5 (1.87)	< 5	< 5	37 (1.65)	19 (2.11)	
	PE	10 (0.29)	10 (0.18)	12 (5.00)	10 (3.74)	< 5	< 5	29 (1.29)	18 (2.00)	
	ATE	23 (0.66)	28 (0.51)	30 (12.51)	22 (8.23)	< 5	6 (0.51)	184 (8.22)	104 (11.56)	
	IS	< 5	8 (0.14)	20 (8.34)	9 (3.37)	< 5	< 5	114 (5.09)	57 (6.34)	
	TIA	10 (0.29)	12 (0.22)	6 (2.50)	5 (1.87)	< 5	< 5	40 (1.79)	34 (3.78)	
	MI	12 (0.35)	8 (0.14)	7 (2.92)	11 (4.11)	< 5	5 (0.42)	38 (1.70)	23 (2.56)	
	HF	58 (1.67)	89 (1.61)	157 (65.47)	108 (40.39)	< 5	5 (0.42)	398 (17.77)	228 (25.35)	
	HS	< 5	< 5	< 5	< 5	< 5	< 5	21 (0.94)	< 5	
	MP	< 5	< 5	< 5	< 5	< 5	< 5	< 5	< 5	
181 to 365 days	VTE	10 (0.29)	11 (0.20)	45 (18.76)	22 (8.23)	< 5	< 5	26 (1.16)	11 (1.22)	
	DVT	5 (0.14)	6 (0.11)	16 (6.67)	13 (4.86)	< 5	< 5	16 (0.71)	7 (0.78)	
	PE	5 (0.14)	5 (0.09)	34 (14.18)	10 (3.74)	< 5	< 5	12 (0.54)	< 5	
	ATE	14 (0.40)	23 (0.42)	51 (21.27)	40 (14.96)	< 5	< 5	104 (4.64)	39 (4.34)	
	IS	< 5	6 (0.11)	30 (12.51)	19 (7.11)	< 5	< 5	54 (2.41)	24 (2.67)	
	TIA	8 (0.23)	7 (0.13)	16 (6.67)	17 (6.36)	< 5	< 5	25 (1.12)	9 (1.00)	
	MI	< 5	11 (0.20)	12 (5.00)	12 (4.49)	< 5	< 5	29 (1.29)	7 (0.78)	
	HF	49 (1.41)	53 (0.96)	253 (105.50)	191 (71.44)	< 5	6 (0.51)	195 (8.71)	117 (13.01)	
	HS	< 5	< 5	< 5	< 5	< 5	< 5	5 (0.22)	7 (0.78)	
	MP	< 5	< 5	< 5	< 5	< 5	< 5	< 5	< 5	
Cohort 2			N = 1,975,726	N = 1,563,569	N = 34,317	N = 4,572	N = 583,399	N = 486,619	N = 433,151	N = 819,590
0 to 30 days	VTE	345 (1.75)	220 (1.41)	88 (25.64)	8 (17.50)	42 (0.72)	24 (0.49)	404 (9.33)	400 (4.88)	
	DVT	74 (0.37)	65 (0.42)	16 (4.66)	< 5	9 (0.15)	5 (0.10)	119 (2.75)	165 (2.01)	
	PE	278 (1.41)	165 (1.06)	73 (21.27)	5 (10.94)	34 (0.58)	19 (0.39)	315 (7.27)	269 (3.28)	

Cohort	Time window	Outcome	AURUM		CORIVA		GOLD		SIDIAPI		
			Unvaccinated	Vaccinated	Unvaccinated	Vaccinated	Unvaccinated	Vaccinated	Unvaccinated	Vaccinated	
		ATE	74 (0.37)	104 (0.67)	129 (37.59)	5 (10.94)	8 (0.14)	6 (0.12)	345 (7.96)	669 (8.16)	
		IS	11 (0.06)	14 (0.09)	79 (23.02)	< 5	< 5	< 5	188 (4.34)	346 (4.22)	
		TIA	17 (0.09)	24 (0.15)	24 (6.99)	< 5	< 5	< 5	46 (1.06)	122 (1.49)	
		MI	46 (0.23)	68 (0.43)	36 (10.49)	< 5	6 (0.10)	6 (0.12)	128 (2.96)	239 (2.92)	
		HF	73 (0.37)	146 (0.93)	393 (114.52)	20 (43.74)	5 (0.09)	13 (0.27)	637 (14.71)	1,331 (16.24)	
		HS	6 (0.03)	5 (0.03)	< 5	< 5	< 5	< 5	39 (0.90)	77 (0.94)	
		MP	21 (0.11)	7 (0.04)	< 5	< 5	< 5	< 5	29 (0.67)	37 (0.45)	
	31 to 90 days	VTE	85 (0.43)	75 (0.48)	37 (10.78)	< 5	7 (0.12)	9 (0.18)	106 (2.45)	187 (2.28)	
		DVT	48 (0.24)	32 (0.20)	23 (6.70)	< 5	< 5	5 (0.10)	61 (1.41)	119 (1.45)	
		PE	41 (0.21)	45 (0.29)	17 (4.95)	< 5	< 5	< 5	55 (1.27)	87 (1.06)	
		ATE	39 (0.20)	92 (0.59)	31 (9.03)	< 5	7 (0.12)	9 (0.18)	201 (4.64)	437 (5.33)	
		IS	6 (0.03)	11 (0.07)	21 (6.12)	< 5	< 5	< 5	96 (2.22)	231 (2.82)	
		TIA	11 (0.06)	33 (0.21)	6 (1.75)	< 5	< 5	6 (0.12)	54 (1.25)	115 (1.40)	
		MI	23 (0.12)	50 (0.32)	10 (2.91)	< 5	< 5	< 5	64 (1.48)	113 (1.38)	
	91 to 180 days	HF	50 (0.25)	99 (0.63)	143 (41.67)	10 (21.87)	5 (0.09)	7 (0.14)	265 (6.12)	622 (7.59)	
		HS	6 (0.03)	< 5	< 5	< 5	< 5	< 5	19 (0.44)	27 (0.33)	
		MP	14 (0.07)	< 5	< 5	< 5	< 5	< 5	8 (0.18)	8 (0.10)	
		VTE	38 (0.19)	37 (0.24)	24 (6.99)	5 (10.94)	8 (0.14)	< 5	100 (2.31)	109 (1.33)	
		DVT	21 (0.11)	21 (0.13)	11 (3.21)	< 5	< 5	< 5	56 (1.29)	71 (0.87)	
		PE	17 (0.09)	19 (0.12)	14 (4.08)	< 5	7 (0.12)	< 5	51 (1.18)	46 (0.56)	
		ATE	31 (0.16)	43 (0.28)	28 (8.16)	< 5	5 (0.09)	< 5	171 (3.95)	394 (4.81)	
	181 to 365 days	IS	< 5	< 5	17 (4.95)	< 5	< 5	< 5	88 (2.03)	202 (2.46)	
		TIA	13 (0.07)	18 (0.12)	7 (2.04)	< 5	< 5	< 5	40 (0.92)	109 (1.33)	
		MI	17 (0.09)	25 (0.16)	7 (2.04)	< 5	< 5	< 5	49 (1.13)	104 (1.27)	
		HF	31 (0.16)	65 (0.42)	167 (48.66)	14 (30.62)	< 5	< 5	212 (4.89)	534 (6.52)	
		HS	< 5	< 5	< 5	< 5	< 5	< 5	18 (0.42)	35 (0.43)	
		MP	5 (0.03)	< 5	< 5	< 5	< 5	< 5	12 (0.28)	9 (0.11)	
		VTE	16 (0.08)	12 (0.08)	47 (13.70)	< 5	< 5	< 5	31 (0.72)	52 (0.63)	
	Cohort 3	0 to 30 days	DVT	8 (0.04)	5 (0.03)	24 (6.99)	< 5	< 5	< 5	18 (0.42)	36 (0.44)
			PE	9 (0.05)	8 (0.05)	28 (8.16)	< 5	< 5	< 5	16 (0.37)	19 (0.23)
ATE			12 (0.06)	17 (0.11)	57 (16.61)	5 (10.94)	< 5	< 5	97 (2.24)	151 (1.84)	
IS			< 5	< 5	36 (10.49)	< 5	< 5	< 5	54 (1.25)	71 (0.87)	
TIA			< 5	5 (0.03)	15 (4.37)	< 5	< 5	< 5	21 (0.48)	46 (0.56)	
MI			7 (0.04)	10 (0.06)	11 (3.21)	< 5	< 5	< 5	27 (0.62)	45 (0.55)	
HF			19 (0.10)	34 (0.22)	268 (78.10)	17 (37.18)	< 5	< 5	94 (2.17)	209 (2.55)	
HS			< 5	< 5	< 5	< 5	< 5	< 5	< 5	10 (0.12)	
MP			< 5	< 5	< 5	< 5	< 5	< 5	< 5	< 5	
				N = 1,510,401	N = 1,528,031	N = 96,423	N = 24,050	N = 417,996	N = 462,832	N = 869,497	N = 954,232
	31 to 90 days	VTE	268 (1.77)	142 (0.93)	122 (12.65)	8 (3.33)	32 (0.77)	17 (0.37)	425 (4.89)	180 (1.89)	
		DVT	53 (0.35)	41 (0.27)	25 (2.59)	6 (2.49)	7 (0.17)	< 5	134 (1.54)	78 (0.82)	
		PE	224 (1.48)	105 (0.69)	98 (10.16)	< 5	26 (0.62)	13 (0.28)	327 (3.76)	118 (1.24)	
		ATE	34 (0.23)	49 (0.32)	133 (13.79)	11 (4.57)	< 5	12 (0.26)	315 (3.62)	275 (2.88)	
		IS	5 (0.03)	5 (0.03)	73 (7.57)	8 (3.33)	< 5	< 5	155 (1.78)	130 (1.36)	
		TIA	6 (0.04)	17 (0.11)	26 (2.70)	< 5	< 5	< 5	32 (0.37)	53 (0.56)	
		MI	23 (0.15)	27 (0.18)	42 (4.36)	< 5	< 5	9 (0.19)	137 (1.58)	113 (1.18)	
		HF	33 (0.22)	38 (0.25)	398 (41.28)	34 (14.14)	< 5	< 5	478 (5.50)	256 (2.68)	
		HS	< 5	< 5	6 (0.62)	< 5	< 5	< 5	34 (0.39)	35 (0.37)	
	MP	14 (0.09)	6 (0.04)	< 5	< 5	< 5	< 5	27 (0.31)	20 (0.21)		
		N = 1,510,401	N = 1,528,031	N = 96,423	N = 24,050	N = 417,996	N = 462,832	N = 869,497	N = 954,232		

Cohort	Time window	Outcome	AURUM		CORIVA		GOLD		SIDAP	
			Unvaccinated	Vaccinated	Unvaccinated	Vaccinated	Unvaccinated	Vaccinated	Unvaccinated	Vaccinated
		DVT	28 (0.19)	27 (0.18)	30 (3.11)	< 5	< 5	< 5	79 (0.91)	60 (0.63)
		PE	33 (0.22)	19 (0.12)	18 (1.87)	5 (2.08)	< 5	< 5	47 (0.54)	37 (0.39)
		ATE	14 (0.09)	33 (0.22)	41 (4.25)	12 (4.99)	< 5	8 (0.17)	169 (1.94)	207 (2.17)
		IS	< 5	< 5	24 (2.49)	5 (2.08)	< 5	< 5	74 (0.85)	87 (0.91)
		TIA	< 5	14 (0.09)	6 (0.62)	6 (2.49)	< 5	< 5	50 (0.58)	35 (0.37)
		MI	11 (0.07)	16 (0.10)	16 (1.66)	< 5	< 5	5 (0.11)	57 (0.66)	93 (0.97)
		HF	22 (0.15)	26 (0.17)	175 (18.15)	15 (6.24)	< 5	< 5	185 (2.13)	154 (1.61)
		HS	< 5	< 5	< 5	< 5	< 5	< 5	13 (0.15)	19 (0.20)
		MP	9 (0.06)	8 (0.05)	7 (0.73)	< 5	< 5	< 5	12 (0.14)	11 (0.12)
	91 to 180 days	VTE	28 (0.19)	25 (0.16)	41 (4.25)	9 (3.74)	5 (0.12)	< 5	90 (1.04)	92 (0.96)
		DVT	14 (0.09)	15 (0.10)	25 (2.59)	5 (2.08)	< 5	< 5	54 (0.62)	61 (0.64)
		PE	16 (0.11)	13 (0.09)	16 (1.66)	< 5	< 5	< 5	41 (0.47)	34 (0.36)
		ATE	8 (0.05)	28 (0.18)	43 (4.46)	8 (3.33)	< 5	< 5	172 (1.98)	199 (2.09)
		IS	< 5	< 5	19 (1.97)	5 (2.08)	< 5	< 5	78 (0.90)	92 (0.96)
		TIA	< 5	9 (0.06)	13 (1.35)	< 5	< 5	< 5	30 (0.35)	47 (0.49)
		MI	< 5	18 (0.12)	16 (1.66)	< 5	< 5	< 5	66 (0.76)	69 (0.72)
		HF	12 (0.08)	12 (0.08)	206 (21.36)	18 (7.48)	< 5	< 5	168 (1.93)	133 (1.39)
		HS	< 5	< 5	< 5	< 5	< 5	< 5	16 (0.18)	13 (0.14)
	181 to 365 days	MP	< 5	< 5	6 (0.62)	< 5	< 5	< 5	11 (0.13)	14 (0.15)
		VTE	< 5	9 (0.06)	69 (7.16)	15 (6.24)	< 5	< 5	39 (0.45)	19 (0.20)
DVT		< 5	< 5	42 (4.36)	12 (4.99)	< 5	< 5	24 (0.28)	14 (0.15)	
PE		< 5	6 (0.04)	30 (3.11)	5 (2.08)	< 5	< 5	18 (0.21)	6 (0.06)	
ATE		< 5	< 5	80 (8.30)	8 (3.33)	< 5	< 5	56 (0.64)	58 (0.61)	
IS		< 5	< 5	37 (3.84)	< 5	< 5	< 5	28 (0.32)	22 (0.23)	
TIA		< 5	< 5	23 (2.39)	< 5	< 5	< 5	11 (0.13)	7 (0.07)	
MI		< 5	< 5	27 (2.80)	< 5	< 5	< 5	18 (0.21)	32 (0.34)	
HF		5 (0.03)	< 5	314 (32.56)	35 (14.55)	< 5	< 5	63 (0.72)	36 (0.38)	
Cohort 4			N = 2,027,763	N = 2,085,598	N = 147,545	N = 22,245	N = 469,876	N = 550,437	N = 1,061,634	N = 880,950
0 to 30 days	VTE	337 (1.66)	50 (0.24)	120 (8.13)	< 5	36 (0.77)	11 (0.20)	388 (3.65)	98 (1.11)	
	DVT	55 (0.27)	17 (0.08)	24 (1.63)	< 5	6 (0.13)	< 5	123 (1.16)	48 (0.54)	
	PE	294 (1.45)	34 (0.16)	97 (6.57)	< 5	31 (0.66)	8 (0.15)	297 (2.80)	55 (0.62)	
	ATE	26 (0.13)	8 (0.04)	121 (8.20)	10 (4.50)	< 5	< 5	268 (2.52)	95 (1.08)	
	IS	< 5	< 5	69 (4.68)	< 5	< 5	< 5	136 (1.28)	47 (0.53)	
	TIA	6 (0.03)	< 5	22 (1.49)	< 5	< 5	< 5	36 (0.34)	12 (0.14)	
	MI	16 (0.08)	< 5	38 (2.58)	< 5	< 5	< 5	103 (0.97)	39 (0.44)	
	HF	28 (0.14)	< 5	370 (25.08)	18 (8.09)	< 5	< 5	430 (4.05)	75 (0.85)	
	HS	< 5	< 5	< 5	< 5	< 5	< 5	33 (0.31)	13 (0.15)	
31 to 90 days	MP	13 (0.06)	8 (0.04)	7 (0.47)	< 5	< 5	< 5	31 (0.29)	17 (0.19)	
	VTE	56 (0.28)	22 (0.11)	45 (3.05)	< 5	6 (0.13)	< 5	106 (1.00)	48 (0.54)	
	DVT	21 (0.10)	12 (0.06)	30 (2.03)	< 5	< 5	< 5	73 (0.69)	32 (0.36)	
	PE	38 (0.19)	10 (0.05)	18 (1.22)	< 5	5 (0.11)	< 5	42 (0.40)	17 (0.19)	
	ATE	12 (0.06)	9 (0.04)	39 (2.64)	< 5	< 5	< 5	141 (1.33)	75 (0.85)	
	IS	< 5	< 5	22 (1.49)	< 5	< 5	< 5	62 (0.58)	30 (0.34)	
	TIA	< 5	< 5	7 (0.47)	< 5	< 5	< 5	42 (0.40)	23 (0.26)	
	MI	9 (0.04)	7 (0.03)	15 (1.02)	< 5	< 5	< 5	46 (0.43)	25 (0.28)	
	HF	14 (0.07)	9 (0.04)	160 (10.84)	16 (7.19)	< 5	< 5	153 (1.44)	47 (0.53)	
HS	5 (0.02)	< 5	< 5	< 5	< 5	< 5	12 (0.11)	5 (0.06)		

Cohort	Time window	Outcome	AURUM		CORIVA		GOLD		SIDIAP	
			Unvaccinated	Vaccinated	Unvaccinated	Vaccinated	Unvaccinated	Vaccinated	Unvaccinated	Vaccinated
91 to 180 days		MP	8 (0.04)	< 5	8 (0.54)	< 5	< 5	< 5	14 (0.13)	11 (0.12)
		VTE	25 (0.12)	9 (0.04)	42 (2.85)	7 (3.15)	< 5	< 5	85 (0.80)	52 (0.59)
		DVT	9 (0.04)	7 (0.03)	28 (1.90)	5 (2.25)	< 5	< 5	54 (0.51)	33 (0.37)
		PE	17 (0.08)	< 5	15 (1.02)	< 5	< 5	< 5	36 (0.34)	22 (0.25)
		ATE	< 5	6 (0.03)	32 (2.17)	12 (5.39)	< 5	< 5	141 (1.33)	86 (0.98)
		IS	< 5	< 5	14 (0.95)	5 (2.25)	< 5	< 5	64 (0.60)	42 (0.48)
		TIA	< 5	< 5	10 (0.68)	< 5	< 5	< 5	29 (0.27)	17 (0.19)
		MI	< 5	< 5	12 (0.81)	< 5	< 5	< 5	50 (0.47)	27 (0.31)
		HF	10 (0.05)	< 5	182 (12.34)	13 (5.84)	< 5	< 5	159 (1.50)	54 (0.61)
		HS	< 5	< 5	< 5	< 5	< 5	< 5	17 (0.16)	6 (0.07)
181 to 365 days		MP	< 5	< 5	6 (0.41)	< 5	< 5	< 5	14 (0.13)	6 (0.07)
		VTE	< 5	< 5	72 (4.88)	10 (4.50)	< 5	< 5	41 (0.39)	8 (0.09)
		DVT	< 5	< 5	45 (3.05)	9 (4.05)	< 5	< 5	26 (0.24)	6 (0.07)
		PE	< 5	< 5	30 (2.03)	< 5	< 5	< 5	16 (0.15)	< 5
		ATE	< 5	< 5	67 (4.54)	10 (4.50)	< 5	< 5	42 (0.40)	16 (0.18)
		IS	< 5	< 5	32 (2.17)	< 5	< 5	< 5	18 (0.17)	11 (0.12)
		TIA	< 5	< 5	19 (1.29)	< 5	< 5	< 5	8 (0.08)	< 5
		MI	< 5	< 5	22 (1.49)	< 5	< 5	< 5	17 (0.16)	5 (0.06)
		HF	< 5	< 5	289 (19.59)	13 (5.84)	< 5	< 5	51 (0.48)	11 (0.12)
		HS	< 5	< 5	7 (0.47)	< 5	< 5	< 5	< 5	< 5
	MP	< 5	< 5	7 (0.47)	< 5	< 5	< 5	6 (0.06)	< 5	

VTE = Venous thromboembolism (DVT + PE), DVT = Deep vein thrombosis, PE = Pulmonary embolism, ATE = Arterial thromboembolism (IS + TIA + MI), IS = Ischemic stroke, TIA = Transient ischemic attack, MI = Myocardial infarction, HF = Heart failure, HS = Hemorrhagic stroke, MP = Myocarditis or Pericarditis

Table S29: Number of records (and risk per 10,000 individuals) for post COVID-19 cardiac and thromboembolic complications, across cohorts and databases, stratified by exposure status (ChAdOx1 vaccine).

Cohort	Time window	Outcome	AURUM		GOLD		SIDIAP	
			Unvaccinated	Vaccinated	Unvaccinated	Vaccinated	Unvaccinated	Vaccinated
Cohort 1			N = 344,687	N = 219,804	N = 168,972	N = 82,406		
	0 to 30 days	VTE	138 (4.00)	41 (1.87)	14 (0.83)	< 5		
		DVT	34 (0.99)	12 (0.55)	< 5	< 5		
		PE	112 (3.25)	31 (1.41)	12 (0.71)	< 5		
		ATE	53 (1.54)	25 (1.14)	9 (0.53)	6 (0.73)		
		IS	13 (0.38)	< 5	< 5	< 5		
		TIA	12 (0.35)	7 (0.32)	< 5	< 5		
		MI	29 (0.84)	17 (0.77)	7 (0.41)	< 5		
		HF	119 (3.45)	72 (3.28)	20 (1.18)	5 (0.61)		
		HS	< 5	< 5	< 5	< 5		
		MP	< 5	< 5	< 5	< 5		
		31 to 90 days	VTE	25 (0.73)	14 (0.64)	< 5	< 5	
	DVT		9 (0.26)	8 (0.36)	< 5	< 5		
	PE		16 (0.46)	7 (0.32)	< 5	< 5		
	ATE		16 (0.46)	20 (0.91)	< 5	< 5		
	IS		< 5	< 5	< 5	< 5		
	TIA		6 (0.17)	9 (0.41)	< 5	< 5		
	MI		11 (0.32)	9 (0.41)	< 5	< 5		
	HF		69 (2.00)	42 (1.91)	6 (0.36)	5 (0.61)		
	HS		< 5	< 5	< 5	< 5		
	MP		< 5	< 5	< 5	< 5		
	91 to 180 days		VTE	13 (0.38)	15 (0.68)	6 (0.36)	< 5	
		DVT	5 (0.15)	5 (0.23)	< 5	< 5		
		PE	8 (0.23)	10 (0.45)	< 5	< 5		
		ATE	22 (0.64)	10 (0.45)	< 5	6 (0.73)		
		IS	< 5	< 5	< 5	< 5		
		TIA	10 (0.29)	6 (0.27)	< 5	< 5		
		MI	11 (0.32)	< 5	< 5	5 (0.61)		
		HF	54 (1.57)	38 (1.73)	< 5	< 5		
		HS	< 5	< 5	< 5	< 5		
		MP	< 5	< 5	< 5	< 5		
		181 to 365 days	VTE	6 (0.17)	< 5	< 5	< 5	
	DVT		< 5	< 5	< 5	< 5		
	PE		< 5	< 5	< 5	< 5		
	ATE		13 (0.38)	9 (0.41)	< 5	< 5		
	IS		< 5	< 5	< 5	< 5		
	TIA		6 (0.17)	< 5	< 5	< 5		
	MI		< 5	< 5	< 5	< 5		
	HF		49 (1.42)	20 (0.91)	< 5	5 (0.61)		
	HS		< 5	< 5	< 5	< 5		
	MP		< 5	< 5	< 5	< 5		
Cohort 2				N = 1,975,770	N = 969,262	N = 582,791	N = 302,999	N = 433,636
	0 to 30 days	VTE	347 (1.76)	158 (1.63)	44 (0.75)	19 (0.63)	403 (9.29)	90 (2.78)
		DVT	75 (0.38)	47 (0.48)	9 (0.15)	< 5	122 (2.81)	45 (1.39)
		PE	280 (1.42)	120 (1.24)	36 (0.62)	15 (0.50)	311 (7.17)	55 (1.70)

Cohort	Time window	Outcome	AURUM		GOLD		SIDIAP	
			Unvaccinated	Vaccinated	Unvaccinated	Vaccinated	Unvaccinated	Vaccinated
	31 to 90 days	ATE	70 (0.35)	75 (0.77)	9 (0.15)	< 5	341 (7.86)	131 (4.05)
		IS	10 (0.05)	12 (0.12)	< 5	< 5	186 (4.29)	52 (1.61)
		TIA	15 (0.08)	13 (0.13)	< 5	< 5	45 (1.04)	23 (0.71)
		MI	45 (0.23)	52 (0.54)	7 (0.12)	< 5	127 (2.93)	62 (1.92)
		HF	74 (0.37)	103 (1.06)	5 (0.09)	11 (0.36)	642 (14.81)	123 (3.81)
		HS	5 (0.03)	< 5	< 5	< 5	38 (0.88)	7 (0.22)
		MP	20 (0.10)	6 (0.06)	< 5	< 5	29 (0.67)	10 (0.31)
		VTE	93 (0.47)	55 (0.57)	6 (0.10)	9 (0.30)	107 (2.47)	36 (1.11)
		DVT	50 (0.25)	25 (0.26)	< 5	5 (0.17)	60 (1.38)	25 (0.77)
		PE	46 (0.23)	32 (0.33)	< 5	< 5	57 (1.31)	18 (0.56)
		ATE	37 (0.19)	57 (0.59)	8 (0.14)	5 (0.17)	204 (4.70)	107 (3.31)
		IS	6 (0.03)	6 (0.06)	< 5	< 5	97 (2.24)	58 (1.79)
	TIA	11 (0.06)	25 (0.26)	< 5	< 5	55 (1.27)	24 (0.74)	
	MI	21 (0.11)	28 (0.29)	< 5	< 5	65 (1.50)	27 (0.84)	
	HF	47 (0.24)	68 (0.70)	6 (0.10)	7 (0.23)	269 (6.20)	62 (1.92)	
	HS	6 (0.03)	< 5	< 5	< 5	18 (0.42)	7 (0.22)	
	MP	14 (0.07)	< 5	< 5	< 5	8 (0.18)	< 5	
	91 to 180 days	VTE	39 (0.20)	30 (0.31)	6 (0.10)	< 5	118 (2.72)	23 (0.71)
		DVT	20 (0.10)	16 (0.17)	< 5	< 5	66 (1.52)	16 (0.50)
		PE	19 (0.10)	16 (0.17)	6 (0.10)	< 5	60 (1.38)	8 (0.25)
		ATE	28 (0.14)	28 (0.29)	5 (0.09)	< 5	187 (4.31)	106 (3.28)
		IS	< 5	< 5	< 5	< 5	96 (2.21)	40 (1.24)
		TIA	12 (0.06)	13 (0.13)	< 5	< 5	42 (0.97)	32 (0.99)
		MI	15 (0.08)	15 (0.15)	< 5	< 5	55 (1.27)	37 (1.14)
		HF	26 (0.13)	44 (0.45)	< 5	< 5	231 (5.33)	60 (1.86)
		HS	< 5	< 5	< 5	< 5	17 (0.39)	< 5
		MP	< 5	< 5	< 5	< 5	12 (0.28)	< 5
	181 to 365 days	VTE	23 (0.12)	5 (0.05)	< 5	< 5	35 (0.81)	16 (0.50)
		DVT	9 (0.05)	< 5	< 5	< 5	19 (0.44)	13 (0.40)
		PE	15 (0.08)	< 5	< 5	< 5	18 (0.42)	< 5
		ATE	13 (0.07)	11 (0.11)	< 5	< 5	110 (2.54)	46 (1.42)
		IS	< 5	< 5	< 5	< 5	57 (1.31)	21 (0.65)
		TIA	< 5	< 5	< 5	< 5	25 (0.58)	13 (0.40)
		MI	9 (0.05)	7 (0.07)	< 5	< 5	33 (0.76)	16 (0.50)
		HF	20 (0.10)	23 (0.24)	< 5	< 5	110 (2.54)	26 (0.80)
		HS	< 5	< 5	< 5	< 5	6 (0.14)	< 5
MP		< 5	< 5	< 5	< 5	< 5	< 5	
Cohort 3		N = 1,510,493	N = 1,473,602	N = 418,184	N = 423,876	N = 873,400	N = 84,204	
0 to 30 days	VTE	267 (1.77)	139 (0.94)	33 (0.79)	16 (0.38)	431 (4.93)	27 (3.21)	
	DVT	52 (0.34)	41 (0.28)	7 (0.17)	< 5	137 (1.57)	9 (1.07)	
	PE	224 (1.48)	101 (0.69)	27 (0.65)	12 (0.28)	331 (3.79)	22 (2.61)	
	ATE	33 (0.22)	47 (0.32)	< 5	12 (0.28)	319 (3.65)	32 (3.80)	
	IS	5 (0.03)	5 (0.03)	< 5	< 5	154 (1.76)	13 (1.54)	
	TIA	6 (0.04)	16 (0.11)	< 5	< 5	33 (0.38)	5 (0.59)	
	MI	22 (0.15)	26 (0.18)	< 5	9 (0.21)	141 (1.61)	16 (1.90)	
	HF	32 (0.21)	28 (0.19)	< 5	< 5	486 (5.56)	51 (6.06)	
	HS	< 5	< 5	< 5	< 5	34 (0.39)	< 5	
	MP	14 (0.09)	6 (0.04)	< 5	< 5	27 (0.31)	6 (0.71)	
31 to 90 days	VTE	63 (0.42)	44 (0.30)	< 5	7 (0.17)	121 (1.39)	9 (1.07)	

Cohort	Time window	Outcome	AURUM		GOLD		SIDIAP	
			Unvaccinated	Vaccinated	Unvaccinated	Vaccinated	Unvaccinated	Vaccinated
		DVT	30 (0.20)	26 (0.18)	< 5	< 5	82 (0.94)	< 5
		PE	36 (0.24)	18 (0.12)	< 5	< 5	51 (0.58)	6 (0.71)
		ATE	14 (0.09)	31 (0.21)	< 5	7 (0.17)	174 (1.99)	25 (2.97)
		IS	< 5	< 5	< 5	< 5	78 (0.89)	11 (1.31)
		TIA	< 5	13 (0.09)	< 5	< 5	50 (0.57)	< 5
		MI	11 (0.07)	16 (0.11)	< 5	< 5	58 (0.66)	10 (1.19)
		HF	21 (0.14)	23 (0.16)	< 5	< 5	194 (2.22)	25 (2.97)
		HS	5 (0.03)	< 5	< 5	< 5	13 (0.15)	< 5
		MP	9 (0.06)	7 (0.05)	< 5	< 5	14 (0.16)	< 5
	91 to 180 days	VTE	29 (0.19)	26 (0.18)	5 (0.12)	< 5	103 (1.18)	14 (1.66)
		DVT	15 (0.10)	15 (0.10)	< 5	< 5	60 (0.69)	7 (0.83)
		PE	16 (0.11)	14 (0.10)	< 5	< 5	48 (0.55)	8 (0.95)
		ATE	8 (0.05)	26 (0.18)	< 5	< 5	189 (2.16)	30 (3.56)
		IS	< 5	< 5	< 5	< 5	88 (1.01)	14 (1.66)
		TIA	< 5	8 (0.05)	< 5	< 5	33 (0.38)	10 (1.19)
		MI	< 5	17 (0.12)	< 5	< 5	71 (0.81)	8 (0.95)
		HF	11 (0.07)	12 (0.08)	< 5	< 5	181 (2.07)	12 (1.43)
		HS	< 5	< 5	< 5	< 5	16 (0.18)	< 5
		MP	< 5	< 5	< 5	< 5	12 (0.14)	< 5
	181 to 365 days	VTE	< 5	11 (0.07)	< 5	< 5	45 (0.52)	7 (0.83)
		DVT	< 5	5 (0.03)	< 5	< 5	27 (0.31)	< 5
		PE	< 5	7 (0.05)	< 5	< 5	22 (0.25)	5 (0.59)
		ATE	< 5	< 5	< 5	< 5	79 (0.90)	15 (1.78)
		IS	< 5	< 5	< 5	< 5	37 (0.42)	6 (0.71)
		TIA	< 5	< 5	< 5	< 5	15 (0.17)	< 5
		MI	< 5	< 5	< 5	< 5	28 (0.32)	8 (0.95)
		HF	< 5	< 5	< 5	< 5	78 (0.89)	6 (0.71)
		HS	< 5	< 5	< 5	< 5	5 (0.06)	< 5
		MP	< 5	< 5	< 5	< 5	< 5	< 5
	Cohort 4			N = 2,066,318	N = 542,670	N = 485,154	N = 147,744	
	0 to 30 days	VTE	349 (1.69)	27 (0.50)	38 (0.78)	8 (0.54)		
		DVT	56 (0.27)	7 (0.13)	6 (0.12)	< 5		
		PE	305 (1.48)	21 (0.39)	33 (0.68)	6 (0.41)		
		ATE	26 (0.13)	5 (0.09)	< 5	< 5		
		IS	< 5	< 5	< 5	< 5		
		TIA	5 (0.02)	< 5	< 5	< 5		
MI		17 (0.08)	< 5	< 5	< 5			
HF		28 (0.14)	< 5	< 5	< 5			
HS		< 5	< 5	< 5	< 5			
MP		15 (0.07)	< 5	< 5	< 5			
31 to 90 days		VTE	61 (0.30)	14 (0.26)	5 (0.10)	< 5		
		DVT	24 (0.12)	8 (0.15)	< 5	< 5		
		PE	40 (0.19)	6 (0.11)	< 5	< 5		
		ATE	13 (0.06)	< 5	< 5	< 5		
		IS	< 5	< 5	< 5	< 5		
		TIA	< 5	< 5	< 5	< 5		
		MI	9 (0.04)	< 5	< 5	< 5		
		HF	14 (0.07)	< 5	< 5	< 5		
HS		5 (0.02)	< 5	< 5	< 5			

Cohort	Time window	Outcome	AURUM		GOLD		SIDIAP		
			Unvaccinated	Vaccinated	Unvaccinated	Vaccinated	Unvaccinated	Vaccinated	
91 to 180 days		MP	8 (0.04)	< 5	< 5	< 5			
		VTE	29 (0.14)	< 5	< 5	< 5			
		DVT	10 (0.05)	< 5	< 5	< 5			
		PE	20 (0.10)	< 5	< 5	< 5			
		ATE	< 5	< 5	< 5	< 5			
		IS	< 5	< 5	< 5	< 5			
		TIA	< 5	< 5	< 5	< 5			
		MI	< 5	< 5	< 5	< 5			
		HF	10 (0.05)	< 5	< 5	< 5			
		HS	< 5	< 5	< 5	< 5			
		MP	< 5	< 5	< 5	< 5			
	181 to 365 days		VTE	< 5	< 5	< 5	< 5		
			DVT	< 5	< 5	< 5	< 5		
		PE	< 5	< 5	< 5	< 5			
		ATE	< 5	< 5	< 5	< 5			
		IS	< 5	< 5	< 5	< 5			
		TIA	< 5	< 5	< 5	< 5			
		MI	< 5	< 5	< 5	< 5			
		HF	< 5	< 5	< 5	< 5			
		HS	< 5	< 5	< 5	< 5			
		MP	< 5	< 5	< 5	< 5			

VTE = Venous thromboembolism (DVT + PE), DVT = Deep vein thrombosis, PE = Pulmonary embolism, ATE = Arterial thromboembolism (IS + TIA + MI), IS = Ischemic stroke, TIA = Transient ischemic attack, MI = Myocardial infarction, HF = Heart failure, HS = Hemorrhagic stroke, MP = Myocarditis or Pericarditis

Table S30: Number of records (and risk per 10,000 individuals) for post COVID-19 cardiac and thromboembolic complications, across cohorts and databases, stratified by exposure status (ChAdOx1 vaccine). Follow-up ends at first vaccine dose after index date.

Cohort	Time window	Outcome	AURUM		GOLD		SIDIAP	
			Unvaccinated	Vaccinated	Unvaccinated	Vaccinated	Unvaccinated	Vaccinated
Cohort 1			N = 344,687	N = 219,804	N = 168,972	N = 82,406		
	0 to 30 days	VTE	77 (2.23)	14 (0.64)	7 (0.41)	< 5		
		DVT	16 (0.46)	< 5	< 5	< 5		
		PE	64 (1.86)	13 (0.59)	6 (0.36)	< 5		
		ATE	18 (0.52)	10 (0.45)	7 (0.41)	< 5		
		IS	6 (0.17)	< 5	< 5	< 5		
		TIA	< 5	< 5	< 5	< 5		
		MI	9 (0.26)	6 (0.27)	5 (0.30)	< 5		
		HF	42 (1.22)	28 (1.27)	9 (0.53)	< 5		
		HS	< 5	< 5	< 5	< 5		
		MP	< 5	< 5	< 5	< 5		
		31 to 90 days	VTE	12 (0.35)	5 (0.23)	< 5	< 5	
	DVT		5 (0.15)	< 5	< 5	< 5		
	PE		7 (0.20)	< 5	< 5	< 5		
	ATE		6 (0.17)	8 (0.36)	< 5	< 5		
	IS		< 5	< 5	< 5	< 5		
	TIA		< 5	< 5	< 5	< 5		
	MI		5 (0.15)	< 5	< 5	< 5		
	HF		26 (0.75)	20 (0.91)	< 5	< 5		
	HS		< 5	< 5	< 5	< 5		
	MP		< 5	< 5	< 5	< 5		
	91 to 180 days		VTE	6 (0.17)	5 (0.23)	< 5	< 5	
		DVT	< 5	< 5	< 5	< 5		
		PE	< 5	< 5	< 5	< 5		
		ATE	10 (0.29)	< 5	< 5	< 5		
		IS	< 5	< 5	< 5	< 5		
		TIA	5 (0.15)	< 5	< 5	< 5		
		MI	< 5	< 5	< 5	< 5		
		HF	31 (0.90)	19 (0.86)	< 5	< 5		
		HS	< 5	< 5	< 5	< 5		
		MP	< 5	< 5	< 5	< 5		
		181 to 365 days	VTE	5 (0.15)	< 5	< 5	< 5	
	DVT		< 5	< 5	< 5	< 5		
	PE		< 5	< 5	< 5	< 5		
	ATE		9 (0.26)	8 (0.36)	< 5	< 5		
	IS		< 5	< 5	< 5	< 5		
	TIA		< 5	< 5	< 5	< 5		
	MI		< 5	< 5	< 5	< 5		
	HF		35 (1.02)	18 (0.82)	< 5	5 (0.61)		
	HS		< 5	< 5	< 5	< 5		
	MP		< 5	< 5	< 5	< 5		
Cohort 2				N = 1,975,770	N = 969,262	N = 582,791	N = 302,999	N = 433,636
	0 to 30 days	VTE	243 (1.23)	40 (0.41)	33 (0.57)	< 5	262 (6.04)	9 (0.28)
		DVT	42 (0.21)	13 (0.13)	8 (0.14)	< 5	68 (1.57)	5 (0.15)
		PE	206 (1.04)	30 (0.31)	26 (0.45)	< 5	213 (4.91)	6 (0.19)

Cohort	Time window	Outcome	AURUM		GOLD		SIDIAP		
			Unvaccinated	Vaccinated	Unvaccinated	Vaccinated	Unvaccinated	Vaccinated	
		ATE	38 (0.19)	11 (0.11)	< 5	< 5	168 (3.87)	6 (0.19)	
		IS	6 (0.03)	< 5	< 5	< 5	91 (2.10)	< 5	
		TIA	7 (0.04)	< 5	< 5	< 5	16 (0.37)	< 5	
		MI	25 (0.13)	9 (0.09)	< 5	< 5	65 (1.50)	< 5	
		HF	46 (0.23)	32 (0.33)	5 (0.09)	< 5	383 (8.83)	12 (0.37)	
		HS	5 (0.03)	< 5	< 5	< 5	17 (0.39)	< 5	
		MP	11 (0.06)	< 5	< 5	< 5	13 (0.30)	< 5	
	31 to 90 days	VTE	49 (0.25)	8 (0.08)	< 5	< 5	59 (1.36)	< 5	
		DVT	25 (0.13)	5 (0.05)	< 5	< 5	31 (0.71)	< 5	
		PE	27 (0.14)	< 5	< 5	< 5	34 (0.78)	< 5	
		ATE	16 (0.08)	9 (0.09)	< 5	< 5	86 (1.98)	6 (0.19)	
		IS	< 5	< 5	< 5	< 5	43 (0.99)	< 5	
		TIA	< 5	< 5	< 5	< 5	23 (0.53)	< 5	
		MI	11 (0.06)	6 (0.06)	< 5	< 5	27 (0.62)	< 5	
	91 to 180 days	HF	24 (0.12)	13 (0.13)	< 5	< 5	135 (3.11)	7 (0.22)	
		HS	< 5	< 5	< 5	< 5	7 (0.16)	< 5	
		MP	6 (0.03)	< 5	< 5	< 5	< 5	< 5	
		VTE	25 (0.13)	12 (0.12)	< 5	< 5	65 (1.50)	< 5	
		DVT	11 (0.06)	7 (0.07)	< 5	< 5	35 (0.81)	< 5	
		PE	14 (0.07)	5 (0.05)	< 5	< 5	34 (0.78)	< 5	
		ATE	12 (0.06)	10 (0.10)	< 5	< 5	91 (2.10)	6 (0.19)	
	181 to 365 days	IS	< 5	< 5	< 5	< 5	49 (1.13)	< 5	
		TIA	7 (0.04)	< 5	< 5	< 5	19 (0.44)	< 5	
		MI	6 (0.03)	6 (0.06)	< 5	< 5	26 (0.60)	< 5	
		HF	16 (0.08)	18 (0.19)	< 5	< 5	118 (2.72)	< 5	
		HS	< 5	< 5	< 5	< 5	7 (0.16)	< 5	
		MP	< 5	< 5	< 5	< 5	7 (0.16)	< 5	
		VTE	14 (0.07)	5 (0.05)	< 5	< 5	15 (0.35)	9 (0.28)	
	Cohort 3	0 to 30 days	DVT	< 5	< 5	< 5	< 5	9 (0.21)	7 (0.22)
			PE	10 (0.05)	< 5	< 5	< 5	7 (0.16)	< 5
			ATE	11 (0.06)	10 (0.10)	< 5	< 5	66 (1.52)	10 (0.31)
			IS	< 5	< 5	< 5	< 5	33 (0.76)	< 5
			TIA	< 5	< 5	< 5	< 5	20 (0.46)	< 5
			MI	8 (0.04)	6 (0.06)	< 5	< 5	15 (0.35)	5 (0.15)
			HF	18 (0.09)	20 (0.21)	< 5	< 5	76 (1.75)	9 (0.28)
			HS	< 5	< 5	< 5	< 5	< 5	< 5
MP			< 5	< 5	< 5	< 5	< 5	< 5	
N = 1,510,493			N = 1,473,602	N = 418,184	N = 423,876	N = 873,400	N = 84,204		
Cohort 3	31 to 90 days	VTE	244 (1.62)	23 (0.16)	28 (0.67)	< 5	334 (3.82)	5 (0.59)	
		DVT	44 (0.29)	< 5	6 (0.14)	< 5	96 (1.10)	< 5	
		PE	209 (1.38)	19 (0.13)	23 (0.55)	< 5	267 (3.06)	< 5	
		ATE	28 (0.19)	8 (0.05)	< 5	< 5	217 (2.48)	< 5	
		IS	< 5	< 5	< 5	< 5	102 (1.17)	< 5	
		TIA	5 (0.03)	< 5	< 5	< 5	21 (0.24)	< 5	
		MI	19 (0.13)	7 (0.05)	< 5	< 5	100 (1.14)	< 5	
		HF	30 (0.20)	11 (0.07)	< 5	< 5	374 (4.28)	5 (0.59)	
		HS	< 5	< 5	< 5	< 5	20 (0.23)	< 5	
	MP	9 (0.06)	< 5	< 5	< 5	19 (0.22)	< 5		
VTE	46 (0.30)	< 5	< 5	< 5	86 (0.98)	< 5			

Cohort	Time window	Outcome	AURUM		GOLD		SIDIAP	
			Unvaccinated	Vaccinated	Unvaccinated	Vaccinated	Unvaccinated	Vaccinated
		DVT	21 (0.14)	< 5	< 5	< 5	57 (0.65)	< 5
		PE	28 (0.19)	< 5	< 5	< 5	39 (0.45)	< 5
		ATE	11 (0.07)	6 (0.04)	< 5	< 5	110 (1.26)	< 5
		IS	< 5	< 5	< 5	< 5	55 (0.63)	< 5
		TIA	< 5	< 5	< 5	< 5	27 (0.31)	< 5
		MI	9 (0.06)	< 5	< 5	< 5	36 (0.41)	< 5
		HF	14 (0.09)	5 (0.03)	< 5	< 5	142 (1.63)	< 5
		HS	< 5	< 5	< 5	< 5	7 (0.08)	< 5
		MP	8 (0.05)	< 5	< 5	< 5	9 (0.10)	< 5
	91 to 180 days	VTE	24 (0.16)	8 (0.05)	< 5	< 5	65 (0.74)	< 5
		DVT	11 (0.07)	6 (0.04)	< 5	< 5	37 (0.42)	< 5
		PE	14 (0.09)	< 5	< 5	< 5	32 (0.37)	< 5
		ATE	< 5	7 (0.05)	< 5	< 5	116 (1.33)	6 (0.71)
		IS	< 5	< 5	< 5	< 5	57 (0.65)	5 (0.59)
		TIA	< 5	< 5	< 5	< 5	22 (0.25)	< 5
		MI	< 5	< 5	< 5	< 5	40 (0.46)	< 5
		HF	10 (0.07)	< 5	< 5	< 5	122 (1.40)	< 5
		HS	< 5	< 5	< 5	< 5	9 (0.10)	< 5
	MP	< 5	< 5	< 5	< 5	8 (0.09)	< 5	
	181 to 365 days	VTE	< 5	9 (0.06)	< 5	< 5	37 (0.42)	< 5
		DVT	< 5	< 5	< 5	< 5	23 (0.26)	< 5
		PE	< 5	6 (0.04)	< 5	< 5	16 (0.18)	< 5
		ATE	< 5	< 5	< 5	< 5	60 (0.69)	8 (0.95)
		IS	< 5	< 5	< 5	< 5	26 (0.30)	< 5
		TIA	< 5	< 5	< 5	< 5	14 (0.16)	< 5
		MI	< 5	< 5	< 5	< 5	21 (0.24)	< 5
		HF	< 5	< 5	< 5	< 5	65 (0.74)	5 (0.59)
		HS	< 5	< 5	< 5	< 5	< 5	< 5
	MP	< 5	< 5	< 5	< 5	< 5	< 5	
	Cohort 4		N = 2,066,318	N = 542,670	N = 485,154	N = 147,744		
	0 to 30 days	VTE	346 (1.67)	8 (0.15)	38 (0.78)	6 (0.41)		
		DVT	56 (0.27)	< 5	6 (0.12)	< 5		
		PE	302 (1.46)	7 (0.13)	33 (0.68)	6 (0.41)		
		ATE	26 (0.13)	< 5	< 5	< 5		
		IS	< 5	< 5	< 5	< 5		
		TIA	5 (0.02)	< 5	< 5	< 5		
MI		17 (0.08)	< 5	< 5	< 5			
HF		28 (0.14)	< 5	< 5	< 5			
HS		< 5	< 5	< 5	< 5			
MP		14 (0.07)	< 5	< 5	< 5			
31 to 90 days		VTE	60 (0.29)	8 (0.15)	< 5	< 5		
		DVT	23 (0.11)	< 5	< 5	< 5		
		PE	40 (0.19)	5 (0.09)	< 5	< 5		
		ATE	13 (0.06)	< 5	< 5	< 5		
		IS	< 5	< 5	< 5	< 5		
		TIA	< 5	< 5	< 5	< 5		
		MI	9 (0.04)	< 5	< 5	< 5		
		HF	14 (0.07)	< 5	< 5	< 5		
	HS	< 5	< 5	< 5	< 5			

Cohort	Time window	Outcome	AURUM		GOLD		SIDIAP			
			Unvaccinated	Vaccinated	Unvaccinated	Vaccinated	Unvaccinated	Vaccinated		
91 to 180 days		MP	7 (0.03)	< 5	< 5	< 5				
		VTE	29 (0.14)	< 5	< 5	< 5				
		DVT	10 (0.05)	< 5	< 5	< 5				
		PE	20 (0.10)	< 5	< 5	< 5				
		ATE	< 5	< 5	< 5	< 5				
		IS	< 5	< 5	< 5	< 5				
		TIA	< 5	< 5	< 5	< 5				
		MI	< 5	< 5	< 5	< 5				
		HF	10 (0.05)	< 5	< 5	< 5				
		HS	< 5	< 5	< 5	< 5				
		MP	< 5	< 5	< 5	< 5				
		181 to 365 days		VTE	< 5	< 5	< 5	< 5		
				DVT	< 5	< 5	< 5	< 5		
PE	< 5			< 5	< 5	< 5				
ATE	< 5			< 5	< 5	< 5				
IS	< 5			< 5	< 5	< 5				
TIA	< 5			< 5	< 5	< 5				
MI	< 5			< 5	< 5	< 5				
HF	< 5			< 5	< 5	< 5				
HS	< 5			< 5	< 5	< 5				
MP	< 5			< 5	< 5	< 5				

VTE = Venous thromboembolism (DVT + PE), DVT = Deep vein thrombosis, PE = Pulmonary embolism, ATE = Arterial thromboembolism (IS + TIA + MI), IS = Ischemic stroke, TIA = Transient ischemic attack, MI = Myocardial infarction, HF = Heart failure, HS = Hemorrhagic stroke, MP = Myocarditis or Pericarditis

Table S31: Number of records (and risk per 10,000 individuals) for post COVID-19 cardiac and thromboembolic complications, across cohorts and databases, stratified by exposure status (ChAdOx1 vaccine). Only first outcome after COVID-19 captured.

Cohort	Time window	Outcome	AURUM		GOLD		SIDIAP	
			Unvaccinated	Vaccinated	Unvaccinated	Vaccinated	Unvaccinated	Vaccinated
Cohort 1			N = 344,687	N = 219,804	N = 168,972	N = 82,406		
	0 to 30 days	VTE	138 (4.00)	41 (1.87)	14 (0.83)	< 5		
		DVT	34 (0.99)	12 (0.55)	< 5	< 5		
		PE	112 (3.25)	31 (1.41)	12 (0.71)	< 5		
		ATE	53 (1.54)	25 (1.14)	9 (0.53)	6 (0.73)		
		IS	13 (0.38)	< 5	< 5	< 5		
		TIA	12 (0.35)	7 (0.32)	< 5	< 5		
		MI	29 (0.84)	17 (0.77)	7 (0.41)	< 5		
		HF	119 (3.45)	72 (3.28)	20 (1.18)	5 (0.61)		
		HS	< 5	< 5	< 5	< 5		
		MP	< 5	< 5	< 5	< 5		
	31 to 90 days	VTE	25 (0.73)	14 (0.64)	< 5	< 5		
		DVT	9 (0.26)	8 (0.36)	< 5	< 5		
		PE	16 (0.46)	7 (0.32)	< 5	< 5		
		ATE	16 (0.46)	20 (0.91)	< 5	< 5		
		IS	< 5	< 5	< 5	< 5		
		TIA	6 (0.17)	9 (0.41)	< 5	< 5		
		MI	11 (0.32)	9 (0.41)	< 5	< 5		
		HF	69 (2.00)	39 (1.77)	6 (0.36)	5 (0.61)		
		HS	< 5	< 5	< 5	< 5		
		MP	< 5	< 5	< 5	< 5		
	91 to 180 days	VTE	13 (0.38)	15 (0.68)	6 (0.36)	< 5		
		DVT	5 (0.15)	5 (0.23)	< 5	< 5		
		PE	8 (0.23)	10 (0.45)	< 5	< 5		
		ATE	22 (0.64)	10 (0.45)	< 5	6 (0.73)		
		IS	< 5	< 5	< 5	< 5		
		TIA	10 (0.29)	6 (0.27)	< 5	< 5		
		MI	11 (0.32)	< 5	< 5	5 (0.61)		
		HF	50 (1.45)	35 (1.59)	< 5	< 5		
		HS	< 5	< 5	< 5	< 5		
		MP	< 5	< 5	< 5	< 5		
	181 to 365 days	VTE	5 (0.15)	< 5	< 5	< 5		
		DVT	< 5	< 5	< 5	< 5		
		PE	< 5	< 5	< 5	< 5		
		ATE	13 (0.38)	9 (0.41)	< 5	< 5		
		IS	< 5	< 5	< 5	< 5		
		TIA	6 (0.17)	< 5	< 5	< 5		
		MI	< 5	< 5	< 5	< 5		
		HF	45 (1.31)	18 (0.82)	< 5	5 (0.61)		
		HS	< 5	< 5	< 5	< 5		
		MP	< 5	< 5	< 5	< 5		
Cohort 2			N = 1,975,770	N = 969,262	N = 582,791	N = 302,999	N = 433,636	N = 323,204
	0 to 30 days	VTE	347 (1.76)	158 (1.63)	44 (0.75)	19 (0.63)	403 (9.29)	90 (2.78)
		DVT	75 (0.38)	47 (0.48)	9 (0.15)	< 5	122 (2.81)	45 (1.39)
		PE	280 (1.42)	120 (1.24)	36 (0.62)	15 (0.50)	311 (7.17)	55 (1.70)

Cohort	Time window	Outcome	AURUM		GOLD		SIDIAP		
			Unvaccinated	Vaccinated	Unvaccinated	Vaccinated	Unvaccinated	Vaccinated	
		ATE	70 (0.35)	75 (0.77)	9 (0.15)	< 5	341 (7.86)	131 (4.05)	
		IS	10 (0.05)	12 (0.12)	< 5	< 5	186 (4.29)	52 (1.61)	
		TIA	15 (0.08)	13 (0.13)	< 5	< 5	45 (1.04)	23 (0.71)	
		MI	45 (0.23)	52 (0.54)	7 (0.12)	< 5	127 (2.93)	62 (1.92)	
		HF	74 (0.37)	103 (1.06)	5 (0.09)	11 (0.36)	642 (14.81)	123 (3.81)	
		HS	5 (0.03)	< 5	< 5	< 5	38 (0.88)	7 (0.22)	
		MP	20 (0.10)	6 (0.06)	< 5	< 5	29 (0.67)	10 (0.31)	
	31 to 90 days	VTE	90 (0.46)	54 (0.56)	6 (0.10)	9 (0.30)	103 (2.38)	34 (1.05)	
		DVT	49 (0.25)	25 (0.26)	< 5	5 (0.17)	58 (1.34)	23 (0.71)	
		PE	44 (0.22)	31 (0.32)	< 5	< 5	54 (1.25)	16 (0.50)	
		ATE	37 (0.19)	56 (0.58)	8 (0.14)	5 (0.17)	199 (4.59)	106 (3.28)	
		IS	6 (0.03)	6 (0.06)	< 5	< 5	95 (2.19)	57 (1.76)	
		TIA	11 (0.06)	24 (0.25)	< 5	< 5	54 (1.25)	24 (0.74)	
		MI	21 (0.11)	28 (0.29)	< 5	< 5	63 (1.45)	27 (0.84)	
	91 to 180 days	HF	47 (0.24)	65 (0.67)	5 (0.09)	7 (0.23)	260 (6.00)	61 (1.89)	
		HS	6 (0.03)	< 5	< 5	< 5	18 (0.42)	7 (0.22)	
		MP	14 (0.07)	< 5	< 5	< 5	8 (0.18)	< 5	
		VTE	35 (0.18)	28 (0.29)	6 (0.10)	< 5	104 (2.40)	21 (0.65)	
		DVT	19 (0.10)	15 (0.15)	< 5	< 5	57 (1.31)	16 (0.50)	
		PE	16 (0.08)	15 (0.15)	6 (0.10)	< 5	55 (1.27)	6 (0.19)	
		ATE	27 (0.14)	28 (0.29)	5 (0.09)	< 5	173 (3.99)	106 (3.28)	
	181 to 365 days	IS	< 5	< 5	< 5	< 5	88 (2.03)	40 (1.24)	
		TIA	12 (0.06)	13 (0.13)	< 5	< 5	40 (0.92)	32 (0.99)	
		MI	14 (0.07)	15 (0.15)	< 5	< 5	51 (1.18)	37 (1.14)	
		HF	25 (0.13)	41 (0.42)	< 5	< 5	215 (4.96)	54 (1.67)	
		HS	< 5	< 5	< 5	< 5	17 (0.39)	< 5	
		MP	< 5	< 5	< 5	< 5	12 (0.28)	< 5	
		VTE	22 (0.11)	< 5	< 5	< 5	29 (0.67)	14 (0.43)	
	Cohort 3	0 to 30 days	DVT	8 (0.04)	< 5	< 5	< 5	16 (0.37)	12 (0.37)
			PE	15 (0.08)	< 5	< 5	< 5	15 (0.35)	< 5
			ATE	12 (0.06)	10 (0.10)	< 5	< 5	96 (2.21)	40 (1.24)
			IS	< 5	< 5	< 5	< 5	50 (1.15)	19 (0.59)
			TIA	< 5	< 5	< 5	< 5	22 (0.51)	12 (0.37)
			MI	8 (0.04)	6 (0.06)	< 5	< 5	29 (0.67)	13 (0.40)
			HF	17 (0.09)	22 (0.23)	< 5	< 5	93 (2.14)	25 (0.77)
			HS	< 5	< 5	< 5	< 5	6 (0.14)	< 5
MP			< 5	< 5	< 5	< 5	< 5	< 5	
				N = 1,510,493	N = 1,473,602	N = 418,184	N = 423,876	N = 873,400	N = 84,204
	31 to 90 days	VTE	267 (1.77)	139 (0.94)	33 (0.79)	16 (0.38)	431 (4.93)	27 (3.21)	
		DVT	52 (0.34)	41 (0.28)	7 (0.17)	< 5	137 (1.57)	9 (1.07)	
		PE	224 (1.48)	101 (0.69)	27 (0.65)	12 (0.28)	331 (3.79)	22 (2.61)	
		ATE	33 (0.22)	47 (0.32)	< 5	12 (0.28)	319 (3.65)	32 (3.80)	
		IS	5 (0.03)	5 (0.03)	< 5	< 5	154 (1.76)	13 (1.54)	
		TIA	6 (0.04)	16 (0.11)	< 5	< 5	33 (0.38)	5 (0.59)	
		MI	22 (0.15)	26 (0.18)	< 5	9 (0.21)	141 (1.61)	16 (1.90)	
		HF	32 (0.21)	28 (0.19)	< 5	< 5	486 (5.56)	51 (6.06)	
		HS	< 5	< 5	< 5	< 5	34 (0.39)	< 5	
	MP	14 (0.09)	6 (0.04)	< 5	< 5	27 (0.31)	6 (0.71)		
		60 (0.40)	44 (0.30)	< 5	6 (0.14)	115 (1.32)	9 (1.07)		

Cohort	Time window	Outcome	AURUM		GOLD		SIDIAP	
			Unvaccinated	Vaccinated	Unvaccinated	Vaccinated	Unvaccinated	Vaccinated
		DVT	29 (0.19)	26 (0.18)	< 5	< 5	79 (0.90)	< 5
		PE	34 (0.23)	18 (0.12)	< 5	< 5	47 (0.54)	6 (0.71)
		ATE	14 (0.09)	31 (0.21)	< 5	7 (0.17)	172 (1.97)	25 (2.97)
		IS	< 5	< 5	< 5	< 5	77 (0.88)	11 (1.31)
		TIA	< 5	13 (0.09)	< 5	< 5	50 (0.57)	< 5
		MI	11 (0.07)	16 (0.11)	< 5	< 5	57 (0.65)	10 (1.19)
		HF	21 (0.14)	23 (0.16)	< 5	< 5	187 (2.14)	25 (2.97)
		HS	5 (0.03)	< 5	< 5	< 5	13 (0.15)	< 5
		MP	9 (0.06)	7 (0.05)	< 5	< 5	14 (0.16)	< 5
	91 to 180 days	VTE	28 (0.19)	25 (0.17)	5 (0.12)	< 5	92 (1.05)	13 (1.54)
		DVT	14 (0.09)	15 (0.10)	< 5	< 5	56 (0.64)	7 (0.83)
		PE	16 (0.11)	13 (0.09)	< 5	< 5	41 (0.47)	7 (0.83)
		ATE	8 (0.05)	26 (0.18)	< 5	< 5	174 (1.99)	28 (3.33)
		IS	< 5	< 5	< 5	< 5	77 (0.88)	12 (1.43)
		TIA	< 5	8 (0.05)	< 5	< 5	30 (0.34)	10 (1.19)
		MI	< 5	17 (0.12)	< 5	< 5	69 (0.79)	8 (0.95)
		HF	11 (0.07)	10 (0.07)	< 5	< 5	169 (1.93)	12 (1.43)
		HS	< 5	< 5	< 5	< 5	16 (0.18)	< 5
		MP	< 5	< 5	< 5	< 5	12 (0.14)	< 5
	181 to 365 days	VTE	< 5	9 (0.06)	< 5	< 5	39 (0.45)	< 5
		DVT	< 5	< 5	< 5	< 5	24 (0.27)	< 5
		PE	< 5	6 (0.04)	< 5	< 5	18 (0.21)	< 5
		ATE	< 5	< 5	< 5	< 5	62 (0.71)	15 (1.78)
		IS	< 5	< 5	< 5	< 5	30 (0.34)	6 (0.71)
		TIA	< 5	< 5	< 5	< 5	13 (0.15)	< 5
		MI	< 5	< 5	< 5	< 5	20 (0.23)	8 (0.95)
		HF	< 5	< 5	< 5	< 5	65 (0.74)	6 (0.71)
		HS	< 5	< 5	< 5	< 5	< 5	< 5
		MP	< 5	< 5	< 5	< 5	< 5	< 5
	Cohort 4		N = 2,066,318	N = 542,670	N = 485,154	N = 147,744		
	0 to 30 days	VTE	349 (1.69)	27 (0.50)	38 (0.78)	8 (0.54)		
		DVT	56 (0.27)	7 (0.13)	6 (0.12)	< 5		
		PE	305 (1.48)	21 (0.39)	33 (0.68)	6 (0.41)		
		ATE	26 (0.13)	5 (0.09)	< 5	< 5		
		IS	< 5	< 5	< 5	< 5		
		TIA	5 (0.02)	< 5	< 5	< 5		
MI		17 (0.08)	< 5	< 5	< 5			
HF		28 (0.14)	< 5	< 5	< 5			
HS		< 5	< 5	< 5	< 5			
MP		15 (0.07)	< 5	< 5	< 5			
31 to 90 days		VTE	58 (0.28)	14 (0.26)	5 (0.10)	< 5		
		DVT	23 (0.11)	8 (0.15)	< 5	< 5		
		PE	38 (0.18)	6 (0.11)	< 5	< 5		
		ATE	13 (0.06)	< 5	< 5	< 5		
		IS	< 5	< 5	< 5	< 5		
		TIA	< 5	< 5	< 5	< 5		
		MI	9 (0.04)	< 5	< 5	< 5		
		HF	14 (0.07)	< 5	< 5	< 5		
		HS	5 (0.02)	< 5	< 5	< 5		

Cohort	Time window	Outcome	AURUM		GOLD		SIDIAP			
			Unvaccinated	Vaccinated	Unvaccinated	Vaccinated	Unvaccinated	Vaccinated		
91 to 180 days		MP	8 (0.04)	< 5	< 5	< 5				
		VTE	28 (0.14)	< 5	< 5	< 5				
		DVT	9 (0.04)	< 5	< 5	< 5				
		PE	20 (0.10)	< 5	< 5	< 5				
		ATE	< 5	< 5	< 5	< 5				
		IS	< 5	< 5	< 5	< 5				
		TIA	< 5	< 5	< 5	< 5				
		MI	< 5	< 5	< 5	< 5				
		HF	10 (0.05)	< 5	< 5	< 5				
		HS	< 5	< 5	< 5	< 5				
		MP	< 5	< 5	< 5	< 5				
		181 to 365 days		VTE	< 5	< 5	< 5	< 5		
				DVT	< 5	< 5	< 5	< 5		
PE	< 5			< 5	< 5	< 5				
ATE	< 5			< 5	< 5	< 5				
IS	< 5			< 5	< 5	< 5				
TIA	< 5			< 5	< 5	< 5				
MI	< 5			< 5	< 5	< 5				
HF	< 5			< 5	< 5	< 5				
HS	< 5			< 5	< 5	< 5				
MP	< 5			< 5	< 5	< 5				

VTE = Venous thromboembolism (DVT + PE), DVT = Deep vein thrombosis, PE = Pulmonary embolism, ATE = Arterial thromboembolism (IS + TIA + MI), IS = Ischemic stroke, TIA = Transient ischemic attack, MI = Myocardial infarction, HF = Heart failure, HS = Hemorrhagic stroke, MP = Myocarditis or Pericarditis

Table S32: Number of records (and risk per 10,000 individuals) for post COVID-19 cardiac and thromboembolic complications, across cohorts and databases, stratified by exposure status (BNT162b2 vaccine).

Cohort	Time window	Outcome	AURUM		CORIVA		GOLD		SIDIAP	
			Unvaccinated	Vaccinated	Unvaccinated	Vaccinated	Unvaccinated	Vaccinated	Unvaccinated	Vaccinated
Cohort 1			N = 348,052	N = 332,790	N = 24,073	N = 19,686	N = 169,459	N = 32,755	N = 223,960	N = 88,896
0 to 30 days	VTE	167 (4.80)	76 (2.28)	97 (40.29)	31 (15.75)	15 (0.89)	< 5	251 (11.21)	94 (10.57)	
	DVT	39 (1.12)	15 (0.45)	18 (7.48)	8 (4.06)	< 5	< 5	76 (3.39)	29 (3.26)	
	PE	138 (3.96)	64 (1.92)	81 (33.65)	24 (12.19)	12 (0.71)	< 5	187 (8.35)	75 (8.44)	
	ATE	62 (1.78)	45 (1.35)	125 (51.93)	37 (18.80)	8 (0.47)	< 5	353 (15.76)	206 (23.17)	
	IS	16 (0.46)	5 (0.15)	77 (31.99)	18 (9.14)	< 5	< 5	196 (8.75)	116 (13.05)	
	TIA	14 (0.40)	11 (0.33)	23 (9.55)	7 (3.56)	< 5	< 5	58 (2.59)	41 (4.61)	
	MI	34 (0.98)	29 (0.87)	37 (15.37)	19 (9.65)	6 (0.35)	< 5	115 (5.13)	61 (6.86)	
	HF	136 (3.91)	126 (3.79)	438 (181.95)	154 (78.23)	20 (1.18)	< 5	1,203 (53.71)	634 (71.32)	
	HS	< 5	< 5	< 5	< 5	< 5	< 5	46 (2.05)	14 (1.57)	
	MP	< 5	< 5	< 5	< 5	< 5	< 5	16 (0.71)	< 5	
31 to 90 days	VTE	31 (0.89)	26 (0.78)	38 (15.79)	8 (4.06)	5 (0.30)	< 5	91 (4.06)	44 (4.95)	
	DVT	13 (0.37)	7 (0.21)	23 (9.55)	< 5	< 5	< 5	55 (2.46)	29 (3.26)	
	PE	18 (0.52)	19 (0.57)	17 (7.06)	< 5	< 5	< 5	42 (1.88)	19 (2.14)	
	ATE	20 (0.57)	23 (0.69)	33 (13.71)	20 (10.16)	< 5	< 5	222 (9.91)	128 (14.40)	
	IS	< 5	< 5	21 (8.72)	10 (5.08)	< 5	< 5	112 (5.00)	71 (7.99)	
	TIA	10 (0.29)	10 (0.30)	11 (4.57)	7 (3.56)	< 5	< 5	72 (3.21)	32 (3.60)	
	MI	11 (0.32)	11 (0.33)	10 (4.15)	< 5	< 5	< 5	52 (2.32)	29 (3.26)	
	HF	75 (2.15)	71 (2.13)	149 (61.90)	67 (34.03)	6 (0.35)	< 5	493 (22.01)	296 (33.30)	
	HS	< 5	< 5	< 5	< 5	< 5	< 5	16 (0.71)	13 (1.46)	
	MP	< 5	< 5	< 5	< 5	< 5	< 5	< 5	< 5	
91 to 180 days	VTE	17 (0.49)	6 (0.18)	25 (10.39)	13 (6.60)	6 (0.35)	< 5	70 (3.13)	40 (4.50)	
	DVT	6 (0.17)	< 5	13 (5.40)	< 5	< 5	< 5	41 (1.83)	23 (2.59)	
	PE	11 (0.32)	< 5	14 (5.82)	10 (5.08)	< 5	< 5	34 (1.52)	20 (2.25)	
	ATE	27 (0.78)	18 (0.54)	32 (13.29)	18 (9.14)	< 5	< 5	201 (8.97)	110 (12.37)	
	IS	< 5	6 (0.18)	19 (7.89)	6 (3.05)	< 5	< 5	126 (5.63)	59 (6.64)	
	TIA	13 (0.37)	6 (0.18)	8 (3.32)	< 5	< 5	< 5	45 (2.01)	34 (3.82)	
	MI	12 (0.34)	6 (0.18)	9 (3.74)	11 (5.59)	< 5	< 5	39 (1.74)	26 (2.92)	
	HF	68 (1.95)	57 (1.71)	172 (71.45)	95 (48.26)	< 5	< 5	432 (19.29)	249 (28.01)	
	HS	< 5	< 5	< 5	< 5	< 5	< 5	23 (1.03)	< 5	
	MP	< 5	< 5	< 5	< 5	< 5	< 5	< 5	< 5	
181 to 365 days	VTE	15 (0.43)	10 (0.30)	59 (24.51)	21 (10.67)	< 5	< 5	35 (1.56)	12 (1.35)	
	DVT	< 5	6 (0.18)	19 (7.89)	13 (6.60)	< 5	< 5	22 (0.98)	8 (0.90)	
	PE	11 (0.32)	< 5	45 (18.69)	9 (4.57)	< 5	< 5	15 (0.67)	< 5	
	ATE	19 (0.55)	14 (0.42)	57 (23.68)	31 (15.75)	< 5	< 5	124 (5.54)	52 (5.85)	
	IS	< 5	< 5	33 (13.71)	15 (7.62)	< 5	< 5	58 (2.59)	33 (3.71)	
	TIA	12 (0.34)	< 5	15 (6.23)	13 (6.60)	< 5	< 5	35 (1.56)	13 (1.46)	
	MI	< 5	7 (0.21)	15 (6.23)	9 (4.57)	< 5	< 5	35 (1.56)	8 (0.90)	
	HF	66 (1.90)	38 (1.14)	276 (114.65)	146 (74.16)	< 5	< 5	234 (10.45)	149 (16.76)	
	HS	< 5	< 5	< 5	< 5	< 5	< 5	8 (0.36)	9 (1.01)	
	MP	< 5	< 5	< 5	< 5	< 5	< 5	< 5	< 5	
Cohort 2			N = 1,976,163	N = 594,262	N = 34,320	N = 4,067	N = 584,309	N = 180,670	N = 433,111	N = 445,581
0 to 30 days	VTE	344 (1.74)	62 (1.04)	89 (25.93)	8 (19.67)	40 (0.68)	5 (0.28)	396 (9.14)	265 (5.95)	
	DVT	72 (0.36)	18 (0.30)	16 (4.66)	< 5	8 (0.14)	< 5	117 (2.70)	96 (2.15)	
	PE	279 (1.41)	45 (0.76)	74 (21.56)	5 (12.29)	33 (0.56)	< 5	309 (7.13)	189 (4.24)	

Cohort	Time window	Outcome	AURUM		CORIVA		GOLD		SIDAP		
			Unvaccinated	Vaccinated	Unvaccinated	Vaccinated	Unvaccinated	Vaccinated	Unvaccinated	Vaccinated	
		ATE	71 (0.36)	29 (0.49)	128 (37.30)	< 5	9 (0.15)	< 5	347 (8.01)	489 (10.97)	
		IS	11 (0.06)	< 5	79 (23.02)	< 5	< 5	< 5	192 (4.43)	267 (5.99)	
		TIA	14 (0.07)	11 (0.19)	23 (6.70)	< 5	< 5	< 5	45 (1.04)	90 (2.02)	
		MI	46 (0.23)	16 (0.27)	36 (10.49)	< 5	6 (0.10)	< 5	127 (2.93)	163 (3.66)	
		HF	78 (0.39)	43 (0.72)	392 (114.22)	17 (41.80)	6 (0.10)	< 5	639 (14.75)	1,137 (25.52)	
		HS	6 (0.03)	< 5	< 5	< 5	< 5	< 5	38 (0.88)	61 (1.37)	
		MP	20 (0.10)	< 5	< 5	< 5	< 5	< 5	30 (0.69)	22 (0.49)	
	31 to 90 days	VTE	92 (0.47)	21 (0.35)	36 (10.49)	< 5	7 (0.12)	< 5	108 (2.49)	128 (2.87)	
		DVT	51 (0.26)	7 (0.12)	22 (6.41)	< 5	< 5	< 5	62 (1.43)	81 (1.82)	
		PE	44 (0.22)	14 (0.24)	17 (4.95)	< 5	< 5	< 5	56 (1.29)	56 (1.26)	
		ATE	38 (0.19)	36 (0.61)	33 (9.62)	< 5	8 (0.14)	< 5	201 (4.64)	313 (7.02)	
		IS	7 (0.04)	5 (0.08)	23 (6.70)	< 5	< 5	< 5	97 (2.24)	167 (3.75)	
		TIA	11 (0.06)	9 (0.15)	7 (2.04)	< 5	< 5	< 5	54 (1.25)	86 (1.93)	
		MI	21 (0.11)	22 (0.37)	10 (2.91)	< 5	< 5	< 5	63 (1.45)	80 (1.80)	
	91 to 180 days	HF	50 (0.25)	35 (0.59)	151 (44.00)	10 (24.59)	5 (0.09)	< 5	269 (6.21)	554 (12.43)	
		HS	5 (0.03)	< 5	< 5	< 5	< 5	< 5	18 (0.42)	19 (0.43)	
		MP	14 (0.07)	< 5	< 5	< 5	< 5	< 5	8 (0.18)	< 5	
		VTE	42 (0.21)	10 (0.17)	28 (8.16)	5 (12.29)	7 (0.12)	< 5	112 (2.59)	96 (2.15)	
		DVT	21 (0.11)	6 (0.10)	14 (4.08)	< 5	< 5	< 5	62 (1.43)	59 (1.32)	
		PE	21 (0.11)	5 (0.08)	15 (4.37)	< 5	7 (0.12)	< 5	56 (1.29)	45 (1.01)	
		ATE	31 (0.16)	15 (0.25)	29 (8.45)	< 5	5 (0.09)	< 5	184 (4.25)	287 (6.44)	
	181 to 365 days	IS	< 5	< 5	17 (4.95)	< 5	< 5	< 5	96 (2.22)	168 (3.77)	
		TIA	13 (0.07)	5 (0.08)	7 (2.04)	< 5	< 5	< 5	42 (0.97)	76 (1.71)	
		MI	17 (0.09)	10 (0.17)	8 (2.33)	< 5	< 5	< 5	52 (1.20)	63 (1.41)	
		HF	29 (0.15)	25 (0.42)	172 (50.12)	13 (31.96)	< 5	< 5	227 (5.24)	472 (10.59)	
		HS	< 5	< 5	< 5	< 5	< 5	< 5	18 (0.42)	34 (0.76)	
		MP	< 5	< 5	< 5	< 5	< 5	< 5	12 (0.28)	< 5	
		VTE	19 (0.10)	8 (0.13)	55 (16.03)	< 5	< 5	< 5	36 (0.83)	40 (0.90)	
	Cohort 3			N = 1,510,323	N = 54,102	N = 96,471	N = 18,645	N = 416,549	N = 36,748	N = 869,109	N = 706,435
		0 to 30 days	DVT	7 (0.04)	< 5	27 (7.87)	< 5	< 5	< 5	21 (0.48)	26 (0.58)
			PE	13 (0.07)	7 (0.12)	33 (9.62)	< 5	< 5	< 5	18 (0.42)	16 (0.36)
			ATE	14 (0.07)	7 (0.12)	62 (18.07)	< 5	< 5	< 5	110 (2.54)	123 (2.76)
			IS	< 5	< 5	40 (11.66)	< 5	< 5	< 5	59 (1.36)	58 (1.30)
TIA			< 5	< 5	16 (4.66)	< 5	< 5	< 5	24 (0.55)	39 (0.88)	
MI			10 (0.05)	< 5	12 (3.50)	< 5	< 5	< 5	32 (0.74)	32 (0.72)	
HF			25 (0.13)	12 (0.20)	285 (83.04)	15 (36.88)	< 5	< 5	107 (2.47)	212 (4.76)	
HS			< 5	< 5	< 5	< 5	< 5	< 5	7 (0.16)	12 (0.27)	
MP			< 5	< 5	< 5	< 5	< 5	< 5	< 5	< 5	
31 to 90 days	VTE	267 (1.77)	< 5	124 (12.85)	7 (3.75)	33 (0.79)	< 5	422 (4.86)	114 (1.61)		
	DVT	52 (0.34)	< 5	25 (2.59)	5 (2.68)	7 (0.17)	< 5	132 (1.52)	51 (0.72)		
	PE	224 (1.48)	< 5	100 (10.37)	< 5	27 (0.65)	< 5	326 (3.75)	71 (1.01)		
	ATE	34 (0.23)	< 5	131 (13.58)	8 (4.29)	< 5	< 5	314 (3.61)	197 (2.79)		
	IS	5 (0.03)	< 5	73 (7.57)	6 (3.22)	< 5	< 5	154 (1.77)	95 (1.34)		
	TIA	6 (0.04)	< 5	24 (2.49)	< 5	< 5	< 5	32 (0.37)	42 (0.59)		
	MI	23 (0.15)	< 5	42 (4.35)	< 5	< 5	< 5	137 (1.58)	78 (1.10)		
	HF	32 (0.21)	10 (1.85)	401 (41.57)	16 (8.58)	< 5	< 5	476 (5.48)	163 (2.31)		
	HS	< 5	< 5	5 (0.52)	< 5	< 5	< 5	34 (0.39)	26 (0.37)		
	MP	14 (0.09)	< 5	< 5	< 5	< 5	< 5	27 (0.31)	13 (0.18)		
	VTE	61 (0.40)	< 5	46 (4.77)	5 (2.68)	< 5	< 5	120 (1.38)	65 (0.92)		

Cohort	Time window	Outcome	AURUM		CORIVA		GOLD		SIDAP	
			Unvaccinated	Vaccinated	Unvaccinated	Vaccinated	Unvaccinated	Vaccinated	Unvaccinated	Vaccinated
		DVT	29 (0.19)	< 5	31 (3.21)	< 5	< 5	< 5	81 (0.93)	47 (0.67)
		PE	35 (0.23)	< 5	19 (1.97)	< 5	< 5	< 5	51 (0.59)	23 (0.33)
		ATE	14 (0.09)	< 5	43 (4.46)	10 (5.36)	< 5	< 5	171 (1.97)	144 (2.04)
		IS	< 5	< 5	24 (2.49)	< 5	< 5	< 5	75 (0.86)	55 (0.78)
		TIA	< 5	< 5	8 (0.83)	6 (3.22)	< 5	< 5	50 (0.58)	28 (0.40)
		MI	11 (0.07)	< 5	16 (1.66)	< 5	< 5	< 5	58 (0.67)	69 (0.98)
		HF	22 (0.15)	< 5	184 (19.07)	11 (5.90)	< 5	< 5	193 (2.22)	111 (1.57)
		HS	5 (0.03)	< 5	< 5	< 5	< 5	< 5	13 (0.15)	14 (0.20)
		MP	9 (0.06)	< 5	7 (0.73)	< 5	< 5	< 5	13 (0.15)	9 (0.13)
	91 to 180 days	VTE	29 (0.19)	< 5	49 (5.08)	8 (4.29)	5 (0.12)	< 5	103 (1.19)	71 (1.01)
		DVT	15 (0.10)	< 5	31 (3.21)	5 (2.68)	< 5	< 5	60 (0.69)	45 (0.64)
		PE	16 (0.11)	< 5	18 (1.87)	< 5	< 5	< 5	48 (0.55)	27 (0.38)
		ATE	8 (0.05)	< 5	45 (4.66)	7 (3.75)	< 5	< 5	185 (2.13)	141 (2.00)
		IS	< 5	< 5	20 (2.07)	< 5	< 5	< 5	88 (1.01)	65 (0.92)
		TIA	< 5	< 5	13 (1.35)	< 5	< 5	< 5	33 (0.38)	29 (0.41)
		MI	< 5	< 5	17 (1.76)	< 5	< 5	< 5	67 (0.77)	53 (0.75)
		HF	11 (0.07)	< 5	214 (22.18)	12 (6.44)	< 5	< 5	181 (2.08)	100 (1.42)
		HS	< 5	< 5	< 5	< 5	< 5	< 5	16 (0.18)	10 (0.14)
	181 to 365 days	MP	< 5	< 5	6 (0.62)	< 5	< 5	< 5	11 (0.13)	9 (0.13)
		VTE	< 5	< 5	82 (8.50)	14 (7.51)	< 5	< 5	42 (0.48)	17 (0.24)
		DVT	< 5	< 5	47 (4.87)	12 (6.44)	< 5	< 5	24 (0.28)	14 (0.20)
		PE	< 5	< 5	38 (3.94)	< 5	< 5	< 5	22 (0.25)	< 5
		ATE	< 5	< 5	86 (8.91)	6 (3.22)	< 5	< 5	70 (0.81)	45 (0.64)
		IS	< 5	< 5	42 (4.35)	< 5	< 5	< 5	35 (0.40)	17 (0.24)
		TIA	< 5	< 5	22 (2.28)	< 5	< 5	< 5	11 (0.13)	7 (0.10)
		MI	< 5	< 5	30 (3.11)	< 5	< 5	< 5	25 (0.29)	24 (0.34)
		HF	5 (0.03)	< 5	350 (36.28)	26 (13.94)	< 5	< 5	73 (0.84)	31 (0.44)
	Cohort 4			N = 2,014,161	N = 1,335,671	N = 147,553	N = 15,683	N = 465,326	N = 365,096	N = 1,068,043
0 to 30 days	VTE	331 (1.64)	20 (0.15)	121 (8.20)	< 5	36 (0.77)	< 5	386 (3.61)	66 (1.14)	
	DVT	52 (0.26)	9 (0.07)	24 (1.63)	< 5	6 (0.13)	< 5	124 (1.16)	35 (0.60)	
	PE	290 (1.44)	11 (0.08)	98 (6.64)	< 5	31 (0.67)	< 5	298 (2.79)	35 (0.60)	
	ATE	25 (0.12)	< 5	122 (8.27)	8 (5.10)	< 5	< 5	277 (2.59)	55 (0.95)	
	IS	< 5	< 5	70 (4.74)	< 5	< 5	< 5	139 (1.30)	29 (0.50)	
	TIA	6 (0.03)	< 5	22 (1.49)	< 5	< 5	< 5	37 (0.35)	7 (0.12)	
	MI	15 (0.07)	< 5	38 (2.58)	< 5	< 5	< 5	108 (1.01)	20 (0.34)	
	HF	26 (0.13)	< 5	373 (25.28)	13 (8.29)	< 5	< 5	425 (3.98)	44 (0.76)	
	HS	< 5	< 5	< 5	< 5	< 5	< 5	32 (0.30)	7 (0.12)	
31 to 90 days	MP	14 (0.07)	< 5	7 (0.47)	< 5	< 5	< 5	33 (0.31)	11 (0.19)	
	VTE	57 (0.28)	7 (0.05)	46 (3.12)	< 5	< 5	< 5	114 (1.07)	33 (0.57)	
	DVT	21 (0.10)	< 5	31 (2.10)	< 5	< 5	< 5	80 (0.75)	23 (0.40)	
	PE	39 (0.19)	< 5	19 (1.29)	< 5	< 5	< 5	44 (0.41)	11 (0.19)	
	ATE	13 (0.06)	< 5	40 (2.71)	< 5	< 5	< 5	146 (1.37)	51 (0.88)	
	IS	< 5	< 5	23 (1.56)	< 5	< 5	< 5	64 (0.60)	21 (0.36)	
	TIA	< 5	< 5	8 (0.54)	< 5	< 5	< 5	41 (0.38)	12 (0.21)	
	MI	9 (0.04)	< 5	15 (1.02)	< 5	< 5	< 5	50 (0.47)	21 (0.36)	
	HF	14 (0.07)	6 (0.04)	167 (11.32)	11 (7.01)	< 5	< 5	162 (1.52)	28 (0.48)	
HS	5 (0.02)	< 5	< 5	< 5	< 5	< 5	12 (0.11)	5 (0.09)		

Cohort	Time window	Outcome	AURUM		CORIVA		GOLD		SIDIAP	
			Unvaccinated	Vaccinated	Unvaccinated	Vaccinated	Unvaccinated	Vaccinated	Unvaccinated	Vaccinated
91 to 180 days		MP	8 (0.04)	< 5	8 (0.54)	< 5	< 5	< 5	14 (0.13)	8 (0.14)
		VTE	24 (0.12)	9 (0.07)	46 (3.12)	7 (4.46)	< 5	< 5	88 (0.82)	45 (0.78)
		DVT	11 (0.05)	7 (0.05)	31 (2.10)	6 (3.83)	< 5	< 5	53 (0.50)	28 (0.48)
		PE	14 (0.07)	< 5	16 (1.08)	< 5	< 5	< 5	40 (0.37)	20 (0.34)
		ATE	< 5	< 5	33 (2.24)	8 (5.10)	< 5	< 5	150 (1.40)	71 (1.22)
		IS	< 5	< 5	14 (0.95)	< 5	< 5	< 5	72 (0.67)	37 (0.64)
		TIA	< 5	< 5	10 (0.68)	< 5	< 5	< 5	29 (0.27)	14 (0.24)
		MI	< 5	< 5	13 (0.88)	< 5	< 5	< 5	52 (0.49)	20 (0.34)
		HF	9 (0.04)	< 5	185 (12.54)	9 (5.74)	< 5	< 5	176 (1.65)	35 (0.60)
		HS	< 5	< 5	< 5	< 5	< 5	< 5	20 (0.19)	< 5
181 to 365 days		MP	< 5	< 5	6 (0.41)	< 5	< 5	< 5	14 (0.13)	< 5
		VTE	< 5	< 5	80 (5.42)	6 (3.83)	< 5	< 5	51 (0.48)	10 (0.17)
		DVT	< 5	< 5	48 (3.25)	6 (3.83)	< 5	< 5	33 (0.31)	8 (0.14)
		PE	< 5	< 5	35 (2.37)	< 5	< 5	< 5	19 (0.18)	< 5
		ATE	< 5	< 5	72 (4.88)	6 (3.83)	< 5	< 5	56 (0.52)	21 (0.36)
		IS	< 5	< 5	35 (2.37)	< 5	< 5	< 5	28 (0.26)	11 (0.19)
		TIA	< 5	< 5	19 (1.29)	< 5	< 5	< 5	10 (0.09)	< 5
		MI	< 5	< 5	25 (1.69)	< 5	< 5	< 5	19 (0.18)	9 (0.16)
		HF	< 5	< 5	311 (21.08)	10 (6.38)	< 5	< 5	63 (0.59)	8 (0.14)
		HS	< 5	< 5	7 (0.47)	< 5	< 5	< 5	6 (0.06)	< 5
	MP	< 5	< 5	7 (0.47)	< 5	< 5	< 5	6 (0.06)	< 5	

VTE = Venous thromboembolism (DVT + PE), DVT = Deep vein thrombosis, PE = Pulmonary embolism, ATE = Arterial thromboembolism (IS + TIA + MI), IS = Ischemic stroke, TIA = Transient ischemic attack, MI = Myocardial infarction, HF = Heart failure, HS = Hemorrhagic stroke, MP = Myocarditis or Pericarditis

Table S33: Number of records (and risk per 10,000 individuals) for post COVID-19 cardiac and thromboembolic complications, across cohorts and databases, stratified by exposure status (BNT162b2 vaccine). Follow-up ends at first vaccine dose after index date.

Cohort	Time window	Outcome	AURUM		CORIVA		GOLD		SIDIAP	
			Unvaccinated	Vaccinated	Unvaccinated	Vaccinated	Unvaccinated	Vaccinated	Unvaccinated	Vaccinated
Cohort 1			N = 348,052	N = 332,790	N = 24,073	N = 19,686	N = 169,459	N = 32,755	N = 223,960	N = 88,896
0 to 30 days	VTE	106 (3.05)	31 (0.93)	78 (32.40)	< 5	8 (0.47)	< 5	76 (3.39)	< 5	
	DVT	21 (0.60)	8 (0.24)	12 (4.98)	< 5	< 5	< 5	19 (0.85)	< 5	
	PE	90 (2.59)	24 (0.72)	68 (28.25)	< 5	6 (0.35)	< 5	61 (2.72)	< 5	
	ATE	27 (0.78)	18 (0.54)	89 (36.97)	< 5	6 (0.35)	< 5	78 (3.48)	5 (0.56)	
	IS	9 (0.26)	< 5	50 (20.77)	< 5	< 5	< 5	46 (2.05)	< 5	
	TIA	5 (0.14)	< 5	17 (7.06)	< 5	< 5	< 5	7 (0.31)	< 5	
	MI	14 (0.40)	14 (0.42)	30 (12.46)	< 5	< 5	< 5	27 (1.21)	< 5	
	HF	59 (1.70)	45 (1.35)	352 (146.22)	17 (8.64)	9 (0.53)	< 5	301 (13.44)	23 (2.59)	
	HS	< 5	< 5	< 5	< 5	< 5	< 5	7 (0.31)	< 5	
	MP	< 5	< 5	< 5	< 5	< 5	< 5	< 5	< 5	
31 to 90 days	VTE	18 (0.52)	15 (0.45)	29 (12.05)	< 5	< 5	< 5	15 (0.67)	< 5	
	DVT	9 (0.26)	< 5	16 (6.65)	< 5	< 5	< 5	9 (0.40)	< 5	
	PE	9 (0.26)	11 (0.33)	15 (6.23)	< 5	< 5	< 5	6 (0.27)	< 5	
	ATE	9 (0.26)	8 (0.24)	20 (8.31)	< 5	< 5	< 5	42 (1.88)	5 (0.56)	
	IS	< 5	< 5	11 (4.57)	< 5	< 5	< 5	20 (0.89)	< 5	
	TIA	5 (0.14)	< 5	6 (2.49)	< 5	< 5	< 5	14 (0.63)	< 5	
	MI	5 (0.14)	< 5	9 (3.74)	< 5	< 5	< 5	11 (0.49)	< 5	
	HF	32 (0.92)	36 (1.08)	115 (47.77)	13 (6.60)	< 5	< 5	87 (3.88)	8 (0.90)	
	HS	< 5	< 5	< 5	< 5	< 5	< 5	< 5	< 5	
	MP	< 5	< 5	< 5	< 5	< 5	< 5	< 5	< 5	
91 to 180 days	VTE	10 (0.29)	< 5	19 (7.89)	< 5	< 5	< 5	20 (0.89)	< 5	
	DVT	< 5	< 5	11 (4.57)	< 5	< 5	< 5	9 (0.40)	< 5	
	PE	6 (0.17)	< 5	10 (4.15)	< 5	< 5	< 5	11 (0.49)	< 5	
	ATE	15 (0.43)	10 (0.30)	22 (9.14)	< 5	< 5	< 5	31 (1.38)	< 5	
	IS	< 5	< 5	10 (4.15)	< 5	< 5	< 5	16 (0.71)	< 5	
	TIA	8 (0.23)	< 5	7 (2.91)	< 5	< 5	< 5	9 (0.40)	< 5	
	MI	5 (0.14)	< 5	8 (3.32)	< 5	< 5	< 5	7 (0.31)	< 5	
	HF	43 (1.24)	32 (0.96)	134 (55.66)	12 (6.10)	< 5	< 5	86 (3.84)	6 (0.67)	
	HS	< 5	< 5	< 5	< 5	< 5	< 5	< 5	< 5	
	MP	< 5	< 5	< 5	< 5	< 5	< 5	< 5	< 5	
181 to 365 days	VTE	14 (0.40)	7 (0.21)	48 (19.94)	< 5	< 5	< 5	10 (0.45)	< 5	
	DVT	< 5	< 5	13 (5.40)	< 5	< 5	< 5	5 (0.22)	< 5	
	PE	11 (0.32)	< 5	40 (16.62)	< 5	< 5	< 5	5 (0.22)	< 5	
	ATE	15 (0.43)	11 (0.33)	45 (18.69)	< 5	< 5	< 5	42 (1.88)	8 (0.90)	
	IS	< 5	< 5	25 (10.39)	< 5	< 5	< 5	18 (0.80)	5 (0.56)	
	TIA	10 (0.29)	< 5	13 (5.40)	< 5	< 5	< 5	13 (0.58)	< 5	
	MI	< 5	6 (0.18)	12 (4.98)	< 5	< 5	< 5	11 (0.49)	< 5	
	HF	52 (1.49)	35 (1.05)	218 (90.56)	29 (14.73)	< 5	< 5	84 (3.75)	20 (2.25)	
	HS	< 5	< 5	< 5	< 5	< 5	< 5	< 5	< 5	
	MP	< 5	< 5	< 5	< 5	< 5	< 5	< 5	< 5	
Cohort 2			N = 1,976,163	N = 594,262	N = 34,320	N = 4,067	N = 584,309	N = 180,670	N = 433,111	N = 445,581
0 to 30 days	VTE	240 (1.21)	14 (0.24)	71 (20.69)	< 5	29 (0.50)	< 5	255 (5.89)	14 (0.31)	
	DVT	39 (0.20)	6 (0.10)	10 (2.91)	< 5	7 (0.12)	< 5	63 (1.45)	< 5	
	PE	205 (1.04)	8 (0.13)	62 (18.07)	< 5	23 (0.39)	< 5	211 (4.87)	12 (0.27)	

Cohort	Time window	Outcome	AURUM		CORIVA		GOLD		SIDAP	
			Unvaccinated	Vaccinated	Unvaccinated	Vaccinated	Unvaccinated	Vaccinated	Unvaccinated	Vaccinated
	31 to 90 days	ATE	39 (0.20)	14 (0.24)	89 (25.93)	< 5	< 5	< 5	175 (4.04)	16 (0.36)
		IS	7 (0.04)	< 5	52 (15.15)	< 5	< 5	< 5	97 (2.24)	8 (0.18)
		TIA	6 (0.03)	< 5	16 (4.66)	< 5	< 5	< 5	17 (0.39)	< 5
		MI	26 (0.13)	8 (0.13)	27 (7.87)	< 5	< 5	< 5	65 (1.50)	5 (0.11)
		HF	50 (0.25)	15 (0.25)	312 (90.91)	< 5	6 (0.10)	< 5	380 (8.77)	56 (1.26)
		HS	6 (0.03)	< 5	< 5	< 5	< 5	< 5	17 (0.39)	< 5
		MP	11 (0.06)	< 5	< 5	< 5	< 5	< 5	14 (0.32)	< 5
	91 to 180 days	VTE	49 (0.25)	5 (0.08)	24 (6.99)	< 5	< 5	< 5	60 (1.39)	6 (0.13)
		DVT	26 (0.13)	< 5	13 (3.79)	< 5	< 5	< 5	33 (0.76)	< 5
		PE	26 (0.13)	< 5	13 (3.79)	< 5	< 5	< 5	33 (0.76)	< 5
		ATE	17 (0.09)	9 (0.15)	20 (5.83)	< 5	< 5	< 5	85 (1.96)	7 (0.16)
		IS	< 5	< 5	13 (3.79)	< 5	< 5	< 5	43 (0.99)	< 5
		TIA	< 5	< 5	< 5	< 5	< 5	< 5	23 (0.53)	< 5
		MI	11 (0.06)	< 5	9 (2.62)	< 5	< 5	< 5	26 (0.60)	< 5
		HF	27 (0.14)	17 (0.29)	107 (31.18)	< 5	< 5	< 5	135 (3.12)	19 (0.43)
		HS	< 5	< 5	< 5	< 5	< 5	< 5	7 (0.16)	< 5
		MP	6 (0.03)	< 5	< 5	< 5	< 5	< 5	< 5	< 5
	181 to 365 days	VTE	28 (0.14)	< 5	22 (6.41)	< 5	5 (0.09)	< 5	59 (1.36)	< 5
		DVT	12 (0.06)	< 5	11 (3.21)	< 5	< 5	< 5	31 (0.72)	< 5
		PE	16 (0.08)	< 5	12 (3.50)	< 5	< 5	< 5	30 (0.69)	< 5
		ATE	14 (0.07)	5 (0.08)	18 (5.24)	< 5	< 5	< 5	87 (2.01)	10 (0.22)
		IS	< 5	< 5	7 (2.04)	< 5	< 5	< 5	48 (1.11)	5 (0.11)
		TIA	7 (0.04)	< 5	6 (1.75)	< 5	< 5	< 5	19 (0.44)	< 5
		MI	8 (0.04)	< 5	7 (2.04)	< 5	< 5	< 5	23 (0.53)	< 5
		HF	19 (0.10)	9 (0.15)	130 (37.88)	< 5	< 5	< 5	114 (2.63)	25 (0.56)
		HS	< 5	< 5	< 5	< 5	< 5	< 5	7 (0.16)	< 5
	MP	< 5	< 5	< 5	< 5	< 5	< 5	7 (0.16)	< 5	
	181 to 365 days	VTE	10 (0.05)	7 (0.12)	39 (11.36)	< 5	< 5	< 5	16 (0.37)	10 (0.22)
		DVT	< 5	< 5	15 (4.37)	< 5	< 5	< 5	11 (0.25)	6 (0.13)
		PE	8 (0.04)	5 (0.08)	28 (8.16)	< 5	< 5	< 5	7 (0.16)	< 5
		ATE	12 (0.06)	6 (0.10)	44 (12.82)	< 5	< 5	< 5	65 (1.50)	19 (0.43)
		IS	< 5	< 5	29 (8.45)	< 5	< 5	< 5	35 (0.81)	9 (0.20)
		TIA	< 5	< 5	12 (3.50)	< 5	< 5	< 5	19 (0.44)	5 (0.11)
		MI	9 (0.05)	< 5	8 (2.33)	< 5	< 5	< 5	13 (0.30)	5 (0.11)
		HF	23 (0.12)	11 (0.19)	213 (62.06)	< 5	< 5	< 5	73 (1.69)	27 (0.61)
		HS	< 5	< 5	< 5	< 5	< 5	< 5	5 (0.12)	< 5
MP		< 5	< 5	< 5	< 5	< 5	< 5	< 5	< 5	
Cohort 3		N = 1,510,323	N = 54,102	N = 96,471	N = 18,645	N = 416,549	N = 36,748	N = 869,109	N = 706,435	
0 to 30 days	VTE	244 (1.62)	< 5	105 (10.88)	< 5	28 (0.67)	< 5	326 (3.75)	< 5	
	DVT	44 (0.29)	< 5	19 (1.97)	< 5	6 (0.14)	< 5	92 (1.06)	< 5	
	PE	209 (1.38)	< 5	88 (9.12)	< 5	23 (0.55)	< 5	262 (3.01)	< 5	
	ATE	29 (0.19)	< 5	95 (9.85)	< 5	< 5	< 5	212 (2.44)	< 5	
	IS	< 5	< 5	53 (5.49)	< 5	< 5	< 5	102 (1.17)	< 5	
	TIA	5 (0.03)	< 5	16 (1.66)	< 5	< 5	< 5	20 (0.23)	< 5	
	MI	20 (0.13)	< 5	31 (3.21)	< 5	< 5	< 5	96 (1.10)	< 5	
	HF	30 (0.20)	7 (1.29)	329 (34.10)	< 5	< 5	< 5	364 (4.19)	5 (0.07)	
	HS	< 5	< 5	< 5	< 5	< 5	< 5	20 (0.23)	< 5	
	MP	9 (0.06)	< 5	< 5	< 5	< 5	< 5	19 (0.22)	< 5	
31 to 90 days	VTE	44 (0.29)	< 5	32 (3.32)	< 5	< 5	< 5	85 (0.98)	< 5	

Cohort	Time window	Outcome	AURUM		CORIVA		GOLD		SIDAP	
			Unvaccinated	Vaccinated	Unvaccinated	Vaccinated	Unvaccinated	Vaccinated	Unvaccinated	Vaccinated
		DVT	20 (0.13)	< 5	19 (1.97)	< 5	< 5	< 5	56 (0.64)	< 5
		PE	27 (0.18)	< 5	16 (1.66)	< 5	< 5	< 5	39 (0.45)	< 5
		ATE	11 (0.07)	< 5	34 (3.52)	< 5	< 5	< 5	107 (1.23)	< 5
		IS	< 5	< 5	16 (1.66)	< 5	< 5	< 5	52 (0.60)	< 5
		TIA	< 5	< 5	6 (0.62)	< 5	< 5	< 5	27 (0.31)	< 5
		MI	9 (0.06)	< 5	15 (1.55)	< 5	< 5	< 5	36 (0.41)	< 5
		HF	15 (0.10)	< 5	133 (13.79)	< 5	< 5	< 5	141 (1.62)	< 5
		HS	< 5	< 5	< 5	< 5	< 5	< 5	7 (0.08)	< 5
		MP	8 (0.05)	< 5	6 (0.62)	< 5	< 5	< 5	8 (0.09)	< 5
	91 to 180 days	VTE	24 (0.16)	< 5	38 (3.94)	< 5	< 5	< 5	65 (0.75)	< 5
		DVT	11 (0.07)	< 5	23 (2.38)	< 5	< 5	< 5	37 (0.43)	< 5
		PE	14 (0.09)	< 5	16 (1.66)	< 5	< 5	< 5	32 (0.37)	< 5
		ATE	< 5	< 5	26 (2.70)	< 5	< 5	< 5	113 (1.30)	6 (0.08)
		IS	< 5	< 5	11 (1.14)	< 5	< 5	< 5	57 (0.66)	< 5
		TIA	< 5	< 5	9 (0.93)	< 5	< 5	< 5	22 (0.25)	< 5
		MI	< 5	< 5	10 (1.04)	< 5	< 5	< 5	37 (0.43)	< 5
		HF	10 (0.07)	< 5	166 (17.21)	< 5	< 5	< 5	122 (1.40)	< 5
		HS	< 5	< 5	< 5	< 5	< 5	< 5	9 (0.10)	< 5
	181 to 365 days	MP	< 5	< 5	< 5	< 5	< 5	< 5	7 (0.08)	< 5
		VTE	< 5	< 5	62 (6.43)	< 5	< 5	< 5	34 (0.39)	< 5
		DVT	< 5	< 5	32 (3.32)	< 5	< 5	< 5	20 (0.23)	< 5
		PE	< 5	< 5	33 (3.42)	< 5	< 5	< 5	16 (0.18)	< 5
		ATE	< 5	< 5	60 (6.22)	< 5	< 5	< 5	51 (0.59)	6 (0.08)
		IS	< 5	< 5	31 (3.21)	< 5	< 5	< 5	24 (0.28)	< 5
		TIA	< 5	< 5	16 (1.66)	< 5	< 5	< 5	10 (0.12)	< 5
		MI	< 5	< 5	20 (2.07)	< 5	< 5	< 5	18 (0.21)	< 5
		HF	5 (0.03)	< 5	270 (27.99)	< 5	< 5	< 5	60 (0.69)	< 5
	HS	< 5	< 5	< 5	< 5	< 5	< 5	< 5	< 5	
MP	< 5	< 5	< 5	< 5	< 5	< 5	< 5	< 5		
Cohort 4		N = 2,014,161	N = 1,335,671	N = 147,553	N = 15,683	N = 465,326	N = 365,096	N = 1,068,043	N = 580,329	
0 to 30 days	VTE	328 (1.63)	9 (0.07)	106 (7.18)	< 5	36 (0.77)	< 5	347 (3.25)	18 (0.31)	
	DVT	52 (0.26)	5 (0.04)	21 (1.42)	< 5	6 (0.13)	< 5	105 (0.98)	8 (0.14)	
	PE	287 (1.42)	< 5	87 (5.90)	< 5	31 (0.67)	< 5	271 (2.54)	10 (0.17)	
	ATE	25 (0.12)	< 5	94 (6.37)	< 5	< 5	< 5	234 (2.19)	9 (0.16)	
	IS	< 5	< 5	53 (3.59)	< 5	< 5	< 5	114 (1.07)	6 (0.10)	
	TIA	6 (0.03)	< 5	16 (1.08)	< 5	< 5	< 5	28 (0.26)	< 5	
	MI	15 (0.07)	< 5	30 (2.03)	< 5	< 5	< 5	98 (0.92)	< 5	
	HF	26 (0.13)	< 5	316 (21.42)	< 5	< 5	< 5	363 (3.40)	7 (0.12)	
	HS	< 5	< 5	< 5	< 5	< 5	< 5	23 (0.22)	< 5	
MP	13 (0.06)	< 5	6 (0.41)	< 5	< 5	< 5	30 (0.28)	< 5		
31 to 90 days	VTE	56 (0.28)	< 5	34 (2.30)	< 5	< 5	< 5	93 (0.87)	6 (0.10)	
	DVT	20 (0.10)	< 5	21 (1.42)	< 5	< 5	< 5	64 (0.60)	< 5	
	PE	39 (0.19)	< 5	16 (1.08)	< 5	< 5	< 5	38 (0.36)	< 5	
	ATE	13 (0.06)	< 5	32 (2.17)	< 5	< 5	< 5	117 (1.10)	< 5	
	IS	< 5	< 5	16 (1.08)	< 5	< 5	< 5	51 (0.48)	< 5	
	TIA	< 5	< 5	5 (0.34)	< 5	< 5	< 5	31 (0.29)	< 5	
	MI	9 (0.04)	< 5	14 (0.95)	< 5	< 5	< 5	43 (0.40)	< 5	
	HF	14 (0.07)	6 (0.04)	126 (8.54)	< 5	< 5	< 5	140 (1.31)	< 5	
	HS	< 5	< 5	< 5	< 5	< 5	< 5	9 (0.08)	< 5	

Cohort	Time window	Outcome	AURUM		CORIVA		GOLD		SIDIAP	
			Unvaccinated	Vaccinated	Unvaccinated	Vaccinated	Unvaccinated	Vaccinated	Unvaccinated	Vaccinated
91 to 180 days		MP	7 (0.03)	< 5	6 (0.41)	< 5	< 5	< 5	11 (0.10)	< 5
		VTE	24 (0.12)	8 (0.06)	41 (2.78)	< 5	< 5	< 5	69 (0.65)	< 5
		DVT	11 (0.05)	7 (0.05)	27 (1.83)	< 5	< 5	< 5	38 (0.36)	< 5
		PE	14 (0.07)	< 5	15 (1.02)	< 5	< 5	< 5	35 (0.33)	< 5
		ATE	< 5	< 5	24 (1.63)	< 5	< 5	< 5	124 (1.16)	9 (0.16)
		IS	< 5	< 5	10 (0.68)	< 5	< 5	< 5	61 (0.57)	7 (0.12)
		TIA	< 5	< 5	9 (0.61)	< 5	< 5	< 5	27 (0.25)	< 5
		MI	< 5	< 5	9 (0.61)	< 5	< 5	< 5	39 (0.37)	< 5
		HF	9 (0.04)	< 5	149 (10.10)	< 5	< 5	< 5	142 (1.33)	9 (0.16)
		HS	< 5	< 5	< 5	< 5	< 5	< 5	16 (0.15)	< 5
181 to 365 days		MP	< 5	< 5	< 5	< 5	< 5	< 5	12 (0.11)	< 5
		VTE	< 5	< 5	64 (4.34)	< 5	< 5	< 5	51 (0.48)	7 (0.12)
		DVT	< 5	< 5	36 (2.44)	< 5	< 5	< 5	33 (0.31)	5 (0.09)
		PE	< 5	< 5	31 (2.10)	< 5	< 5	< 5	19 (0.18)	< 5
		ATE	< 5	< 5	56 (3.80)	< 5	< 5	< 5	54 (0.51)	15 (0.26)
		IS	< 5	< 5	28 (1.90)	< 5	< 5	< 5	26 (0.24)	10 (0.17)
		TIA	< 5	< 5	15 (1.02)	< 5	< 5	< 5	10 (0.09)	< 5
		MI	< 5	< 5	19 (1.29)	< 5	< 5	< 5	19 (0.18)	5 (0.09)
		HF	< 5	< 5	242 (16.40)	< 5	< 5	< 5	61 (0.57)	< 5
		HS	< 5	< 5	6 (0.41)	< 5	< 5	< 5	5 (0.05)	< 5
	MP	< 5	< 5	< 5	< 5	< 5	< 5	6 (0.06)	< 5	

VTE = Venous thromboembolism (DVT + PE), DVT = Deep vein thrombosis, PE = Pulmonary embolism, ATE = Arterial thromboembolism (IS + TIA + MI), IS = Ischemic stroke, TIA = Transient ischemic attack, MI = Myocardial infarction, HF = Heart failure, HS = Hemorrhagic stroke, MP = Myocarditis or Pericarditis

Table S34: Number of records (and risk per 10,000 individuals) for post COVID-19 cardiac and thromboembolic complications, across cohorts and databases, stratified by exposure status (BNT162b2 vaccine). Only first outcome after COVID-19 captured.

Cohort	Time window	Outcome	AURUM		CORIVA		GOLD		SIDIAP	
			Unvaccinated	Vaccinated	Unvaccinated	Vaccinated	Unvaccinated	Vaccinated	Unvaccinated	Vaccinated
Cohort 1			N = 348,052	N = 332,790	N = 24,073	N = 19,686	N = 169,459	N = 32,755	N = 223,960	N = 88,896
	0 to 30 days	VTE	167 (4.80)	76 (2.28)	97 (40.29)	31 (15.75)	15 (0.89)	< 5	251 (11.21)	94 (10.57)
		DVT	39 (1.12)	15 (0.45)	18 (7.48)	8 (4.06)	< 5	< 5	76 (3.39)	29 (3.26)
		PE	138 (3.96)	64 (1.92)	81 (33.65)	24 (12.19)	12 (0.71)	< 5	187 (8.35)	75 (8.44)
		ATE	62 (1.78)	45 (1.35)	125 (51.93)	37 (18.80)	8 (0.47)	< 5	353 (15.76)	206 (23.17)
		IS	16 (0.46)	5 (0.15)	77 (31.99)	18 (9.14)	< 5	< 5	196 (8.75)	116 (13.05)
		TIA	14 (0.40)	11 (0.33)	23 (9.55)	7 (3.56)	< 5	< 5	58 (2.59)	41 (4.61)
		MI	34 (0.98)	29 (0.87)	37 (15.37)	19 (9.65)	6 (0.35)	< 5	115 (5.13)	61 (6.86)
		HF	136 (3.91)	126 (3.79)	438 (181.95)	154 (78.23)	20 (1.18)	< 5	1,203 (53.71)	634 (71.32)
		HS	< 5	< 5	< 5	< 5	< 5	< 5	46 (2.05)	14 (1.57)
		MP	< 5	< 5	< 5	< 5	< 5	< 5	16 (0.71)	< 5
	31 to 90 days	VTE	31 (0.89)	25 (0.75)	37 (15.37)	8 (4.06)	5 (0.30)	< 5	88 (3.93)	43 (4.84)
		DVT	13 (0.37)	7 (0.21)	22 (9.14)	< 5	< 5	< 5	53 (2.37)	28 (3.15)
		PE	18 (0.52)	18 (0.54)	17 (7.06)	< 5	< 5	< 5	41 (1.83)	19 (2.14)
		ATE	20 (0.57)	23 (0.69)	30 (12.46)	20 (10.16)	< 5	< 5	216 (9.64)	125 (14.06)
		IS	< 5	< 5	18 (7.48)	10 (5.08)	< 5	< 5	110 (4.91)	69 (7.76)
		TIA	10 (0.29)	10 (0.30)	10 (4.15)	7 (3.56)	< 5	< 5	70 (3.13)	32 (3.60)
		MI	11 (0.32)	11 (0.33)	10 (4.15)	< 5	< 5	< 5	49 (2.19)	28 (3.15)
		HF	75 (2.15)	70 (2.10)	142 (58.99)	65 (33.02)	6 (0.35)	< 5	473 (21.12)	288 (32.40)
		HS	< 5	< 5	< 5	< 5	< 5	< 5	16 (0.71)	12 (1.35)
		MP	< 5	< 5	< 5	< 5	< 5	< 5	< 5	< 5
	91 to 180 days	VTE	17 (0.49)	< 5	22 (9.14)	12 (6.10)	6 (0.35)	< 5	62 (2.77)	35 (3.94)
		DVT	6 (0.17)	< 5	10 (4.15)	< 5	< 5	< 5	37 (1.65)	19 (2.14)
		PE	11 (0.32)	< 5	14 (5.82)	9 (4.57)	< 5	< 5	29 (1.29)	18 (2.02)
		ATE	27 (0.78)	18 (0.54)	31 (12.88)	15 (7.62)	< 5	< 5	185 (8.26)	102 (11.47)
		IS	< 5	6 (0.18)	19 (7.89)	5 (2.54)	< 5	< 5	114 (5.09)	56 (6.30)
		TIA	13 (0.37)	6 (0.18)	8 (3.32)	< 5	< 5	< 5	41 (1.83)	33 (3.71)
		MI	12 (0.34)	6 (0.18)	8 (3.32)	10 (5.08)	< 5	< 5	38 (1.70)	22 (2.47)
		HF	64 (1.84)	54 (1.62)	166 (68.96)	91 (46.23)	< 5	< 5	398 (17.77)	226 (25.42)
		HS	< 5	< 5	< 5	< 5	< 5	< 5	21 (0.94)	< 5
		MP	< 5	< 5	< 5	< 5	< 5	< 5	< 5	< 5
	181 to 365 days	VTE	12 (0.34)	10 (0.30)	50 (20.77)	21 (10.67)	< 5	< 5	26 (1.16)	10 (1.12)
		DVT	< 5	6 (0.18)	16 (6.65)	13 (6.60)	< 5	< 5	16 (0.71)	7 (0.79)
		PE	9 (0.26)	< 5	39 (16.20)	9 (4.57)	< 5	< 5	12 (0.54)	< 5
		ATE	18 (0.52)	14 (0.42)	51 (21.19)	31 (15.75)	< 5	< 5	104 (4.64)	38 (4.27)
		IS	< 5	< 5	28 (11.63)	15 (7.62)	< 5	< 5	50 (2.23)	23 (2.59)
		TIA	11 (0.32)	< 5	14 (5.82)	13 (6.60)	< 5	< 5	28 (1.25)	9 (1.01)
		MI	< 5	7 (0.21)	14 (5.82)	9 (4.57)	< 5	< 5	30 (1.34)	7 (0.79)
		HF	60 (1.72)	35 (1.05)	257 (106.76)	139 (70.61)	< 5	< 5	192 (8.57)	117 (13.16)
		HS	< 5	< 5	< 5	< 5	< 5	< 5	6 (0.27)	7 (0.79)
		MP	< 5	< 5	< 5	< 5	< 5	< 5	< 5	< 5
Cohort 2			N = 1,976,163	N = 594,262	N = 34,320	N = 4,067	N = 584,309	N = 180,670	N = 433,111	N = 445,581
	0 to 30 days	VTE	344 (1.74)	62 (1.04)	89 (25.93)	8 (19.67)	40 (0.68)	5 (0.28)	396 (9.14)	265 (5.95)
		DVT	72 (0.36)	18 (0.30)	16 (4.66)	< 5	8 (0.14)	< 5	117 (2.70)	96 (2.15)
		PE	279 (1.41)	45 (0.76)	74 (21.56)	5 (12.29)	33 (0.56)	< 5	309 (7.13)	189 (4.24)

Cohort	Time window	Outcome	AURUM		CORIVA		GOLD		SIDAP		
			Unvaccinated	Vaccinated	Unvaccinated	Vaccinated	Unvaccinated	Vaccinated	Unvaccinated	Vaccinated	
		ATE	71 (0.36)	29 (0.49)	128 (37.30)	< 5	9 (0.15)	< 5	347 (8.01)	489 (10.97)	
		IS	11 (0.06)	< 5	79 (23.02)	< 5	< 5	< 5	192 (4.43)	267 (5.99)	
		TIA	14 (0.07)	11 (0.19)	23 (6.70)	< 5	< 5	< 5	45 (1.04)	90 (2.02)	
		MI	46 (0.23)	16 (0.27)	36 (10.49)	< 5	6 (0.10)	< 5	127 (2.93)	163 (3.66)	
		HF	78 (0.39)	43 (0.72)	392 (114.22)	17 (41.80)	6 (0.10)	< 5	639 (14.75)	1,137 (25.52)	
		HS	6 (0.03)	< 5	< 5	< 5	< 5	< 5	38 (0.88)	61 (1.37)	
		MP	20 (0.10)	< 5	< 5	< 5	< 5	< 5	30 (0.69)	22 (0.49)	
	31 to 90 days	VTE	89 (0.45)	21 (0.35)	36 (10.49)	< 5	7 (0.12)	< 5	104 (2.40)	123 (2.76)	
		DVT	50 (0.25)	7 (0.12)	22 (6.41)	< 5	< 5	< 5	60 (1.39)	77 (1.73)	
		PE	42 (0.21)	14 (0.24)	17 (4.95)	< 5	< 5	< 5	53 (1.22)	55 (1.23)	
		ATE	38 (0.19)	36 (0.61)	31 (9.03)	< 5	8 (0.14)	< 5	196 (4.53)	307 (6.89)	
		IS	7 (0.04)	5 (0.08)	21 (6.12)	< 5	< 5	< 5	95 (2.19)	162 (3.64)	
		TIA	11 (0.06)	9 (0.15)	6 (1.75)	< 5	< 5	< 5	53 (1.22)	85 (1.91)	
		MI	21 (0.11)	22 (0.37)	10 (2.91)	< 5	< 5	< 5	61 (1.41)	79 (1.77)	
	91 to 180 days	HF	50 (0.25)	34 (0.57)	143 (41.67)	10 (24.59)	5 (0.09)	< 5	260 (6.00)	534 (11.98)	
		HS	5 (0.03)	< 5	< 5	< 5	< 5	< 5	18 (0.42)	19 (0.43)	
		MP	14 (0.07)	< 5	< 5	< 5	< 5	< 5	8 (0.18)	< 5	
		VTE	38 (0.19)	9 (0.15)	24 (6.99)	5 (12.29)	7 (0.12)	< 5	100 (2.31)	84 (1.89)	
		DVT	20 (0.10)	6 (0.10)	11 (3.21)	< 5	< 5	< 5	55 (1.27)	52 (1.17)	
		PE	18 (0.09)	< 5	14 (4.08)	< 5	7 (0.12)	< 5	51 (1.18)	39 (0.88)	
		ATE	30 (0.15)	15 (0.25)	28 (8.16)	< 5	5 (0.09)	< 5	171 (3.95)	265 (5.95)	
	181 to 365 days	IS	< 5	< 5	17 (4.95)	< 5	< 5	< 5	88 (2.03)	148 (3.32)	
		TIA	13 (0.07)	5 (0.08)	7 (2.04)	< 5	< 5	< 5	40 (0.92)	72 (1.62)	
		MI	16 (0.08)	10 (0.17)	7 (2.04)	< 5	< 5	< 5	49 (1.13)	62 (1.39)	
		HF	28 (0.14)	24 (0.40)	167 (48.66)	13 (31.96)	< 5	< 5	211 (4.87)	438 (9.83)	
		HS	< 5	< 5	< 5	< 5	< 5	< 5	18 (0.42)	33 (0.74)	
		MP	< 5	< 5	< 5	< 5	< 5	< 5	12 (0.28)	< 5	
		VTE	17 (0.09)	8 (0.13)	48 (13.99)	< 5	< 5	< 5	30 (0.69)	30 (0.67)	
	Cohort 3			N = 1,510,323	N = 54,102	N = 96,471	N = 18,645	N = 416,549	N = 36,748	N = 869,109	N = 706,435
		0 to 30 days	DVT	6 (0.03)	< 5	25 (7.28)	< 5	< 5	< 5	18 (0.42)	20 (0.45)
			PE	12 (0.06)	7 (0.12)	28 (8.16)	< 5	< 5	< 5	15 (0.35)	12 (0.27)
			ATE	11 (0.06)	7 (0.12)	57 (16.61)	< 5	< 5	< 5	96 (2.22)	103 (2.31)
			IS	< 5	< 5	36 (10.49)	< 5	< 5	< 5	51 (1.18)	51 (1.14)
TIA			< 5	< 5	15 (4.37)	< 5	< 5	< 5	22 (0.51)	29 (0.65)	
MI			8 (0.04)	< 5	11 (3.21)	< 5	< 5	< 5	28 (0.65)	29 (0.65)	
HF			22 (0.11)	12 (0.20)	267 (77.80)	15 (36.88)	< 5	< 5	90 (2.08)	178 (3.99)	
HS			< 5	< 5	< 5	< 5	< 5	< 5	6 (0.14)	9 (0.20)	
MP			< 5	< 5	< 5	< 5	< 5	< 5	< 5	< 5	
31 to 90 days	VTE	267 (1.77)	< 5	124 (12.85)	7 (3.75)	33 (0.79)	< 5	422 (4.86)	114 (1.61)		
	DVT	52 (0.34)	< 5	25 (2.59)	5 (2.68)	7 (0.17)	< 5	132 (1.52)	51 (0.72)		
	PE	224 (1.48)	< 5	100 (10.37)	< 5	27 (0.65)	< 5	326 (3.75)	71 (1.01)		
	ATE	34 (0.23)	< 5	131 (13.58)	8 (4.29)	< 5	< 5	314 (3.61)	197 (2.79)		
	IS	5 (0.03)	< 5	73 (7.57)	6 (3.22)	< 5	< 5	154 (1.77)	95 (1.34)		
	TIA	6 (0.04)	< 5	24 (2.49)	< 5	< 5	< 5	32 (0.37)	42 (0.59)		
	MI	23 (0.15)	< 5	42 (4.35)	< 5	< 5	< 5	137 (1.58)	78 (1.10)		
	HF	32 (0.21)	10 (1.85)	401 (41.57)	16 (8.58)	< 5	< 5	476 (5.48)	163 (2.31)		
	HS	< 5	< 5	5 (0.52)	< 5	< 5	< 5	34 (0.39)	26 (0.37)		
	MP	14 (0.09)	< 5	< 5	< 5	< 5	< 5	27 (0.31)	13 (0.18)		
	VTE	58 (0.38)	< 5	45 (4.66)	5 (2.68)	< 5	< 5	114 (1.31)	63 (0.89)		

Cohort	Time window	Outcome	AURUM		CORIVA		GOLD		SIDAP	
			Unvaccinated	Vaccinated	Unvaccinated	Vaccinated	Unvaccinated	Vaccinated	Unvaccinated	Vaccinated
		DVT	28 (0.19)	< 5	30 (3.11)	< 5	< 5	< 5	78 (0.90)	47 (0.67)
		PE	33 (0.22)	< 5	18 (1.87)	< 5	< 5	< 5	47 (0.54)	21 (0.30)
		ATE	14 (0.09)	< 5	42 (4.35)	10 (5.36)	< 5	< 5	169 (1.94)	142 (2.01)
		IS	< 5	< 5	23 (2.38)	< 5	< 5	< 5	74 (0.85)	54 (0.76)
		TIA	< 5	< 5	7 (0.73)	6 (3.22)	< 5	< 5	50 (0.58)	27 (0.38)
		MI	11 (0.07)	< 5	16 (1.66)	< 5	< 5	< 5	57 (0.66)	69 (0.98)
		HF	22 (0.15)	< 5	177 (18.35)	11 (5.90)	< 5	< 5	186 (2.14)	108 (1.53)
		HS	5 (0.03)	< 5	< 5	< 5	< 5	< 5	13 (0.15)	14 (0.20)
		MP	9 (0.06)	< 5	7 (0.73)	< 5	< 5	< 5	13 (0.15)	9 (0.13)
	91 to 180 days	VTE	28 (0.19)	< 5	44 (4.56)	8 (4.29)	5 (0.12)	< 5	92 (1.06)	67 (0.95)
		DVT	14 (0.09)	< 5	27 (2.80)	5 (2.68)	< 5	< 5	56 (0.64)	43 (0.61)
		PE	16 (0.11)	< 5	17 (1.76)	< 5	< 5	< 5	41 (0.47)	25 (0.35)
		ATE	8 (0.05)	< 5	44 (4.56)	7 (3.75)	< 5	< 5	170 (1.96)	137 (1.94)
		IS	< 5	< 5	20 (2.07)	< 5	< 5	< 5	77 (0.89)	62 (0.88)
		TIA	< 5	< 5	13 (1.35)	< 5	< 5	< 5	30 (0.35)	28 (0.40)
		MI	< 5	< 5	16 (1.66)	< 5	< 5	< 5	65 (0.75)	53 (0.75)
		HF	11 (0.07)	< 5	210 (21.77)	12 (6.44)	< 5	< 5	169 (1.94)	97 (1.37)
		HS	< 5	< 5	< 5	< 5	< 5	< 5	16 (0.18)	10 (0.14)
	MP	< 5	< 5	6 (0.62)	< 5	< 5	< 5	11 (0.13)	9 (0.13)	
	181 to 365 days	VTE	< 5	< 5	72 (7.46)	13 (6.97)	< 5	< 5	37 (0.43)	13 (0.18)
		DVT	< 5	< 5	44 (4.56)	11 (5.90)	< 5	< 5	22 (0.25)	11 (0.16)
		PE	< 5	< 5	31 (3.21)	< 5	< 5	< 5	18 (0.21)	< 5
		ATE	< 5	< 5	80 (8.29)	6 (3.22)	< 5	< 5	54 (0.62)	36 (0.51)
		IS	< 5	< 5	38 (3.94)	< 5	< 5	< 5	28 (0.32)	13 (0.18)
		TIA	< 5	< 5	22 (2.28)	< 5	< 5	< 5	9 (0.10)	5 (0.07)
		MI	< 5	< 5	27 (2.80)	< 5	< 5	< 5	18 (0.21)	21 (0.30)
		HF	5 (0.03)	< 5	324 (33.59)	25 (13.41)	< 5	< 5	60 (0.69)	25 (0.35)
		HS	< 5	< 5	6 (0.62)	< 5	< 5	< 5	< 5	< 5
MP	< 5	< 5	5 (0.52)	< 5	< 5	< 5	< 5	< 5		
Cohort 4		N = 2,014,161	N = 1,335,671	N = 147,553	N = 15,683	N = 465,326	N = 365,096	N = 1,068,043	N = 580,329	
0 to 30 days	VTE	331 (1.64)	20 (0.15)	121 (8.20)	< 5	36 (0.77)	< 5	386 (3.61)	66 (1.14)	
	DVT	52 (0.26)	9 (0.07)	24 (1.63)	< 5	6 (0.13)	< 5	124 (1.16)	35 (0.60)	
	PE	290 (1.44)	11 (0.08)	98 (6.64)	< 5	31 (0.67)	< 5	298 (2.79)	35 (0.60)	
	ATE	25 (0.12)	< 5	122 (8.27)	8 (5.10)	< 5	< 5	277 (2.59)	55 (0.95)	
	IS	< 5	< 5	70 (4.74)	< 5	< 5	< 5	139 (1.30)	29 (0.50)	
	TIA	6 (0.03)	< 5	22 (1.49)	< 5	< 5	< 5	37 (0.35)	7 (0.12)	
	MI	15 (0.07)	< 5	38 (2.58)	< 5	< 5	< 5	108 (1.01)	20 (0.34)	
	HF	26 (0.13)	< 5	373 (25.28)	13 (8.29)	< 5	< 5	425 (3.98)	44 (0.76)	
	HS	< 5	< 5	< 5	< 5	< 5	< 5	32 (0.30)	7 (0.12)	
	MP	14 (0.07)	< 5	7 (0.47)	< 5	< 5	< 5	33 (0.31)	11 (0.19)	
31 to 90 days	VTE	54 (0.27)	7 (0.05)	45 (3.05)	< 5	< 5	< 5	109 (1.02)	32 (0.55)	
	DVT	20 (0.10)	< 5	30 (2.03)	< 5	< 5	< 5	76 (0.71)	23 (0.40)	
	PE	37 (0.18)	< 5	18 (1.22)	< 5	< 5	< 5	42 (0.39)	10 (0.17)	
	ATE	13 (0.06)	< 5	39 (2.64)	< 5	< 5	< 5	145 (1.36)	51 (0.88)	
	IS	< 5	< 5	22 (1.49)	< 5	< 5	< 5	64 (0.60)	21 (0.36)	
	TIA	< 5	< 5	7 (0.47)	< 5	< 5	< 5	41 (0.38)	12 (0.21)	
	MI	9 (0.04)	< 5	15 (1.02)	< 5	< 5	< 5	49 (0.46)	21 (0.36)	
	HF	14 (0.07)	6 (0.04)	160 (10.84)	11 (7.01)	< 5	< 5	155 (1.45)	28 (0.48)	
HS	5 (0.02)	< 5	< 5	< 5	< 5	< 5	12 (0.11)	5 (0.09)		

Cohort	Time window	Outcome	AURUM		CORIVA		GOLD		SIDIAP	
			Unvaccinated	Vaccinated	Unvaccinated	Vaccinated	Unvaccinated	Vaccinated	Unvaccinated	Vaccinated
91 to 180 days		MP	8 (0.04)	< 5	8 (0.54)	< 5	< 5	< 5	14 (0.13)	8 (0.14)
		VTE	23 (0.11)	9 (0.07)	42 (2.85)	5 (3.19)	< 5	< 5	82 (0.77)	40 (0.69)
		DVT	10 (0.05)	7 (0.05)	28 (1.90)	< 5	< 5	< 5	50 (0.47)	25 (0.43)
		PE	14 (0.07)	< 5	15 (1.02)	< 5	< 5	< 5	37 (0.35)	18 (0.31)
		ATE	< 5	< 5	32 (2.17)	8 (5.10)	< 5	< 5	139 (1.30)	68 (1.17)
		IS	< 5	< 5	14 (0.95)	< 5	< 5	< 5	64 (0.60)	34 (0.59)
		TIA	< 5	< 5	10 (0.68)	< 5	< 5	< 5	27 (0.25)	14 (0.24)
		MI	< 5	< 5	12 (0.81)	< 5	< 5	< 5	50 (0.47)	20 (0.34)
		HF	9 (0.04)	< 5	180 (12.20)	9 (5.74)	< 5	< 5	163 (1.53)	35 (0.60)
		HS	< 5	< 5	< 5	< 5	< 5	< 5	19 (0.18)	< 5
181 to 365 days		MP	< 5	< 5	6 (0.41)	< 5	< 5	< 5	14 (0.13)	< 5
		VTE	< 5	< 5	72 (4.88)	6 (3.83)	< 5	< 5	44 (0.41)	7 (0.12)
		DVT	< 5	< 5	45 (3.05)	6 (3.83)	< 5	< 5	28 (0.26)	6 (0.10)
		PE	< 5	< 5	30 (2.03)	< 5	< 5	< 5	17 (0.16)	< 5
		ATE	< 5	< 5	67 (4.54)	6 (3.83)	< 5	< 5	44 (0.41)	9 (0.16)
		IS	< 5	< 5	32 (2.17)	< 5	< 5	< 5	21 (0.20)	6 (0.10)
		TIA	< 5	< 5	19 (1.29)	< 5	< 5	< 5	8 (0.07)	< 5
		MI	< 5	< 5	22 (1.49)	< 5	< 5	< 5	16 (0.15)	< 5
		HF	< 5	< 5	288 (19.52)	9 (5.74)	< 5	< 5	53 (0.50)	5 (0.09)
		HS	< 5	< 5	7 (0.47)	< 5	< 5	< 5	5 (0.05)	< 5
	MP	< 5	< 5	7 (0.47)	< 5	< 5	< 5	6 (0.06)	< 5	

VTE = Venous thromboembolism (DVT + PE), DVT = Deep vein thrombosis, PE = Pulmonary embolism, ATE = Arterial thromboembolism (IS + TIA + MI), IS = Ischemic stroke, TIA = Transient ischemic attack, MI = Myocardial infarction, HF = Heart failure, HS = Hemorrhagic stroke, MP = Myocarditis or Pericarditis

Table S35: Number of records (and risk per 10,000 individuals) for post COVID-19 cardiac and thromboembolic complications, across cohorts and databases, stratified by vaccine brand.

Cohort	Time window	Outcome	AURUM		GOLD	
			BNT162b2	ChAdOx1	BNT162b2	ChAdOx1
Cohort 1			N = 332,790	N = 219,804	N = 32,755	N = 82,406
Cohort 1	0 to 30 days	VTE	76 (2.28)	41 (1.87)	< 5	< 5
		DVT	15 (0.45)	12 (0.55)	< 5	< 5
		PE	64 (1.92)	31 (1.41)	< 5	< 5
		ATE	45 (1.35)	25 (1.14)	< 5	6 (0.73)
		IS	5 (0.15)	< 5	< 5	< 5
		TIA	11 (0.33)	7 (0.32)	< 5	< 5
		MI	29 (0.87)	17 (0.77)	< 5	< 5
		HF	126 (3.79)	72 (3.28)	< 5	5 (0.61)
		HS	< 5	< 5	< 5	< 5
		MP	< 5	< 5	< 5	< 5
	31 to 90 days	VTE	26 (0.78)	14 (0.64)	< 5	< 5
		DVT	7 (0.21)	8 (0.36)	< 5	< 5
		PE	19 (0.57)	7 (0.32)	< 5	< 5
		ATE	23 (0.69)	20 (0.91)	< 5	< 5
		IS	< 5	< 5	< 5	< 5
		TIA	10 (0.30)	9 (0.41)	< 5	< 5
		MI	11 (0.33)	9 (0.41)	< 5	< 5
		HF	71 (2.13)	42 (1.91)	< 5	5 (0.61)
		HS	< 5	< 5	< 5	< 5
		MP	< 5	< 5	< 5	< 5
	91 to 180 days	VTE	6 (0.18)	15 (0.68)	< 5	< 5
		DVT	< 5	5 (0.23)	< 5	< 5
		PE	< 5	10 (0.45)	< 5	< 5
		ATE	18 (0.54)	10 (0.45)	< 5	6 (0.73)
		IS	6 (0.18)	< 5	< 5	< 5
		TIA	6 (0.18)	6 (0.27)	< 5	< 5
		MI	6 (0.18)	< 5	< 5	5 (0.61)
		HF	57 (1.71)	38 (1.73)	< 5	< 5
		HS	< 5	< 5	< 5	< 5
		MP	< 5	< 5	< 5	< 5
	181 to 365 days	VTE	10 (0.30)	< 5	< 5	< 5
		DVT	6 (0.18)	< 5	< 5	< 5
		PE	< 5	< 5	< 5	< 5
ATE		14 (0.42)	9 (0.41)	< 5	< 5	
IS		< 5	< 5	< 5	< 5	
TIA		< 5	< 5	< 5	< 5	
MI		7 (0.21)	< 5	< 5	< 5	
HF		38 (1.14)	20 (0.91)	< 5	5 (0.61)	
HS		< 5	< 5	< 5	< 5	
MP		< 5	< 5	< 5	< 5	
Cohort 2			N = 594,262	N = 969,262	N = 180,670	N = 302,999
Cohort 2	0 to 30 days	VTE	62 (1.04)	158 (1.63)	5 (0.28)	19 (0.63)
		DVT	18 (0.30)	47 (0.48)	< 5	< 5
		PE	45 (0.76)	120 (1.24)	< 5	15 (0.50)
		ATE	29 (0.49)	75 (0.77)	< 5	< 5

Cohort	Time window	Outcome	AURUM		GOLD		
			BNT162b2	ChAdOx1	BNT162b2	ChAdOx1	
		IS	< 5	12 (0.12)	< 5	< 5	
		TIA	11 (0.19)	13 (0.13)	< 5	< 5	
		MI	16 (0.27)	52 (0.54)	< 5	< 5	
		HF	43 (0.72)	103 (1.06)	< 5	11 (0.36)	
		HS	< 5	< 5	< 5	< 5	
		MP	< 5	6 (0.06)	< 5	< 5	
	31 to 90 days	VTE	21 (0.35)	55 (0.57)	< 5	9 (0.30)	
		DVT	7 (0.12)	25 (0.26)	< 5	5 (0.17)	
		PE	14 (0.24)	32 (0.33)	< 5	< 5	
		ATE	36 (0.61)	57 (0.59)	< 5	5 (0.17)	
		IS	5 (0.08)	6 (0.06)	< 5	< 5	
		TIA	9 (0.15)	25 (0.26)	< 5	< 5	
		MI	22 (0.37)	28 (0.29)	< 5	< 5	
		HF	35 (0.59)	68 (0.70)	< 5	7 (0.23)	
		HS	< 5	< 5	< 5	< 5	
	91 to 180 days	MP	< 5	< 5	< 5	< 5	
		VTE	10 (0.17)	30 (0.31)	< 5	< 5	
		DVT	6 (0.10)	16 (0.17)	< 5	< 5	
		PE	5 (0.08)	16 (0.17)	< 5	< 5	
		ATE	15 (0.25)	28 (0.29)	< 5	< 5	
		IS	< 5	< 5	< 5	< 5	
		TIA	5 (0.08)	13 (0.13)	< 5	< 5	
		MI	10 (0.17)	15 (0.15)	< 5	< 5	
		HF	25 (0.42)	44 (0.45)	< 5	< 5	
	181 to 365 days	HS	< 5	< 5	< 5	< 5	
		MP	< 5	< 5	< 5	< 5	
		VTE	8 (0.13)	5 (0.05)	< 5	< 5	
		DVT	< 5	< 5	< 5	< 5	
		PE	7 (0.12)	< 5	< 5	< 5	
		ATE	7 (0.12)	11 (0.11)	< 5	< 5	
		IS	< 5	< 5	< 5	< 5	
		TIA	< 5	< 5	< 5	< 5	
		MI	< 5	7 (0.07)	< 5	< 5	
	Cohort 3	HF	12 (0.20)	23 (0.24)	< 5	< 5	
		HS	< 5	< 5	< 5	< 5	
		MP	< 5	< 5	< 5	< 5	
		0 to 30 days	N = 54,102	N = 1,473,602	N = 36,748	N = 423,876	
			VTE	< 5	139 (0.94)	< 5	16 (0.38)
			DVT	< 5	41 (0.28)	< 5	< 5
			PE	< 5	101 (0.69)	< 5	12 (0.28)
			ATE	< 5	47 (0.32)	< 5	12 (0.28)
			IS	< 5	5 (0.03)	< 5	< 5
	TIA		< 5	16 (0.11)	< 5	< 5	
	MI		< 5	26 (0.18)	< 5	9 (0.21)	
	HF		10 (1.85)	28 (0.19)	< 5	< 5	
	31 to 90 days	HS	< 5	< 5	< 5	< 5	
		MP	< 5	6 (0.04)	< 5	< 5	
	31 to 90 days	VTE	< 5	44 (0.30)	< 5	7 (0.17)	
		DVT	< 5	26 (0.18)	< 5	< 5	

Cohort	Time window	Outcome	AURUM		GOLD	
			BNT162b2	ChAdOx1	BNT162b2	ChAdOx1
		PE	< 5	18 (0.12)	< 5	< 5
		ATE	< 5	31 (0.21)	< 5	7 (0.17)
		IS	< 5	< 5	< 5	< 5
		TIA	< 5	13 (0.09)	< 5	< 5
		MI	< 5	16 (0.11)	< 5	< 5
		HF	< 5	23 (0.16)	< 5	< 5
		HS	< 5	< 5	< 5	< 5
		MP	< 5	7 (0.05)	< 5	< 5
	91 to 180 days	VTE	< 5	26 (0.18)	< 5	< 5
		DVT	< 5	15 (0.10)	< 5	< 5
		PE	< 5	14 (0.10)	< 5	< 5
		ATE	< 5	26 (0.18)	< 5	< 5
		IS	< 5	< 5	< 5	< 5
		TIA	< 5	8 (0.05)	< 5	< 5
		MI	< 5	17 (0.12)	< 5	< 5
		HF	< 5	12 (0.08)	< 5	< 5
		HS	< 5	< 5	< 5	< 5
		MP	< 5	< 5	< 5	< 5
	181 to 365 days	VTE	< 5	11 (0.07)	< 5	< 5
		DVT	< 5	5 (0.03)	< 5	< 5
		PE	< 5	7 (0.05)	< 5	< 5
		ATE	< 5	< 5	< 5	< 5
		IS	< 5	< 5	< 5	< 5
		TIA	< 5	< 5	< 5	< 5
		MI	< 5	< 5	< 5	< 5
		HF	< 5	< 5	< 5	< 5
		HS	< 5	< 5	< 5	< 5
		MP	< 5	< 5	< 5	< 5
	Cohort 4		N = 1,335,671	N = 542,670	N = 365,096	N = 147,744
	0 to 30 days	VTE	20 (0.15)	27 (0.50)	< 5	8 (0.54)
		DVT	9 (0.07)	7 (0.13)	< 5	< 5
		PE	11 (0.08)	21 (0.39)	< 5	6 (0.41)
		ATE	< 5	5 (0.09)	< 5	< 5
IS		< 5	< 5	< 5	< 5	
TIA		< 5	< 5	< 5	< 5	
MI		< 5	< 5	< 5	< 5	
HF		< 5	< 5	< 5	< 5	
HS		< 5	< 5	< 5	< 5	
MP		< 5	< 5	< 5	< 5	
31 to 90 days		VTE	7 (0.05)	14 (0.26)	< 5	< 5
		DVT	< 5	8 (0.15)	< 5	< 5
		PE	< 5	6 (0.11)	< 5	< 5
	ATE	< 5	< 5	< 5	< 5	
	IS	< 5	< 5	< 5	< 5	
	TIA	< 5	< 5	< 5	< 5	
	MI	< 5	< 5	< 5	< 5	
	HF	6 (0.04)	< 5	< 5	< 5	
	HS	< 5	< 5	< 5	< 5	
	MP	< 5	< 5	< 5	< 5	

Cohort	Time window	Outcome	AURUM		GOLD	
			BNT162b2	ChAdOx1	BNT162b2	ChAdOx1
91 to 180 days	VTE	9 (0.07)	< 5	< 5	< 5	< 5
	DVT	7 (0.05)	< 5	< 5	< 5	< 5
	PE	< 5	< 5	< 5	< 5	< 5
	ATE	< 5	< 5	< 5	< 5	< 5
	IS	< 5	< 5	< 5	< 5	< 5
	TIA	< 5	< 5	< 5	< 5	< 5
	MI	< 5	< 5	< 5	< 5	< 5
	HF	< 5	< 5	< 5	< 5	< 5
	HS	< 5	< 5	< 5	< 5	< 5
	MP	< 5	< 5	< 5	< 5	< 5
	181 to 365 days	VTE	< 5	< 5	< 5	< 5
DVT		< 5	< 5	< 5	< 5	< 5
PE		< 5	< 5	< 5	< 5	< 5
ATE		< 5	< 5	< 5	< 5	< 5
IS		< 5	< 5	< 5	< 5	< 5
TIA		< 5	< 5	< 5	< 5	< 5
MI		< 5	< 5	< 5	< 5	< 5
HF		< 5	< 5	< 5	< 5	< 5
HS		< 5	< 5	< 5	< 5	< 5
MP		< 5	< 5	< 5	< 5	< 5

VTE = Venous thromboembolism (DVT + PE), DVT = Deep vein thrombosis, PE = Pulmonary embolism, ATE = Arterial thromboembolism (IS + TIA + MI), IS = Ischemic stroke, TIA = Transient ischemic attack, MI = Myocardial infarction, HF = Heart failure, HS = Hemorrhagic stroke, MP = Myocarditis or Pericarditis

Table S36: Number of records (and risk per 10,000 individuals) for post COVID-19 cardiac and thromboembolic complications, across cohorts and databases, stratified by vaccine brand. Follow-up ends at first vaccine dose after index date.

Cohort	Time window	Outcome	AURUM		GOLD	
			BNT162b2	ChAdOx1	BNT162b2	ChAdOx1
Cohort 1			N = 332,790	N = 219,804	N = 32,755	N = 82,406
	0 to 30 days	VTE	31 (0.93)	14 (0.64)	< 5	< 5
		DVT	8 (0.24)	< 5	< 5	< 5
		PE	24 (0.72)	13 (0.59)	< 5	< 5
		ATE	18 (0.54)	10 (0.45)	< 5	< 5
		IS	< 5	< 5	< 5	< 5
		TIA	< 5	< 5	< 5	< 5
		MI	14 (0.42)	6 (0.27)	< 5	< 5
		HF	45 (1.35)	28 (1.27)	< 5	< 5
		HS	< 5	< 5	< 5	< 5
		MP	< 5	< 5	< 5	< 5
		31 to 90 days	VTE	15 (0.45)	5 (0.23)	< 5
	DVT		< 5	< 5	< 5	< 5
	PE		11 (0.33)	< 5	< 5	< 5
	ATE		8 (0.24)	8 (0.36)	< 5	< 5
	IS		< 5	< 5	< 5	< 5
	TIA		< 5	< 5	< 5	< 5
	MI		< 5	< 5	< 5	< 5
	HF		36 (1.08)	20 (0.91)	< 5	< 5
	HS		< 5	< 5	< 5	< 5
	MP		< 5	< 5	< 5	< 5
	91 to 180 days		VTE	< 5	5 (0.23)	< 5
		DVT	< 5	< 5	< 5	< 5
		PE	< 5	< 5	< 5	< 5
		ATE	10 (0.30)	< 5	< 5	< 5
		IS	< 5	< 5	< 5	< 5
		TIA	< 5	< 5	< 5	< 5
		MI	< 5	< 5	< 5	< 5
		HF	32 (0.96)	19 (0.86)	< 5	< 5
		HS	< 5	< 5	< 5	< 5
		MP	< 5	< 5	< 5	< 5
		181 to 365 days	VTE	7 (0.21)	< 5	< 5
	DVT		< 5	< 5	< 5	< 5
	PE		< 5	< 5	< 5	< 5
	ATE		11 (0.33)	8 (0.36)	< 5	< 5
	IS		< 5	< 5	< 5	< 5
	TIA		< 5	< 5	< 5	< 5
	MI		6 (0.18)	< 5	< 5	< 5
	HF		35 (1.05)	18 (0.82)	< 5	5 (0.61)
	HS		< 5	< 5	< 5	< 5
	MP		< 5	< 5	< 5	< 5
Cohort 2				N = 594,262	N = 969,262	N = 180,670
	0 to 30 days	VTE	14 (0.24)	40 (0.41)	< 5	< 5
		DVT	6 (0.10)	13 (0.13)	< 5	< 5
		PE	8 (0.13)	30 (0.31)	< 5	< 5

Cohort	Time window	Outcome	AURUM		GOLD			
			BNT162b2	ChAdOx1	BNT162b2	ChAdOx1		
		ATE	14 (0.24)	11 (0.11)	< 5	< 5		
		IS	< 5	< 5	< 5	< 5		
		TIA	< 5	< 5	< 5	< 5		
		MI	8 (0.13)	9 (0.09)	< 5	< 5		
		HF	15 (0.25)	32 (0.33)	< 5	< 5		
		HS	< 5	< 5	< 5	< 5		
		MP	< 5	< 5	< 5	< 5		
	31 to 90 days	VTE	5 (0.08)	8 (0.08)	< 5	< 5		
		DVT	< 5	5 (0.05)	< 5	< 5		
		PE	< 5	< 5	< 5	< 5		
		ATE	9 (0.15)	9 (0.09)	< 5	< 5		
		IS	< 5	< 5	< 5	< 5		
		TIA	< 5	< 5	< 5	< 5		
		MI	< 5	6 (0.06)	< 5	< 5		
	91 to 180 days	HF	17 (0.29)	13 (0.13)	< 5	< 5		
		HS	< 5	< 5	< 5	< 5		
		MP	< 5	< 5	< 5	< 5		
		VTE	< 5	12 (0.12)	< 5	< 5		
		DVT	< 5	7 (0.07)	< 5	< 5		
		PE	< 5	5 (0.05)	< 5	< 5		
		ATE	5 (0.08)	10 (0.10)	< 5	< 5		
	181 to 365 days	IS	< 5	< 5	< 5	< 5		
		TIA	< 5	< 5	< 5	< 5		
		MI	< 5	6 (0.06)	< 5	< 5		
		HF	9 (0.15)	18 (0.19)	< 5	< 5		
		HS	< 5	< 5	< 5	< 5		
		MP	< 5	< 5	< 5	< 5		
		VTE	7 (0.12)	5 (0.05)	< 5	< 5		
	Cohort 3	0 to 30 days	DVT	< 5	< 5	< 5	< 5	
			PE	5 (0.08)	< 5	< 5	< 5	
			ATE	6 (0.10)	10 (0.10)	< 5	< 5	
			IS	< 5	< 5	< 5	< 5	
			TIA	< 5	< 5	< 5	< 5	
MI			< 5	6 (0.06)	< 5	< 5		
HF			11 (0.19)	20 (0.21)	< 5	< 5		
HS			< 5	< 5	< 5	< 5		
MP			< 5	< 5	< 5	< 5		
			N = 54,102	N = 1,473,602	N = 36,748	N = 423,876		
31 to 90 days			VTE	< 5	23 (0.16)	< 5	< 5	
	DVT	< 5	< 5	< 5	< 5			
	0 to 30 days	PE	< 5	19 (0.13)	< 5	< 5		
		ATE	< 5	8 (0.05)	< 5	< 5		
		IS	< 5	< 5	< 5	< 5		
		TIA	< 5	< 5	< 5	< 5		
		MI	< 5	7 (0.05)	< 5	< 5		
		HF	7 (1.29)	11 (0.07)	< 5	< 5		
		HS	< 5	< 5	< 5	< 5		
		MP	< 5	< 5	< 5	< 5		
		31 to 90 days	VTE	< 5	< 5	< 5	< 5	

Cohort	Time window	Outcome	AURUM		GOLD	
			BNT162b2	ChAdOx1	BNT162b2	ChAdOx1
		DVT	< 5	< 5	< 5	< 5
		PE	< 5	< 5	< 5	< 5
		ATE	< 5	6 (0.04)	< 5	< 5
		IS	< 5	< 5	< 5	< 5
		TIA	< 5	< 5	< 5	< 5
		MI	< 5	< 5	< 5	< 5
		HF	< 5	5 (0.03)	< 5	< 5
		HS	< 5	< 5	< 5	< 5
		MP	< 5	< 5	< 5	< 5
	91 to 180 days	VTE	< 5	8 (0.05)	< 5	< 5
		DVT	< 5	6 (0.04)	< 5	< 5
		PE	< 5	< 5	< 5	< 5
		ATE	< 5	7 (0.05)	< 5	< 5
		IS	< 5	< 5	< 5	< 5
		TIA	< 5	< 5	< 5	< 5
		MI	< 5	< 5	< 5	< 5
		HF	< 5	< 5	< 5	< 5
		HS	< 5	< 5	< 5	< 5
		MP	< 5	< 5	< 5	< 5
	181 to 365 days	VTE	< 5	9 (0.06)	< 5	< 5
		DVT	< 5	< 5	< 5	< 5
		PE	< 5	6 (0.04)	< 5	< 5
		ATE	< 5	< 5	< 5	< 5
		IS	< 5	< 5	< 5	< 5
		TIA	< 5	< 5	< 5	< 5
		MI	< 5	< 5	< 5	< 5
		HF	< 5	< 5	< 5	< 5
		HS	< 5	< 5	< 5	< 5
		MP	< 5	< 5	< 5	< 5
Cohort 4			N = 1,335,671	N = 542,670	N = 365,096	N = 147,744
	0 to 30 days	VTE	9 (0.07)	8 (0.15)	< 5	6 (0.41)
		DVT	5 (0.04)	< 5	< 5	< 5
		PE	< 5	7 (0.13)	< 5	6 (0.41)
		ATE	< 5	< 5	< 5	< 5
		IS	< 5	< 5	< 5	< 5
		TIA	< 5	< 5	< 5	< 5
		MI	< 5	< 5	< 5	< 5
		HF	< 5	< 5	< 5	< 5
		HS	< 5	< 5	< 5	< 5
		MP	< 5	< 5	< 5	< 5
	31 to 90 days	VTE	< 5	8 (0.15)	< 5	< 5
		DVT	< 5	< 5	< 5	< 5
		PE	< 5	5 (0.09)	< 5	< 5
		ATE	< 5	< 5	< 5	< 5
		IS	< 5	< 5	< 5	< 5
		TIA	< 5	< 5	< 5	< 5
		MI	< 5	< 5	< 5	< 5
		HF	6 (0.04)	< 5	< 5	< 5
		HS	< 5	< 5	< 5	< 5

Cohort	Time window	Outcome	AURUM		GOLD	
			BNT162b2	ChAdOx1	BNT162b2	ChAdOx1
		MP	< 5	< 5	< 5	< 5
	91 to 180 days	VTE	8 (0.06)	< 5	< 5	< 5
		DVT	7 (0.05)	< 5	< 5	< 5
		PE	< 5	< 5	< 5	< 5
		ATE	< 5	< 5	< 5	< 5
		IS	< 5	< 5	< 5	< 5
		TIA	< 5	< 5	< 5	< 5
		MI	< 5	< 5	< 5	< 5
		HF	< 5	< 5	< 5	< 5
		HS	< 5	< 5	< 5	< 5
		MP	< 5	< 5	< 5	< 5
		181 to 365 days	VTE	< 5	< 5	< 5
	DVT		< 5	< 5	< 5	< 5
	PE		< 5	< 5	< 5	< 5
	ATE		< 5	< 5	< 5	< 5
	IS		< 5	< 5	< 5	< 5
	TIA		< 5	< 5	< 5	< 5
	MI		< 5	< 5	< 5	< 5
	HF		< 5	< 5	< 5	< 5
	HS		< 5	< 5	< 5	< 5
	MP		< 5	< 5	< 5	< 5

VTE = Venous thromboembolism (DVT + PE), DVT = Deep vein thrombosis, PE = Pulmonary embolism, ATE = Arterial thromboembolism (IS + TIA + MI), IS = Ischemic stroke, TIA = Transient ischemic attack, MI = Myocardial infarction, HF = Heart failure, HS = Hemorrhagic stroke, MP = Myocarditis or Pericarditis

Table S37: Number of records (and risk per 10,000 individuals) for post COVID-19 cardiac and thromboembolic complications, across cohorts and databases, stratified by vaccine brand. Only first outcome after COVID-19 captured.

Cohort	Time window	Outcome	AURUM		GOLD	
			BNT162b2	ChAdOx1	BNT162b2	ChAdOx1
Cohort 1			N = 332,790	N = 219,804	N = 32,755	N = 82,406
	0 to 30 days	VTE	76 (2.28)	41 (1.87)	< 5	< 5
		DVT	15 (0.45)	12 (0.55)	< 5	< 5
		PE	64 (1.92)	31 (1.41)	< 5	< 5
		ATE	45 (1.35)	25 (1.14)	< 5	6 (0.73)
		IS	5 (0.15)	< 5	< 5	< 5
		TIA	11 (0.33)	7 (0.32)	< 5	< 5
		MI	29 (0.87)	17 (0.77)	< 5	< 5
		HF	126 (3.79)	72 (3.28)	< 5	5 (0.61)
		HS	< 5	< 5	< 5	< 5
		MP	< 5	< 5	< 5	< 5
	31 to 90 days	VTE	25 (0.75)	14 (0.64)	< 5	< 5
		DVT	7 (0.21)	8 (0.36)	< 5	< 5
		PE	18 (0.54)	7 (0.32)	< 5	< 5
		ATE	23 (0.69)	20 (0.91)	< 5	< 5
		IS	< 5	< 5	< 5	< 5
		TIA	10 (0.30)	9 (0.41)	< 5	< 5
		MI	11 (0.33)	9 (0.41)	< 5	< 5
		HF	70 (2.10)	39 (1.77)	< 5	5 (0.61)
		HS	< 5	< 5	< 5	< 5
		MP	< 5	< 5	< 5	< 5
	91 to 180 days	VTE	< 5	15 (0.68)	< 5	< 5
		DVT	< 5	5 (0.23)	< 5	< 5
		PE	< 5	10 (0.45)	< 5	< 5
		ATE	18 (0.54)	10 (0.45)	< 5	6 (0.73)
		IS	6 (0.18)	< 5	< 5	< 5
		TIA	6 (0.18)	6 (0.27)	< 5	< 5
		MI	6 (0.18)	< 5	< 5	5 (0.61)
		HF	54 (1.62)	35 (1.59)	< 5	< 5
		HS	< 5	< 5	< 5	< 5
		MP	< 5	< 5	< 5	< 5
	181 to 365 days	VTE	10 (0.30)	< 5	< 5	< 5
		DVT	6 (0.18)	< 5	< 5	< 5
		PE	< 5	< 5	< 5	< 5
		ATE	14 (0.42)	9 (0.41)	< 5	< 5
		IS	< 5	< 5	< 5	< 5
		TIA	< 5	< 5	< 5	< 5
		MI	7 (0.21)	< 5	< 5	< 5
		HF	35 (1.05)	18 (0.82)	< 5	5 (0.61)
		HS	< 5	< 5	< 5	< 5
		MP	< 5	< 5	< 5	< 5
Cohort 2			N = 594,262	N = 969,262	N = 180,670	N = 302,999
	0 to 30 days	VTE	62 (1.04)	158 (1.63)	5 (0.28)	19 (0.63)
		DVT	18 (0.30)	47 (0.48)	< 5	< 5
		PE	45 (0.76)	120 (1.24)	< 5	15 (0.50)


Cohort	Time window	Outcome	AURUM		GOLD		
			BNT162b2	ChAdOx1	BNT162b2	ChAdOx1	
		ATE	29 (0.49)	75 (0.77)	< 5	< 5	
		IS	< 5	12 (0.12)	< 5	< 5	
		TIA	11 (0.19)	13 (0.13)	< 5	< 5	
		MI	16 (0.27)	52 (0.54)	< 5	< 5	
		HF	43 (0.72)	103 (1.06)	< 5	11 (0.36)	
		HS	< 5	< 5	< 5	< 5	
		MP	< 5	6 (0.06)	< 5	< 5	
	31 to 90 days	VTE	21 (0.35)	54 (0.56)	< 5	9 (0.30)	
		DVT	7 (0.12)	25 (0.26)	< 5	5 (0.17)	
		PE	14 (0.24)	31 (0.32)	< 5	< 5	
		ATE	36 (0.61)	56 (0.58)	< 5	5 (0.17)	
		IS	5 (0.08)	6 (0.06)	< 5	< 5	
		TIA	9 (0.15)	24 (0.25)	< 5	< 5	
		MI	22 (0.37)	28 (0.29)	< 5	< 5	
	91 to 180 days	HF	34 (0.57)	65 (0.67)	< 5	7 (0.23)	
		HS	< 5	< 5	< 5	< 5	
		MP	< 5	< 5	< 5	< 5	
		VTE	9 (0.15)	28 (0.29)	< 5	< 5	
		DVT	6 (0.10)	15 (0.15)	< 5	< 5	
		PE	< 5	15 (0.15)	< 5	< 5	
		ATE	15 (0.25)	28 (0.29)	< 5	< 5	
	181 to 365 days	IS	< 5	< 5	< 5	< 5	
		TIA	5 (0.08)	13 (0.13)	< 5	< 5	
		MI	10 (0.17)	15 (0.15)	< 5	< 5	
		HF	24 (0.40)	41 (0.42)	< 5	< 5	
		HS	< 5	< 5	< 5	< 5	
		MP	< 5	< 5	< 5	< 5	
		VTE	8 (0.13)	< 5	< 5	< 5	
	Cohort 3	0 to 30 days	DVT	< 5	< 5	< 5	< 5
			PE	7 (0.12)	< 5	< 5	< 5
			ATE	7 (0.12)	10 (0.10)	< 5	< 5
			IS	< 5	< 5	< 5	< 5
			TIA	< 5	< 5	< 5	< 5
MI			< 5	6 (0.06)	< 5	< 5	
HF			12 (0.20)	22 (0.23)	< 5	< 5	
HS			< 5	< 5	< 5	< 5	
MP			< 5	< 5	< 5	< 5	
N = 54,102			N = 1,473,602	N = 36,748	N = 423,876		
	0 to 30 days	VTE	< 5	139 (0.94)	< 5	16 (0.38)	
		DVT	< 5	41 (0.28)	< 5	< 5	
		PE	< 5	101 (0.69)	< 5	12 (0.28)	
		ATE	< 5	47 (0.32)	< 5	12 (0.28)	
		IS	< 5	5 (0.03)	< 5	< 5	
		TIA	< 5	16 (0.11)	< 5	< 5	
		MI	< 5	26 (0.18)	< 5	9 (0.21)	
		HF	10 (1.85)	28 (0.19)	< 5	< 5	
		HS	< 5	< 5	< 5	< 5	
	MP	< 5	6 (0.04)	< 5	< 5		
31 to 90 days	VTE	< 5	44 (0.30)	< 5	6 (0.14)		

Cohort	Time window	Outcome	AURUM		GOLD	
			BNT162b2	ChAdOx1	BNT162b2	ChAdOx1
		DVT	< 5	26 (0.18)	< 5	< 5
		PE	< 5	18 (0.12)	< 5	< 5
		ATE	< 5	31 (0.21)	< 5	7 (0.17)
		IS	< 5	< 5	< 5	< 5
		TIA	< 5	13 (0.09)	< 5	< 5
		MI	< 5	16 (0.11)	< 5	< 5
		HF	< 5	23 (0.16)	< 5	< 5
		HS	< 5	< 5	< 5	< 5
		MP	< 5	7 (0.05)	< 5	< 5
	91 to 180 days	VTE	< 5	25 (0.17)	< 5	< 5
		DVT	< 5	15 (0.10)	< 5	< 5
		PE	< 5	13 (0.09)	< 5	< 5
		ATE	< 5	26 (0.18)	< 5	< 5
		IS	< 5	< 5	< 5	< 5
		TIA	< 5	8 (0.05)	< 5	< 5
		MI	< 5	17 (0.12)	< 5	< 5
		HF	< 5	10 (0.07)	< 5	< 5
		HS	< 5	< 5	< 5	< 5
		MP	< 5	< 5	< 5	< 5
	181 to 365 days	VTE	< 5	9 (0.06)	< 5	< 5
		DVT	< 5	< 5	< 5	< 5
		PE	< 5	6 (0.04)	< 5	< 5
		ATE	< 5	< 5	< 5	< 5
		IS	< 5	< 5	< 5	< 5
		TIA	< 5	< 5	< 5	< 5
		MI	< 5	< 5	< 5	< 5
		HF	< 5	< 5	< 5	< 5
		HS	< 5	< 5	< 5	< 5
		MP	< 5	< 5	< 5	< 5
Cohort 4			N = 1,335,671	N = 542,670	N = 365,096	N = 147,744
	0 to 30 days	VTE	20 (0.15)	27 (0.50)	< 5	8 (0.54)
		DVT	9 (0.07)	7 (0.13)	< 5	< 5
		PE	11 (0.08)	21 (0.39)	< 5	6 (0.41)
		ATE	< 5	5 (0.09)	< 5	< 5
		IS	< 5	< 5	< 5	< 5
		TIA	< 5	< 5	< 5	< 5
		MI	< 5	< 5	< 5	< 5
		HF	< 5	< 5	< 5	< 5
		HS	< 5	< 5	< 5	< 5
		MP	< 5	< 5	< 5	< 5
	31 to 90 days	VTE	7 (0.05)	14 (0.26)	< 5	< 5
		DVT	< 5	8 (0.15)	< 5	< 5
		PE	< 5	6 (0.11)	< 5	< 5
		ATE	< 5	< 5	< 5	< 5
		IS	< 5	< 5	< 5	< 5
		TIA	< 5	< 5	< 5	< 5
		MI	< 5	< 5	< 5	< 5
		HF	6 (0.04)	< 5	< 5	< 5
		HS	< 5	< 5	< 5	< 5

Cohort	Time window	Outcome	AURUM		GOLD	
			BNT162b2	ChAdOx1	BNT162b2	ChAdOx1
		MP	< 5	< 5	< 5	< 5
	91 to 180 days	VTE	9 (0.07)	< 5	< 5	< 5
		DVT	7 (0.05)	< 5	< 5	< 5
		PE	< 5	< 5	< 5	< 5
		ATE	< 5	< 5	< 5	< 5
		IS	< 5	< 5	< 5	< 5
		TIA	< 5	< 5	< 5	< 5
		MI	< 5	< 5	< 5	< 5
		HF	< 5	< 5	< 5	< 5
		HS	< 5	< 5	< 5	< 5
		MP	< 5	< 5	< 5	< 5
		181 to 365 days	VTE	< 5	< 5	< 5
	DVT		< 5	< 5	< 5	< 5
	PE		< 5	< 5	< 5	< 5
	ATE		< 5	< 5	< 5	< 5
	IS		< 5	< 5	< 5	< 5
	TIA		< 5	< 5	< 5	< 5
	MI		< 5	< 5	< 5	< 5
	HF		< 5	< 5	< 5	< 5
	HS		< 5	< 5	< 5	< 5
	MP		< 5	< 5	< 5	< 5


VTE = Venous thromboembolism (DVT + PE), DVT = Deep vein thrombosis, PE = Pulmonary embolism, ATE = Arterial thromboembolism (IS + TIA + MI), IS = Ischemic stroke, TIA = Transient ischemic attack, MI = Myocardial infarction, HF = Heart failure, HS = Hemorrhagic stroke, MP = Myocarditis or Pericarditis

Figure S8: Forest plots for vaccine effectiveness (any COVID-19 vaccine), meta-analysis across cohorts and databases. Follow-up ends at first vaccine dose after index date. Dashed line represents a level of heterogeneity $I^2 > 0.4$.




VTE = Venous thromboembolism, ATE = Arterial thromboembolism, CD + HS = Cardiac diseases and Hemorrhagic stroke

Figure S9: Forest plots for vaccine effectiveness (any COVID-19 vaccine), meta-analysis across cohorts and databases. Only first outcome after COVID-19 captured. Dashed line represents a level of heterogeneity $I^2 > 0.4$.




VTE = Venous thromboembolism, ATE = Arterial thromboembolism, CD + HS = Cardiac diseases and Hemorrhagic stroke

Figure S10: Forest plots for vaccine effectiveness (ChAdOx1 vaccine), meta-analysis across cohorts and databases. Dashed line represents a level of heterogeneity $I^2 > 0.4$.




VTE = Venous thromboembolism, ATE = Arterial thromboembolism, CD + HS = Cardiac diseases and Hemorrhagic stroke

Figure S11: Forest plots for vaccine effectiveness (ChAdOx1 vaccine), meta-analysis across cohorts and databases. Follow-up ends at first vaccine dose after index date. Dashed line represents a level of heterogeneity $I^2 > 0.4$.




VTE = Venous thromboembolism, ATE = Arterial thromboembolism, CD + HS = Cardiac diseases and Hemorrhagic stroke

Figure S12: Forest plots for vaccine effectiveness (ChAdOx1 vaccine), meta-analysis across cohorts and databases. Only first outcome after COVID-19 captured. Dashed line represents a level of heterogeneity $I^2 > 0.4$.




VTE = Venous thromboembolism, ATE = Arterial thromboembolism, CD + HS = Cardiac diseases and Hemorrhagic stroke

Figure S13: Forest plots for vaccine effectiveness (BNT162b2 vaccine), meta-analysis across cohorts and databases. Dashed line represents a level of heterogeneity $I^2 > 0.4$.




VTE = Venous thromboembolism, ATE = Arterial thromboembolism, CD + HS = Cardiac diseases and Hemorrhagic stroke

Figure S14: Forest plots for vaccine effectiveness (BNT162b2 vaccine), meta-analysis across cohorts and databases. Follow-up ends at first vaccine dose after index date. Dashed line represents a level of heterogeneity $I^2 > 0.4$.



VTE = Venous thromboembolism, ATE = Arterial thromboembolism, CD + HS = Cardiac diseases and Hemorrhagic stroke

Figure S15: Forest plots for vaccine effectiveness (BNT162b2 vaccine), meta-analysis across cohorts and databases. Only first outcome after COVID-19 captured. Dashed line represents a level of heterogeneity $I^2 > 0.4$.



VTE = Venous thromboembolism, ATE = Arterial thromboembolism, CD + HS = Cardiac diseases and Hemorrhagic stroke

Figure S16: Forest plots for vaccine effectiveness (any COVID-19 vaccine) on preventing venous thromboembolism complications, for each cohort and database (meta-analysis estimates across cohorts in the last panel). Dashed line represents a level of heterogeneity $I^2 > 0.4$.




Figure S17: Forest plots for vaccine effectiveness (any COVID-19 vaccine) on preventing venous thromboembolism complications, for each cohort and database (meta-analysis estimates across cohorts in the last panel). Follow-up ends at first vaccine dose after index date. Dashed line represents a level of heterogeneity $I^2 > 0.4$.




Figure S18: Forest plots for vaccine effectiveness (any COVID-19 vaccine) on preventing venous thromboembolism complications, for each cohort and database (meta-analysis estimates across cohorts in the last panel). Only first outcome after COVID-19 captured. Dashed line represents a level of heterogeneity $I^2 > 0.4$.




Figure S19: Forest plots for vaccine effectiveness (ChAdOx1 vaccine) on preventing venous thromboembolism complications, for each cohort and database (meta-analysis estimates across cohorts in the last panel). Dashed line represents a level of heterogeneity $I^2 > 0.4$.




Figure S20: Forest plots for vaccine effectiveness (ChAdOx1 vaccine) on preventing venous thromboembolism complications, for each cohort and database (meta-analysis estimates across cohorts in the last panel). Follow-up ends at first vaccine dose after index date. Dashed line represents a level of heterogeneity $I^2 > 0.4$.




Figure S21: Forest plots for vaccine effectiveness (ChAdOx1 vaccine) on preventing venous thromboembolism complications, for each cohort and database (meta-analysis estimates across cohorts in the last panel). Only first outcome after COVID-19 captured. Dashed line represents a level of heterogeneity $I^2 > 0.4$.




Figure S22: Forest plots for vaccine effectiveness (BNT162b2 vaccine) on preventing venous thromboembolism complications, for each cohort and database (meta-analysis estimates across cohorts in the last panel). Dashed line represents a level of heterogeneity $I^2 > 0.4$.




Figure S23: Forest plots for vaccine effectiveness (BNT162b2 vaccine) on preventing venous thromboembolism complications, for each cohort and database (meta-analysis estimates across cohorts in the last panel). Follow-up ends at first vaccine dose after index date. Dashed line represents a level of heterogeneity $I^2 > 0.4$.




Figure S24: Forest plots for vaccine effectiveness (BNT162b2 vaccine) on preventing venous thromboembolism complications, for each cohort and database (meta-analysis estimates across cohorts in the last panel). Only first outcome after COVID-19 captured. Dashed line represents a level of heterogeneity $I^2 > 0.4$.




Figure S25: Forest plots for vaccine effectiveness (any COVID-19 vaccine) on preventing arterial thromboembolism complications, for each cohort and database (meta-analysis estimates across cohorts in the last panel). Dashed line represents a level of heterogeneity $I^2 > 0.4$.




Figure S26: Forest plots for vaccine effectiveness (any COVID-19 vaccine) on preventing arterial thromboembolism complications, for each cohort and database (meta-analysis estimates across cohorts in the last panel). Follow-up ends at first vaccine dose after index date. Dashed line represents a level of heterogeneity $I^2 > 0.4$.




Figure S27: Forest plots for vaccine effectiveness (any COVID-19 vaccine) on preventing arterial thromboembolism complications, for each cohort and database (meta-analysis estimates across cohorts in the last panel). Only first outcome after COVID-19 captured. Dashed line represents a level of heterogeneity $I^2 > 0.4$.




Figure S28: Forest plots for vaccine effectiveness (ChAdOx1 vaccine) on preventing arterial thromboembolism complications, for each cohort and database (meta-analysis estimates across cohorts in the last panel). Dashed line represents a level of heterogeneity $I^2 > 0.4$.




Figure S29: Forest plots for vaccine effectiveness (ChAdOx1 vaccine) on preventing arterial thromboembolism complications, for each cohort and database (meta-analysis estimates across cohorts in the last panel). Follow-up ends at first vaccine dose after index date. Dashed line represents a level of heterogeneity $I^2 > 0.4$.




Figure S30: Forest plots for vaccine effectiveness (ChAdOx1 vaccine) on preventing arterial thromboembolism complications, for each cohort and database (meta-analysis estimates across cohorts in the last panel). Only first outcome after COVID-19 captured. Dashed line represents a level of heterogeneity $I^2 > 0.4$.




Figure S31: Forest plots for vaccine effectiveness (BNT162b2 vaccine) on preventing arterial thromboembolism complications, for each cohort and database (meta-analysis estimates across cohorts in the last panel). Dashed line represents a level of heterogeneity $I^2 > 0.4$.




Figure S32: Forest plots for vaccine effectiveness (BNT162b2 vaccine) on preventing arterial thromboembolism complications, for each cohort and database (meta-analysis estimates across cohorts in the last panel). Follow-up ends at first vaccine dose after index date. Dashed line represents a level of heterogeneity $I^2 > 0.4$.




Figure S33: Forest plots for vaccine effectiveness (BNT162b2 vaccine) on preventing arterial thromboembolism complications, for each cohort and database (meta-analysis estimates across cohorts in the last panel). Only first outcome after COVID-19 captured. Dashed line represents a level of heterogeneity $I^2 > 0.4$.




Figure S34: Forest plots for vaccine effectiveness (any COVID-19 vaccine) on preventing cardiac diseases and hemorrhagic stroke, for each cohort and database (meta-analysis estimates across cohorts in the last panel). Dashed line represents a level of heterogeneity $I^2 > 0.4$.




Figure S35: Forest plots for vaccine effectiveness (any COVID-19 vaccine) on preventing cardiac diseases and hemorrhagic stroke, for each cohort and database (meta-analysis estimates across cohorts in the last panel). Follow-up ends at first vaccine dose after index date. Dashed line represents a level of heterogeneity $I^2 > 0.4$.




Figure S36: Forest plots for vaccine effectiveness (any COVID-19 vaccine) on preventing cardiac diseases and hemorrhagic stroke, for each cohort and database (meta-analysis estimates across cohorts in the last panel). Only first outcome after COVID-19 captured. Dashed line represents a level of heterogeneity $I^2 > 0.4$.




Figure S37: Forest plots for vaccine effectiveness (ChAdOx1 vaccine) on preventing cardiac diseases and hemorrhagic stroke, for each cohort and database (meta-analysis estimates across cohorts in the last panel). Dashed line represents a level of heterogeneity $I^2 > 0.4$.




Figure S38: Forest plots for vaccine effectiveness (ChAdOx1 vaccine) on preventing cardiac diseases and hemorrhagic stroke, for each cohort and database (meta-analysis estimates across cohorts in the last panel). Follow-up ends at first vaccine dose after index date. Dashed line represents a level of heterogeneity $I^2 > 0.4$.




Figure S39: Forest plots for vaccine effectiveness (ChAdOx1 vaccine) on preventing cardiac diseases and hemorrhagic stroke, for each cohort and database (meta-analysis estimates across cohorts in the last panel). Only first outcome after COVID-19 captured. Dashed line represents a level of heterogeneity $I^2 > 0.4$.




Figure S40: Forest plots for vaccine effectiveness (BNT162b2 vaccine) on preventing cardiac diseases and hemorrhagic stroke, for each cohort and database (meta-analysis estimates across cohorts in the last panel). Dashed line represents a level of heterogeneity $I^2 > 0.4$.




Figure S41: Forest plots for vaccine effectiveness (BNT162b2 vaccine) on preventing cardiac diseases and hemorrhagic stroke, for each cohort and database (meta-analysis estimates across cohorts in the last panel). Follow-up ends at first vaccine dose after index date. Dashed line represents a level of heterogeneity $I^2 > 0.4$.




Figure S42: Forest plots for vaccine effectiveness (BNT162b2 vaccine) on preventing cardiac diseases and hemorrhagic stroke, for each cohort and database (meta-analysis estimates across cohorts in the last panel). Only first outcome after COVID-19 captured. Dashed line represents a level of heterogeneity $I^2 > 0.4$.






Figure S43: Forest plots for comparative effectiveness, meta-analysis across cohorts and databases. Follow-up ends at first vaccine dose after index date. Dashed line represents a level of heterogeneity $I^2 > 0.4$.



VTE = Venous thromboembolism, ATE = Arterial thromboembolism, CD + HS = Cardiac diseases and Hemorrhagic stroke

Figure S44: Forest plots for comparative effectiveness, meta-analysis across cohorts and databases. Only first outcome after COVID-19 captured. Dashed line represents a level of heterogeneity $I^2 > 0.4$.



VTE = Venous thromboembolism, ATE = Arterial thromboembolism, CD + HS = Cardiac diseases and Hemorrhagic stroke

Figure S45: Forest plots for comparative effectiveness on preventing venous thromboembolism complications, for each cohort and database (meta-analysis estimates across cohorts in the last panel). Dashed line represents a level of heterogeneity $I^2 > 0.4$.




Figure S46: Forest plots for comparative effectiveness on preventing venous thromboembolism complications, for each cohort and database (meta-analysis estimates across cohorts in the last panel). Follow-up ends at first vaccine dose after index date. Dashed line represents a level of heterogeneity $I^2 > 0.4$.




Figure S47: Forest plots for comparative effectiveness on preventing venous thromboembolism complications, for each cohort and database (meta-analysis estimates across cohorts in the last panel). Only first outcome after COVID-19 captured. Dashed line represents a level of heterogeneity $I^2 > 0.4$.




Figure S48: Forest plots for comparative effectiveness on preventing arterial thromboembolism complications, for each cohort and database (meta-analysis estimates across cohorts in the last panel). Dashed line represents a level of heterogeneity $I^2 > 0.4$.




Figure S49: Forest plots for comparative effectiveness on preventing arterial thromboembolism complications, for each cohort and database (meta-analysis estimates across cohorts in the last panel). Follow-up ends at first vaccine dose after index date. Dashed line represents a level of heterogeneity $I^2 > 0.4$.




Figure S50: Forest plots for comparative effectiveness on preventing arterial thromboembolism complications, for each cohort and database (meta-analysis estimates across cohorts in the last panel). Only first outcome after COVID-19 captured. Dashed line represents a level of heterogeneity $I^2 > 0.4$.




Figure S51: Forest plots for comparative effectiveness on preventing cardiac diseases and hemorrhagic stroke, for each cohort and database (meta-analysis estimates across cohorts in the last panel). Dashed line represents a level of heterogeneity $I^2 > 0.4$.




Figure S52: Forest plots for comparative effectiveness on preventing cardiac diseases and hemorrhagic stroke, for each cohort and database (meta-analysis estimates across cohorts in the last panel). Follow-up ends at first vaccine dose after index date. Dashed line represents a level of heterogeneity $I^2 > 0.4$.




Figure S53: Forest plots for comparative effectiveness on preventing cardiac diseases and hemorrhagic stroke, for each cohort and database (meta-analysis estimates across cohorts in the last panel). Only first outcome after COVID-19 captured. Dashed line represents a level of heterogeneity $I^2 > 0.4$.

